Insect cells and methods of engineering thereof

By screening and characterizing the insect cell database carried by identifiers, insect cells are engineered to improve the expression and production characteristics of viral vectors, solving the problems of low production efficiency of viral vectors and cell line screening in insect cells, and achieving efficient and low-cost organisms Preparation production.

CN119032179APending Publication Date: 2024-11-2664 X INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202380034708.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-01
Filing Date
2023-02-28
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the biologics market, the low production efficiency of viral vectors in insect cells and the difficulty of cell line screening leads to high manufacturing costs and difficult production.

Method used

Provides a method and platform technology to engineer insect cells to improve the expression and production characteristics of viral vectors such as increased expression, duration and stability by screening and characterizing insect cell banks with identifiers. To evaluate and identify the ability of viral vector production, and to optimize the characteristics of viral vectors through library constructs and perturbations.

Benefits of technology

It improves the expression and production efficiency of viral vectors, simplifies the screening process of cell lines, reduces manufacturing costs, and improves the feasibility and efficiency of production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032179A_ABST
    Figure CN119032179A_ABST
Patent Text Reader

Abstract

The present disclosure provides insect cell lines for expressing viral vectors, and methods of making and using the same. The provided methods employ the use of identifiers that can be packaged into a viral vector to select and / or identify insect cell lines having engineered sequences associated with beneficial characteristics produced by the viral vector. Exemplary viral vectors include AAV vectors.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 315,510 filed on March 1, 2022, the entire contents of which are incorporated herein by reference. Background Art

[0003] The biologics market, such as gene and cell therapies, is expanding but is currently burdened by high manufacturing costs and difficulties associated with scaling up production. There is a continuing need for improved cell lines and methods of isolating them for applications including, but not limited to, biologics production and viral vector production. Summary of the invention

[0004] The present disclosure provides, in particular, methods, systems and compositions for producing and / or expressing viral vectors in insect cells. The present disclosure recognizes that the prior art for expressing viral vectors in insect cells bears the burden of inefficient virus production and inefficient screening of insect cell lines optimized for separation. The present disclosure provides platform technologies for engineering insect cells and / or viral vectors to obtain changed features and other features related to viral vector production. In some embodiments, the method provided makes it possible to produce and / or select insect cell lines with improved viral vector expression and / or production characteristics (e.g., increased viral vector expression, increased expression duration, increased stability, etc.). In some embodiments, the method includes screening viral vectors produced by a library of insect cells with an identifier. The technology provided includes surprising insights, even if the viral vector obtains an identifier of the insect cell expressing it (e.g., including a barcode sequence and / or library variant), thereby making it possible to effectively evaluate, characterize and / or identify the viral vector production ability of cells in the library. For example, in some embodiments, each insect cell population is transformed with a library construct comprising an identifier having a structure suitable for packaging the identifier into a viral vector (e.g., for an AAV vector, the identifier can be located between the AAV ITRs). In some embodiments, a pool of viral vectors produced by such an insect cell population can be screened, selected, and / or characterized by an abundance of unique identifiers.

[0005] In some embodiments, an insect cell is provided that comprises one or more engineered sequences that collectively comprise: (i) at least one identifier located between two viral repeat sequences that are capable of being packaged into a viral vector, and (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein the insect cell produces a viral vector comprising the at least one identifier.

[0006] In some embodiments, the viral vector produced by the insect cell comprises an identifier identical to the identifier of the insect cell producing the viral vector. In some embodiments, the identifier of the viral vector is derived from the identifier of the insect cell producing the viral vector. In some embodiments, the identifier of the viral vector corresponds to the identifier of the insect cell producing the viral vector. In some embodiments, the identifier of the viral vector is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the identifier of the insect cell producing the viral vector.

[0007] In some embodiments, an insect cell comprising one or more engineered sequences is provided, the one or more engineered sequences collectively comprising: (i) at least one identifier located between two viral repeat sequences capable of being packaged into a viral vector, (ii) at least one perturbation, and (iii) at least one polynucleotide comprising one or more nucleic acid sequences necessary to produce a viral vector, wherein the insect cell produces a viral vector comprising at least one identifier. In some embodiments, the insect cell further comprises a payload and / or at least one library variant. In some embodiments, the insect cell further comprises at least one perturbation additional sequence.

[0008] In some embodiments, an insect cell comprising one or more engineered sequences is provided, the one or more engineered sequences collectively comprising: (i) at least one identifier located between two viral repeat sequences capable of being packaged into a viral vector, (ii) at least one library variant, and (iii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein the insect cell produces a viral vector comprising at least one identifier. In some embodiments, the insect cell further comprises a payload and / or at least one perturbation. In some embodiments, the insect cell further comprises at least one perturbation additional sequence.

[0009] In some embodiments, an insect cell comprising one or more engineered sequences is provided, the one or more engineered sequences collectively comprising: (i) at least one identifier located between two viral repeat sequences capable of being packaged into a viral vector, (ii) at least one payload, and (iii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein the insect cell produces a viral vector comprising at least one identifier. In some embodiments, the insect cell further comprises at least one library variant and / or at least one perturbation. In some embodiments, the insect cell further comprises at least one perturbation additional sequence.

[0010] In some embodiments, the insect cell further comprises at least one trans-acting integration sequence and / or at least one cis-acting integration sequence.

[0011] In some embodiments, an insect cell is provided that comprises one or more engineered sequences that collectively comprise: (i) at least one identifier located between two viral repeat sequences that are capable of being packaged into a viral vector; (ii) at least one library variant and / or perturbation; (iii) at least one payload; (iv) at least one perturbation additional sequence; (v) at least one trans-acting integration sequence and / or at least one cis-acting integration sequence; and (vi) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein the insect cell produces a viral vector comprising at least one identifier.

[0012] In some embodiments, an insect cell is provided that comprises one or more engineered sequences that collectively comprise: (i) at least one identifier located between two viral repeat sequences that are capable of being packaged into a viral vector; (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector; and optionally (iii) one or more engineered sequences comprising at least one perturbation, at least one library variant, at least one payload, at least one perturbation additional sequence, at least one trans-acting integration sequence, and / or at least one cis-acting integration sequence, and wherein the insect cell produces a viral vector comprising at least one identifier.

[0013] In some embodiments, an insect cell is provided comprising one or more engineered sequences, the one or more engineered sequences collectively comprising: (i) a library construct, and (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary to produce a viral vector, wherein the library construct comprises an identifier, wherein the identifier is located between two viral repeat sequences capable of being packaged into a viral vector, and wherein the insect cell produces a viral vector comprising the identifier. In some embodiments, the insect cell optionally further comprises one or more engineered sequences, the one or more engineered sequences comprising: at least one perturbation, at least one library variant, at least one payload, at least one perturbation additional sequence, at least one trans-acting integration sequence, and / or at least one cis-acting integration sequence, and wherein the insect cell produces a viral vector comprising at least one identifier.

[0014] In some embodiments, the viral vector produced by the insect cell comprises an identifier identical to a library construct. In some embodiments, the identifier of the viral vector is derived from an identifier of a related library construct. In some embodiments, the identifier of the viral vector corresponds to an identifier of a library construct. In some embodiments, the identifier of the viral vector is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the identifier of the library construct.

[0015] In some embodiments, an insect cell comprising one or more engineered sequences is provided, the one or more engineered sequences collectively comprising: (i) a library construct, and (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein the library construct comprises an identifier, wherein the identifier is located between two viral repeat sequences that can be packaged into a viral vector, and wherein the insect cell produces a viral vector comprising the identifier. In some embodiments, the library construct optionally further comprises one or more engineered sequences, the one or more engineered sequences comprising at least one library variant and / or at least one payload. In some embodiments, the insect cell optionally further comprises one or more engineered sequences, the one or more engineered sequences comprising: at least one perturbation, at least one perturbation additional sequence, at least one trans-acting integration sequence, and / or at least one cis-acting integration sequence, and wherein the insect cell produces a viral vector comprising at least one identifier.

[0016] In some embodiments, an insect cell population is provided that comprises a plurality of insect cells, each of which individually comprises one or more engineered sequences, wherein the one or more engineered sequences collectively comprise: (i) at least one identifier located between two viral repeat sequences that can be packaged into a viral vector, (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary to produce a viral vector, and wherein the insect cell population produces a viral vector that individually comprises at least one identifier. In some embodiments, the insect cell population optionally further comprises one or more engineered sequences, wherein the one or more engineered sequences comprise: at least one perturbation, at least one library variant, at least one payload, at least one perturbation additional sequence, at least one trans-acting integration sequence, and / or at least one cis-acting integration sequence.

[0017] In some embodiments, an insect cell population is provided comprising a plurality of insect cells, each of the plurality of insect cells individually comprising one or more engineered sequences, wherein the one or more engineered sequences collectively comprise: (i) at least one identifier located between two viral repeat sequences capable of being packaged into a viral vector, (ii) at least one library variant and / or perturbation, (iii) at least one payload, and (iv) at least one polynucleotide comprising one or more nucleic acid sequences necessary to produce a viral vector, wherein the insect cell population produces a viral vector that individually comprises at least one identifier. In some embodiments, the insect cells optionally further comprise one or more engineered sequences, wherein the one or more engineered sequences comprise: at least one perturbation additional sequence, at least one trans-acting integration sequence, and / or at least one cis-acting integration sequence.

[0018] In some embodiments, an insect cell population comprising a plurality of insect cells is provided, each of the plurality of insect cells individually comprising one or more engineered sequences, wherein the one or more engineered sequences collectively comprise: (i) a library construct and (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein the library construct comprises an identifier located between two viral repeat sequences capable of being packaged into a viral vector, and wherein the insect cell population produces a viral vector that individually comprises the identifier. In some embodiments, the insect cell population optionally further comprises one or more engineered sequences, wherein the one or more engineered sequences comprise: at least one perturbation, at least one library variant, at least one payload, at least one perturbation additional sequence, at least one trans-acting integration sequence, and / or at least one cis-acting integration sequence.

[0019] In some embodiments, an insect cell population comprising a plurality of insect cells is provided, each of the plurality of insect cells individually comprising one or more engineered sequences, wherein the one or more engineered sequences collectively comprise: (i) a library construct and (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein the library construct comprises an identifier positioned between two viral repeat sequences capable of being packaged into a viral vector, and wherein the insect cell population produces a viral vector individually comprising an identifier. In some embodiments, the library construct optionally further comprises one or more engineered sequences, wherein the one or more engineered sequences comprise at least one library variant and / or at least one payload. In some embodiments, the insect cell population optionally further comprises one or more engineered sequences, wherein the one or more engineered sequences comprise: at least one perturbation, at least one perturbation additional sequence, at least one trans-acting integration sequence, and / or at least one cis-acting integration sequence.

[0020] In some embodiments, the insect cell provided comprises a perturbation (e.g., one or more perturbations). In some embodiments, the insect cell provided produces a viral vector comprising a perturbation (e.g., one or more perturbations). In some embodiments, the insect cell provided comprises a perturbation (e.g., one or more perturbations), and the insect cell also produces a viral vector comprising a perturbation (e.g., one or more perturbations). In some embodiments, at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector comprises a perturbation (e.g., one or more perturbations). In some embodiments, the insect cell provided comprises a perturbation (e.g., one or more perturbations), and at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector comprises a perturbation (e.g., one or more perturbations). In some embodiments, the insect cell provided produces a viral vector comprising a perturbation (e.g., one or more perturbations), and at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector comprises a perturbation (e.g., one or more perturbations). In some embodiments, the insect cell provided comprises a perturbation (e.g., one or more perturbations), and the insect cell also produces a viral vector comprising a perturbation (e.g., one or more perturbations), and at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector comprises a perturbation (e.g., one or more perturbations).

[0021] Insect cells and / or insect cell populations can include any insect cell suitable for expressing viral vectors in the art. In some embodiments, the insect cell is a cell from or derived from an armyworm (e.g., Spodopterafrugiperda), a fruit fly (e.g., Drosophila), or a mosquito (e.g., Aedes albopictus).

[0022] In some embodiments, the insect cell comprises Sf21 cell, Sf9 cell, BTI-TN-5B1-4 (High Five) cell, S2 cell, D.Mel2 cell or any derivative thereof. In some embodiments, the insect cell comprises Sf9 cell and / or its derivative.

[0023] In some embodiments, the insect cells are suitable for suspension cell culture. In some embodiments, the insect cells are suitable for adherent cell culture. In some embodiments, the insect cell population may include cells in suspension cells and / or adherent cells.

[0024] The insect cells and / or methods of the present disclosure can be used to produce any viral vector. In some embodiments, the viral vector produced by the insect cells and / or methods of the present disclosure comprises a perturbation (e.g., one or more perturbations). In some embodiments, the perturbation changes one or more characteristics associated with producing a viral vector (e.g., viral vector stability, etc.) or other characteristics (e.g., altered therapeutic activity, etc.).

[0025] In some embodiments, the insect cells of the insect cell library have been modified to destroy or remove receptors for the produced viral vectors. In some embodiments, the insect cells have been treated with an agent that blocks infection by the viral vectors.

[0026] In some embodiments, the viral vector is an adeno-associated virus (AAV) vector, a baculovirus vector, a lentivirus vector, an adenovirus vector, an alphavirus vector, a sindbis virus vector, a retrovirus vector (e.g., a gammaretrovirus vector), a polyomavirus vector (e.g., a simian virus 40 (SV40) vector), a papillomavirus vector (e.g., a bovine papillomavirus (BPV) vector), a vacciniavirus vector, a herpes simplex virus (HSV) vector, a measles virus vector, a rhabdovirus vector, a rabies virus vector, a vesicular stomatitis virus vector (VSV) vector, picornavirus vector (e.g., poliovirus vector), reovirus vector, Senecavirus vector, echovirus vector (e.g., RIGVIR), Semliki Forest Virus (SFV) vector, flavivirus vector, anellovirus vector, Newcastle Disease Virus (NDV) vector, paramyxovirus vector, Sendai virus vector, orthomyxovirus vector, influenza virus vector, coronavirus vector and / or hybrid virus vector, and / or derivatives, hybrids and / or engineered derivatives thereof.

[0027] In some embodiments, the insect cells, insect cell populations and / or methods provided herein can be used to express adeno-associated virus (AAV) vectors. In some embodiments, the insect cell comprises (i) at least one identifier located between two viral repeat sequences that can be packaged into an AAV vector and (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing an AAV vector. In some embodiments, each of the two viral repeat sequences is an AAV ITR sequence that can be packaged into an AAV vector. In some embodiments, each of the two viral repeat sequences is an insect AAV ITR sequence. In some embodiments, each of the two viral repeat sequences is a human AAV ITR sequence.

[0028] In some embodiments, an insect cell population comprising a plurality of insect cells is provided, wherein each insect cell in the plurality comprises: (i) a nucleic acid sequence comprising a barcode located between two functional AAV ITR sequences, wherein the nucleic acid sequence is integrated into the insect genome located between a pair of cis-acting integration sequences, (ii) one or more library variants that result in one or more perturbations, and (iii) one or more nucleic acid sequences necessary for producing an AAV vector, wherein the insect cell population produces a plurality of AAV vectors, wherein each AAV vector comprises a barcode corresponding to the barcode of the insect cell that produced it. In some embodiments, at least one library variant comprises a gRNA, and the insect cell further comprises an RNA-guided nuclease. In some embodiments, the AAV vector produced by the insect cell further comprises a payload.

[0029] In some embodiments, the cis-acting integration sequence of the insect cell is a viral repeat sequence derived from an invertebrate virus (e.g., Junonia coenia densovirus (JcDNV)). In some embodiments, the cis-acting integration sequence of the insect cell is a recombinase recognition site.

[0030] In some embodiments, one or more perturbations of an insect cell are associated with an increase in AAV production and / or AAV secretion relative to a reference insect cell population lacking the one or more perturbations. In some embodiments, an insect cell comprising the one or more perturbations has at least a 10% increase in AAV production and / or AAV secretion relative to a reference insect cell lacking the one or more perturbations.

[0031] In some embodiments, the two viral repeat sequences of the insect cells and / or library constructs described herein comprise a pair of inverted terminal repeat sequences (ITRs) that are or include human AAV1 ITRs; human AAV2 ITRs; human AAV3bITRs; human AAV4 ITRs; human AAV5 ITRs; human AAV6 ITRs; human AAV7 ITRs; human AAV8 ITRs; human AAV9 ITRs; human AAV10 ITRs; human AAV11 ITRs; human AAV12 ITRs; human AAV13 ITRs, or any combination thereof.

[0032] In some embodiments, the two viral repeat sequences of the insect cells and / or library constructs described herein comprise a pair of inverted terminal repeat sequences (ITRs) that are or include bovine AAV (b-AAV) ITRs; canine AAV (CAAV) ITRs; mouse AAV1 ITRs; goat AAV ITRs; rat AAV ITRs; or avian AAV (AAAV) ITRs.

[0033] In some embodiments, the insect cell comprises one or more polynucleotides encoding one or more proteins necessary for producing an AAV vector, such as an AAV capsid protein. In some embodiments, the AAV vector comprises a human AAV1 capsid protein; a human AAV2 capsid protein; a human AAV3b capsid protein; a human AAV4 capsid protein; a human AAV5 capsid protein; a human AAV6 capsid protein; a human AAV7 capsid protein; a human AAV8 capsid protein; a human AAV9 capsid protein; a human AAV10 capsid protein; a human AAV11 capsid protein; a human AAV12 capsid protein; or a human AAV13 capsid protein. In some embodiments, the AAV vector comprises a human ancestral AAV capsid protein. In some embodiments, the AAV vector comprises a bovine AAV (b-AAV) capsid protein; a canine AAV (CAAV) capsid protein; a mouse AAV1 capsid protein; a goat AAV capsid protein; a rat AAV capsid protein; or an avian AAV (AAAV) capsid protein.

[0034] In some embodiments, the insect cells, insect cell populations and / or methods provided herein can be used to express AAV vectors, wherein the insect cells comprise (i) a library construct comprising at least one identifier located between two AAV ITR sequences that can be packaged into an AAV vector, and (ii) at least one polynucleotide comprising one or more nucleic acid sequences selected from Rep genes, Cap genes, auxiliary genes, or a combination thereof necessary for producing an AAV vector. In some embodiments, at least one polynucleotide comprising one or more nucleic acid sequences necessary for forming an AAV vector comprises: AAV Rep genes, AAV Cap genes, one or more AAV auxiliary genes, or a combination thereof. In some embodiments, the AAV vector is replication-competent. In some embodiments, the AAV vector is conditionally replicable, replication-deficient, replication-incompetent, and / or replication-defective.

[0035] In some embodiments, the insect cells, insect cell populations, and / or methods provided herein can be used to express a baculovirus vector (e.g., an Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) vector).

[0036] In some embodiments, the insect cells, insect cell populations and / or methods provided herein can be used to express lentiviral vectors. In some embodiments, the insect cells contain (i) at least one identifier located between two viral repeat sequences that can be packaged into a lentiviral vector and (ii) at least one polynucleotide containing one or more nucleic acid sequences necessary for producing a lentiviral vector. In some embodiments, each of the two viral repeat sequences is a lentiviral LTR sequence that can be packaged into a lentiviral vector.

[0037] In some embodiments, the two viral repeat sequences of the insect cells and / or library constructs described herein comprise a pair of LTRs, which include HIV LTRs, SIV LTRs, equine infectious anemia virus LTRs, FIV LTRs, Visna virus LTRs, or derivatives or combinations thereof. In some specific embodiments, the lentiviral vector is an HIV vector and the LTRs are HIV LTRs or derivatives thereof. In some embodiments, the lentiviral vector comprises a lentiviral Psi sequence.

[0038] In some embodiments, an insect cell population comprising a plurality of insect cells is provided, wherein each insect cell in the plurality comprises: (i) a nucleic acid sequence comprising a barcode located between two functional lentiviral LTR sequences, wherein the nucleic acid sequence is integrated into the insect genome located between a pair of cis-acting integration sequences, (ii) one or more library variants that result in one or more perturbations, and (iii) one or more nucleic acid sequences necessary for producing a lentiviral vector, wherein the insect cell population produces a plurality of lentiviral vectors, wherein each lentiviral vector comprises a barcode corresponding to the barcode of the insect cell that produced it. In some embodiments, at least one library variant comprises a gRNA, and the insect cell further comprises an RNA-guided nuclease. In some embodiments, the lentiviral vector produced by the insect cell further comprises a payload.

[0039] In some embodiments, the cis-acting integration sequence of the insect cell is a viral repeat sequence derived from a lentivirus. In some embodiments, the cis-acting integration sequence of the insect cell is a recombinase recognition site.

[0040] In some embodiments, the lentiviral LTR comprises HIV LTR, SIV LTR, equine infectious anemia virus LTR, FIV LTR, Visna virus LTR or a derivative or combination thereof. In some specific embodiments, the lentiviral vector is an HIV vector and the LTR is an HIV LTR or a derivative thereof. In some embodiments, the lentiviral vector comprises a lentiviral Psi sequence.

[0041] In some embodiments, one or more perturbations of an insect cell are associated with an increase in lentiviral vector production and / or lentiviral vector secretion relative to a reference insect cell population lacking the one or more perturbations. In some embodiments, an insect cell comprising one or more perturbations has at least a 10% increase in lentiviral vector production and / or lentiviral vector secretion relative to a reference insect cell lacking the one or more perturbations.

[0042] In some embodiments, the lentiviral vector expressed by the insect cells and methods of the present disclosure is a human immunodeficiency virus (HIV) vector, a simian immunodeficiency virus (SIV) vector, an equine infectious anemia virus vector, a feline immunodeficiency virus (FIV) vector, a Visna virus vector, or a derivative thereof.

[0043] In some embodiments, the insect cell comprises one or more polynucleotides encoding one or more proteins necessary for producing a lentiviral vector, such as a lentiviral gag protein or a fragment thereof. In some embodiments, the gag protein comprises one or more domains selected from a matrix (MA), a capsid (CA), and a nucleocapsid (NC) domain. In some embodiments, the insect cell comprises one or more polynucleotides encoding one or more proteins necessary for producing a lentiviral vector, such as a lentiviral envelope protein or a fragment thereof.

[0044] In some embodiments, the lentiviral vector is a pseudotyped lentiviral vector comprising a gag protein and an envelope protein derived from different viruses. In some embodiments, the insect cell comprises one or more polynucleotides encoding one or more proteins necessary for producing a pseudotyped lentiviral vector, wherein the pseudotyped lentiviral vector comprises a gag protein and / or an env protein derived from a human immunodeficiency virus (HIV) vector, a simian immunodeficiency virus (SIV) vector, an equine infectious anemia virus vector, a feline immunodeficiency virus vector, a visna virus vector, or a derivative thereof.

[0045] In some embodiments, the insect cells, insect cell populations and / or methods provided herein can be used to express lentiviral vectors, wherein the insect cells contain (i) a library construct comprising at least one identifier located between two lentiviral LTR and / or Psi sequences, the sequences being capable of being packaged into lentiviral vectors, and (ii) at least one polynucleotide comprising one or more nucleic acid sequences selected from gag genes, env genes, pol genes, or a combination thereof necessary for producing lentiviral vectors. In some embodiments, at least one polynucleotide comprising one or more nucleic acid sequences necessary for forming lentiviral vectors comprises: lentiviral gag genes, lentiviral env genes, lentiviral pol genes, or a combination thereof. In some embodiments, lentiviral vectors are replication-competent. In some embodiments, lentiviral vectors are conditionally replicating, replication-deficient, replication-incompetent, and / or replication-defective.

[0046] In some embodiments, at least one polynucleotide comprising one or more nucleic acid sequences necessary for forming a lentiviral vector comprises: HIV gag gene, HIV env gene, HIV pol gene, or a combination thereof. In some embodiments, the lentiviral vector is a replication-competent HIV vector. In some embodiments, the lentiviral vector is a conditionally replicating, replication-deficient, replication-incompetent, and / or replication-defective HIV vector.

[0047] In some embodiments, the insect cells have been previously or simultaneously genetically modified to destroy or remove the receptors of the lentivirus. In some embodiments, the insect cells have been treated with an agent that blocks infection by a lentiviral vector. In such embodiments, the integration vector and / or cis-acting integration sequence is not derived from a lentivirus.

[0048] In some embodiments, the insect cells, insect cell populations and / or methods provided herein can be used to express herpes simplex virus (HSV) vectors. In some embodiments, the insect cells provided contain (i) at least one identifier located between two viral repeat sequences that can be packaged into an HSV vector and (ii) at least one polynucleotide containing one or more nucleic acid sequences necessary for producing an HSV vector. In some embodiments, the HSV vector is or is derived from herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), human cytomegalovirus (HCMV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpes virus (KSHV), human herpes virus 6 and / or human herpes virus 7 and / or its derivatives.

[0049] In some embodiments, two viral repeat sequences of the insect cells and / or library constructs described herein comprise a terminal alpha sequence.

[0050] In some embodiments, the insect cell comprises one or more polynucleotides encoding one or more proteins necessary for producing an HSV vector, such as an HSV capsid protein or a fragment thereof. In some embodiments, the HSV capsid comprises VP5, VP19C, VP23, pre-VP22a and / or a mature protease (UL26 gene product).

[0051] In some embodiments, the insect cells, insect cell populations and / or methods provided herein can be used to express an HSV vector, wherein the insect cell contains (i) a library construct comprising at least one identifier located between the HSV terminal alpha sequences, which sequences are capable of being packaged into an HSV vector, and (ii) at least one polynucleotide comprising one or more nucleic acid sequences necessary to produce an HSV vector comprising an HSV capsid protein.

[0052] In some embodiments, the insect cells, insect cell populations and / or methods provided herein can be used to express HSV-AAV hybrid vectors. In some embodiments, the HSV-AAV hybrid vector is replication-competent. In some embodiments, the HSV-AAV hybrid vector is conditionally replicating, replication-deficient, replication-incompetent and / or replication-defective.

[0053] In some embodiments, the insect cell and / or insect cell group provided comprises one or more polynucleotides, and the one or more polynucleotides comprise one or more nucleic acid sequences necessary for producing viral vectors. In some embodiments, the polynucleotides comprising one or more nucleic acid sequences necessary for producing viral vectors are free in insect cells. In some embodiments, the polynucleotides comprising one or more nucleic acid sequences necessary for producing viral vectors are present in the insect cell genome. In some embodiments, one or more nucleic acid sequences necessary for producing viral vectors comprise heterologous regulatory elements (e.g., heterologous promoters and / or heterologous enhancers). In some embodiments, one or more nucleic acid sequences necessary for producing viral vectors comprise heterologous promoter sequences, and the heterologous promoter sequences are or include SV40 promoters, elongation factor (EF) -1 promoters, cytomegalovirus (CMV) promoters, phosphoglycerate kinase (PGK) 1 promoters, ubiquitin (Ubc) promoters, human β-actin promoters, tetracycline response elements (TRE) promoters, spleen focus forming virus (SFFV) promoters, mouse stem cell virus (MSCV) promoters, super core promoters (SCP), CAG promoters or derivatives thereof. In some embodiments, one or more nucleic acid sequences necessary for producing viral vectors include heterologous enhancer sequences, which are or include CMV early enhancers, cAMP response elements (CRE) enhancers or derivatives thereof. In some embodiments, one or more nucleic acid sequences necessary for producing viral vectors are under the control of inducible transcription control elements. In some embodiments, one or more nucleic acid sequences necessary for producing viral vectors can be integrated into the insect cell genome and under the control of inducible transcription control elements (e.g., inducible promoters and / or inducible enhancers). In some embodiments, one or more nucleic acid sequences necessary for producing viral vectors can be free in insect cells and under the control of inducible transcription control elements (e.g., inducible promoters and / or inducible enhancers).

[0054] Any engineered sequence of the insect cell and / or insect cell population of the present disclosure can exist free and / or be integrated into the insect cell genome. In some embodiments, one or more engineered sequences can exist free in the insect cell, including but not limited to: identifiers, perturbations, library variants, payloads, perturbation additional sequences, trans-acting integration sequences, and / or cis-acting integration sequences. In some embodiments, one or more engineered sequences can be integrated into the insect cell genome, including but not limited to: identifiers, perturbations, library variants, payloads, perturbation additional sequences, trans-acting integration sequences, and / or cis-acting integration sequences.

[0055] In some embodiments, one or more engineered sequences are present in a viral vector (e.g., an identifier, a perturbation, a payload, etc.). In some embodiments, insect cells and / or insect cell populations express viral vectors that each comprise an identifier and a perturbation. In some embodiments, the viral vector comprises a perturbation that changes one or more features and / or other features (e.g., stability, etc.) associated with viral vector production. In some embodiments, the viral vector further comprises a payload. In some embodiments, the viral vector further comprises a reporter gene and / or a selection marker.

[0056] In some embodiments, the insect cell comprises a library construct, wherein one or more polynucleotides constituting the library construct can be present in the insect cell free, including but not limited to: an identifier, a library variant, a payload, a perturbation additional sequence, a trans-acting integration sequence, and / or a cis-acting integration sequence. In some embodiments, the insect cell comprises a library construct, wherein one or more polynucleotides constituting the library construct can be integrated into the insect cell, including but not limited to: an identifier, a library variant, a payload, a perturbation additional sequence, a trans-acting integration sequence, and / or a cis-acting integration sequence. In some embodiments, one or more polynucleotides constituting the library construct can be integrated into the insect cell with a low copy number, such as four copies or less, three copies or less, two copies or less, or a single copy.

[0057] In some embodiments, one or more engineered sequences include heterologous coding sequences. In some embodiments, one or more engineered sequences include heterologous genes and / or heterologous gene segments. In some embodiments, one or more engineered sequences include heterologous regulatory elements (e.g., heterologous promoters and / or heterologous enhancers). In some embodiments, one or more engineered sequences include heterologous promoter sequences, which are or include SV40 promoters, elongation factor (EF) -1 promoters, cytomegalovirus (CMV) promoters, phosphoglycerate kinase (PGK) 1 promoters, ubiquitin (Ubc) promoters, human β-actin promoters, tetracycline response elements (TRE) promoters, spleen focus forming virus (SFFV) promoters, mouse stem cell virus (MSCV) promoters, super core promoters (SCP), CAG promoters or derivatives thereof. In some embodiments, one or more engineered sequences include heterologous enhancer sequences, which are or include CMV early enhancers, cAMP response elements (CRE) enhancers or derivatives thereof. In some embodiments, one or more engineered sequences comprise an inducible transcriptional control element.

[0058] In some embodiments, the insect cells and / or insect cell populations provided comprise more than one engineered sequence (e.g., an identifier, a perturbation, a library variant, a payload, a perturbation additional sequence, a trans-acting integration sequence, and / or a cis-acting integration sequence). In some embodiments, the insect cells and / or insect cell populations provided comprise two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more engineered sequences. In some embodiments, the insect cells comprise up to 100 engineered sequences.

[0059] In some embodiments, the insect cells and / or insect cell populations provided include library constructs comprising one or more engineered sequences, which may include, for example, identifiers, library variants, payloads, perturbation additional sequences, trans-acting integration sequences, and / or cis-acting integration sequences. In some embodiments, the insect cells of the present disclosure include at least one library construct, wherein the at least one library construct includes at least one engineered sequence. In some embodiments, the library construct includes two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more engineered sequences. In some embodiments, the library construct includes up to 100 engineered sequences.

[0060] In some embodiments, provided insect cells and / or insect cell populations produce viral vectors comprising one or more engineered sequences, which can include, for example: an identifier, a perturbation, a payload, and / or a cis-acting integration sequence.

[0061] In some embodiments, the insect cell of the present disclosure comprises at least one library construct comprising at least one engineered sequence selected from the group consisting of at least one barcode, at least one identifier, at least one library variant, at least one payload, at least one cis-acting integration sequence, or a combination thereof and / or a plurality thereof.

[0062] In some embodiments, the insect cell comprises at least one engineered sequence comprising a barcode. In some embodiments, the barcode comprises a sequence of about 5 to about 25 nucleotides. In some embodiments, the provided insect cell comprises a plurality of unique barcodes, and wherein the plurality of unique barcodes comprises a unique sequence of about 5 to about 25 nucleotides.

[0063] In some embodiments, the library construct comprises at least one barcode. In some embodiments, the library construct comprises an identifier comprising at least one barcode. In some embodiments, the library construct comprises an identifier comprising at least one barcode, wherein the barcode is located between two viral repeat sequences. In some embodiments, the barcode is located between two viral repeat sequences and is not an identifier. In some embodiments, the barcode is not located between two viral repeat sequences.

[0064] In some embodiments, the insect cell comprises at least one engineered sequence comprising a library variant. The library variant may include, but is not limited to, an engineered sequence comprising a gene, an ORF, a gRNA sequence, a non-coding nucleic acid, or a combination thereof. In some embodiments, the insect cell comprises one, two, three, four, five, six, seven, eight, nine, or ten library variants. In some embodiments, the insect cell comprises up to 100 library variants.

[0065] In some embodiments, the insect cell comprises a plurality of library variants, wherein the plurality of library variants comprises at least one engineered sequence, the at least one engineered sequence comprising: at least one unique gene, at least one unique ORF, at least one unique gRNA sequence, and / or at least one unique non-coding nucleic acid or a combination and / or multiple thereof. In some embodiments, the insect cell comprises a plurality of library constructs, wherein the plurality of library constructs comprises: at least one unique gene, at least one unique ORF, at least one unique gRNA sequence, at least one unique non-coding nucleic acid sequence or a combination and / or multiple thereof. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises a plurality of unique genes, a plurality of unique ORFs, a plurality of unique gRNA sequences, a plurality of unique non-coding nucleic acid sequences or a combination thereof.

[0066] In some embodiments, the library construct comprises a gRNA sequence. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises at least one unique gRNA sequence. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises at least 100 unique gRNA sequences.

[0067] In some embodiments, the library construct comprises an ORF. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises at least one unique ORF. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises at least 100 unique ORFs.

[0068] In some embodiments, the library construct comprises a gene. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises at least one unique gene. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises at least 100 unique genes.

[0069] In some embodiments, the library construct comprises a non-coding nucleic acid sequence. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein each of the plurality of library constructs comprises at least one unique non-coding nucleic acid sequence. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises at least 100 unique non-coding nucleic acid sequences.

[0070] In some embodiments, the library construct comprises at least one reporter gene and / or a selectable marker. In some embodiments, one or more polynucleotides comprising the library construct comprise a reporter gene and / or a selectable marker.

[0071] In some embodiments, the library construct comprises an identifier. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein the plurality of library constructs comprises a plurality of identifiers. In some embodiments, the identifier comprises at least one barcode and / or at least one library variant. In some embodiments, the insect cell comprises a library construct comprising an identifier, wherein the identifier comprises at least one barcode and / or at least one library variant. In some embodiments, the insect cell population comprises a plurality of library constructs comprising a plurality of identifiers, wherein the identifier comprises a plurality of barcodes and / or a plurality of library variants.

[0072] In some embodiments, the library construct comprises a plurality of engineered sequences, wherein: a first subset of the plurality of engineered sequences is located between two viral repeat sequences, and a second subset of the plurality of engineered sequences is located outside of the two viral repeat sequences.

[0073] In some embodiments, insect cells and / or insect cell populations are provided that comprise a plurality of engineered sequences comprising at least one library variant and at least one identifier, wherein both the at least one library variant and the at least one identifier are located between two viral repeat sequences. In some embodiments, insect cells and / or insect cell populations are provided that comprise a plurality of engineered sequences comprising at least one library variant, at least one identifier, and at least one payload, wherein the at least one library variant, at least one identifier, and at least one payload are located between two viral repeat sequences.

[0074] In some embodiments, insect cells and / or insect cell populations are provided that comprise a plurality of engineered sequences comprising at least one library variant and at least one identifier, and wherein the at least one identifier is located between two viral repeat sequences, and wherein at least one library variant is located outside of two viral repeat sequences. In some embodiments, insect cells and / or insect cell populations are provided that comprise a plurality of engineered sequences comprising at least one library variant, at least one identifier, and at least one payload, wherein the at least one identifier and at least one payload are located between two viral repeat sequences, and wherein the at least one library variant is located outside of two viral repeat sequences.

[0075] In some embodiments, the insect cells and / or insect cell populations provided comprise a plurality of engineered sequences comprising at least two library variants and at least one identifier, wherein the at least one identifier and at least one of the at least two library variants are located between two viral repeat sequences, and wherein at least one of the at least two library variants is located outside of the two viral repeat sequences. In some embodiments, the insect cells provided further comprise a payload located between the two viral repeat sequences.

[0076] In some embodiments, a library construct is provided comprising at least one library variant and at least one identifier, wherein the at least one library variant and the at least one identifier are both located between two viral repeat sequences. In some embodiments, a library construct is provided comprising: at least one library variant, at least one identifier, and at least one payload, wherein the at least one library variant, at least one identifier, and at least one payload are located between two viral repeat sequences.

[0077] In some embodiments, provided library constructs comprise at least one library variant and at least one identifier, and wherein at least one identifier is located between two viral repeat sequences, and wherein at least one library variant is located outside of two viral repeat sequences. In some embodiments, provided library constructs comprise at least one library variant, at least one identifier, and at least one payload, wherein the at least one identifier and at least one payload are located between two viral repeat sequences, and wherein the at least one library variant is located outside of two viral repeat sequences.

[0078] In some embodiments, a library construct is provided that comprises at least two library variants and at least one identifier, wherein the at least one identifier and at least one of the at least two library variants are located between two viral repeat sequences, and wherein at least one of the at least two library variants is located outside of the two viral repeat sequences. In some embodiments, a library construct is provided that further comprises a payload located between the two viral repeat sequences.

[0079] In some embodiments, at least one identifier comprises a barcode. In some embodiments, the insect cells and / or library constructs provided comprise at least one engineered sequence comprising at least one barcode, and wherein the at least one barcode is located between two viral repeat sequences. In some embodiments, the barcode located between two viral repeat sequences is an identifier. In some embodiments, the insect cells and / or library constructs provided comprise at least one engineered sequence comprising at least one barcode, and wherein the at least one barcode is located outside of two viral repeat sequences.

[0080] In some embodiments, the insect cells and / or library constructs provided comprise a plurality of barcodes. In some embodiments, the insect cells and / or library constructs provided comprise a plurality of barcodes, wherein at least one barcode is located between two viral repeat sequences. In some embodiments, the insect cells and / or library constructs provided comprise a plurality of barcodes, wherein a plurality of barcodes are located between two viral repeat sequences. In some embodiments, at least one barcode located between two viral repeat sequences is an identifier. In some embodiments, the insect cells and / or library constructs provided comprise a plurality of barcodes, wherein a first subset of a plurality of barcodes is located between two viral repeat sequences, and a second subset of a plurality of barcodes is located outside two viral repeat sequences.

[0081] In some embodiments, the insect cell provided comprises more than one copy of a library construct or a portion thereof. In some embodiments, the insect cell provided comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more copies of a library construct or a portion thereof. In some embodiments, the insect cell provided comprises multiple copies of a library construct or a portion thereof. In some embodiments, the insect cell provided comprises one to four copies of a library construct or a portion thereof. In some embodiments, the insect cell provided comprises exactly two copies of a library construct or a portion thereof. In some embodiments, the insect cell provided comprises exactly one copy of a library construct or a portion thereof.

[0082] In some embodiments, the insect cell provided comprises at least one library construct consisting of a single continuous nucleic acid sequence. In some embodiments, the insect cell colony provided comprises a plurality of library constructs, wherein each individual library construct consists of a single continuous nucleic acid sequence, and wherein a plurality of library constructs comprises a plurality of unique nucleic acid sequences. In some embodiments, the library construct comprises more than one discontinuous nucleic acid sequence. In some embodiments, the library construct comprises at least two, three, four, five, six, seven, eight, nine or ten discontinuous nucleic acid sequences. In some embodiments, the library construct comprises up to 100 discontinuous nucleic acid sequences.

[0083] In some embodiments, the insect cell population provided comprises a plurality of library constructs, wherein each individual library construct consists of a discontinuous nucleic acid sequence, and wherein the library construct comprises a plurality of unique nucleic acid sequences. In some embodiments, the nucleic acid derived from each individual insect cell or its derivative comprises at least one unique cell identity sequence during the single cell sequencing method. In some embodiments, more than one nucleic acid sequence or its derivative derived from each individual insect cell comprises a cell identity sequence during the single cell sequencing method. In some embodiments, the nucleic acid derived from each individual library construct or its derivative comprises at least one unique cell identity sequence during the single cell sequencing method. In some embodiments, more than one nucleic acid sequence or its derivative derived from each individual library construct comprises a cell identity sequence during the single cell sequencing method.

[0084] In some embodiments, a population of insect cells is provided that comprises a plurality of library constructs, wherein each insect cell comprises a single library construct consisting of a plurality of discontinuous nucleic acid sequences, and wherein the library construct comprises a plurality of unique nucleic acid sequences, and wherein more than one nucleic acid sequence (or derivative thereof) from the library construct comprises a cell identity sequence during a single cell sequencing method. In some embodiments, all nucleic acid sequences (or derivatives thereof) from the library construct comprise a cell identity sequence during a single cell sequencing method.

[0085] In some embodiments, the insect cells and / or viral vectors provided comprise at least one engineered sequence comprising at least one perturbation. In some embodiments, the insect cells provided comprise at least one perturbation present in the insect cell in a free state. In some embodiments, the insect cells provided comprise at least one perturbation present in the genome of the insect cell. In some embodiments, the insect cells provided comprise at least two perturbations, wherein at least one perturbation is present in a free state and at least one perturbation is present in the genome of the insect cell.

[0086] In some embodiments, the viral vector expressed by the insect cell provided herein comprises a perturbation (e.g., one or more perturbations). In some embodiments, the viral vector comprises an engineered sequence comprising a perturbation present in the viral nucleic acid. In some embodiments, the viral vector comprises an engineered sequence comprising a perturbation present in the ITR. In some embodiments, the viral vector comprises an engineered sequence comprising a perturbation present between the ITRs.

[0087] In some embodiments, the one or more polynucleotides necessary to form a viral vector comprise an engineered sequence comprising a perturbation (e.g., one or more perturbations). In some embodiments, the one or more polynucleotides necessary to form a viral vector exist free and comprise an engineered sequence comprising a perturbation (e.g., one or more perturbations). In some embodiments, the one or more polynucleotides necessary to form a viral vector exist in the genome of an insect cell and comprise an engineered sequence comprising a perturbation (e.g., one or more perturbations).

[0088] In some embodiments, provided insect cells and / or viral vectors comprise multiple unique perturbations. In some embodiments, provided insect cells and / or library constructs comprise at least two, three, four, five, six, seven, eight, or nine unique perturbations.

[0089] In some embodiments, provided insect cells and / or viral vectors comprise at least one perturbation, comprising insertion, deletion, substitution, replacement, epigenetic modification and / or rearrangement of an endogenous genomic coding sequence. In some embodiments, the endogenous coding sequence is or comprises an endogenous gene or gene segment.

[0090] In some embodiments, provided insect cells and / or viral vectors comprise at least one perturbation, comprising insertion, deletion, substitution, replacement, epigenetic modification and / or rearrangement of an endogenous genomic regulatory element. In some embodiments, the endogenous regulatory element is or comprises an endogenous promoter sequence and / or an endogenous enhancer sequence.

[0091] In some embodiments, the insect cell provided comprises at least one perturbation additional sequence. In some embodiments, the perturbation additional sequence comprises an RNA-guided nuclease or a derivative thereof. In some embodiments, the RNA-guided nuclease comprises Cas9, Cpf1 and / or CasZ or a derivative thereof, including a fusion protein comprising a transcriptional regulator (e.g., Cas9-VPR or Cas9-KRAB-MeCP2 fusion), a fusion of a CRISPR protein with a nuclease domain (e.g., Fok1), an enzyme base editor (e.g., BE and ABE fusion versions), a reverse transcriptase fusion (e.g., a guide editor), a CRISPR recombinase (e.g., RecCas9) and a CRISPR transposase (e.g., Tn7-like transposase system Cas12k and a cascade complex with TniQ). In some embodiments, the RNA-guided nuclease comprises Cas9 or a derivative thereof.

[0092] The provided library constructs can be introduced into insect cells using any suitable method known in the art. In some embodiments, the library constructs are introduced into insect cells by transfection and / or transduction. In some embodiments, the library constructs are introduced into insect cells by baculovirus-mediated infection. In some embodiments, the library constructs are introduced into insect cells by lentivirus-mediated transduction.

[0093] In some embodiments, insect cells are provided that comprise a library construct, wherein at least one engineered sequence of the library construct is present episomally. In some embodiments, insect cells are provided that comprise a library construct, wherein the library construct comprises at least one engineered sequence comprising at least one library variant, and wherein each individual cell comprises at least one perturbed additional sequence, and wherein at least one engineered sequence is present episomally.

[0094] In some embodiments, the insect cell provided comprises a library construct, wherein at least one engineered sequence of the library construct comprises at least one library variant, and wherein at least one library variant exists in isolation. In some embodiments, at least one library variant is an effector. In some embodiments, at least one library variant becomes at least one perturbation. In some embodiments, at least one library variant comprises at least one ORF, at least one gene, at least one non-coding nucleic acid sequence and / or at least one gRNA, or a plurality thereof.

[0095] In some embodiments, provided insect cells comprise a library construct, wherein the library construct comprises at least one engineered sequence comprising at least one library variant, the at least one library variant comprising at least one gRNA, and wherein each individual cell comprises at least one perturbed additional sequence comprising an RNA-guided nuclease or a non-RNA-guided nuclease or a derivative thereof, and wherein at least one engineered sequence is present episomally.

[0096] In some embodiments, provided insect cells comprise a library construct, wherein the library construct comprises at least one engineered sequence comprising at least one library variant, wherein the at least one library variant comprises at least one gRNA, wherein each individual cell comprises at least one perturbed additional sequence, wherein the perturbed additional sequence comprises an RNA-guided nuclease or a non-RNA-guided nuclease or a derivative thereof, and wherein at least one engineered sequence is present episomally.

[0097] In some embodiments, the insect cells and / or insect cell populations provided include at least one perturbation. In some embodiments, the insect cells and / or insect cell populations provided include at least one perturbation, the at least one perturbation including a genomic sequence change, an episomal sequence change, and / or an epigenetic modification. In some embodiments, the insect cells and / or insect cell populations provided include at least one perturbation, the at least one perturbation including an insertion, deletion, substitution, and / or rearrangement of an endogenous genomic coding sequence.

[0098] In some embodiments, provided insect cells and / or insect cell populations produce viral vectors that individually comprise at least one perturbation.

[0099] In some embodiments, provided insect cells comprise a library construct, wherein at least one engineered sequence of the library construct is present in the genome of the insect cell. In some embodiments, provided insect cells comprise a library construct, wherein the library construct comprises at least one engineered sequence comprising at least one library variant, and wherein each individual cell comprises at least one perturbed additional sequence, and wherein at least one engineered sequence is present in the genome of the insect cell.

[0100] In some embodiments, the library construct or a portion thereof is inserted into the genome of the insect cell at a random insertion site. In some embodiments, the random insertion site is random within a predetermined subset of genomic locations. In some embodiments, the library construct or a portion thereof is inserted into the genome of the insect cell at a predetermined insertion site.

[0101] In some embodiments, provided insect cells and / or library constructs comprise at least one trans-acting integration sequence, wherein the at least one trans-acting integration sequence comprises (i) at least one integration construct, (ii) at least one recombinase, and / or its polypeptide, protein, nucleic acid, or polynucleotide product, (iii) at least one nuclease, and / or its polypeptide, protein, nucleic acid, or polynucleotide product, (iv) at least one transposase, and / or its polypeptide, protein, nucleic acid, or polynucleotide product, and / or (v) at least one engineered sequence.

[0102] In some embodiments, provided insect cells and / or library constructs comprise at least one trans-acting integration sequence, the trans-acting integration sequence comprising an integration construct. In some embodiments, provided insect cells and / or library constructs comprise at least one pair of cis-acting integration sequences flanking a first set of viral repeat sequences, wherein the cis-acting integration sequences comprise a second set of viral repeat sequences. In some embodiments, the integration construct is an insect viral vector or a derivative thereof.

[0103] In some embodiments, provided insect cells and / or library constructs comprise a first set of viral repeat sequences (eg, for packaging sequences into a viral vector target) and a cis-acting integration sequence comprising a second set of viral repeat sequences.

[0104] In some embodiments, provided insect cells and / or library constructs comprise at least one trans-acting integration sequence comprising a nuclease and / or a polypeptide, protein, nucleic acid, or polynucleotide product thereof.

[0105] In some embodiments, at least one trans-acting integration sequence comprises at least one nuclease, and wherein the at least one nuclease comprises an RNA-guided nuclease or a fusion or derivative thereof. In some embodiments, at least one trans-acting integration sequence comprises at least one nuclease, and wherein the at least one nuclease comprises a non-RNA-guided nuclease or a fusion or derivative thereof. In some embodiments, at least one nuclease comprises Cas9, CasZ, Cpf1, an engineered Fok1 nuclease domain fused to a programmable DNA binding domain such as a TALE protein (TALEN) or a zinc finger protein (ZFN), and / or a large range of nucleases or derivatives thereof. In some embodiments, at least one nuclease comprises Cas9.

[0106] In some embodiments, at least one trans-acting integration sequence further comprises at least one engineered sequence. In some embodiments, at least one trans-acting integration sequence comprises an RNA-guided nuclease or a fusion or derivative thereof, and further comprises at least one gRNA.

[0107] In some embodiments, provided insect cells and / or library constructs comprise at least one pair of cis-acting integration sequences flanking a first set of viral repeat sequences, and wherein the cis-acting integration sequences comprise homology arm sequences.

[0108] In some embodiments, at least one trans-acting integration sequence comprises a recombinase and / or its polypeptide, protein, nucleic acid or polynucleotide product. In some embodiments, provided insect cells and / or library constructs comprise at least one pair of cis-acting integration sequences flanking a first set of viral repeat sequences, and wherein the cis-acting integration sequence comprises a recombinase recognition site. In some embodiments, the recombinase comprises Cre, Flp, Dre, PhiC31 and / or Bxb1, or a derivative thereof.

[0109] In some embodiments, the recombinase comprises a recombinase comprising Cre. In some embodiments, the recombinase recognition site comprises a LoxP site.

[0110] In some embodiments, the recombinase comprises a recombinase comprising Bxb1. In some embodiments, the recombinase recognition site comprises an Att site.

[0111] In some embodiments, the recombinase comprises a recombinase comprising Flp. In some embodiments, the recombinase recognition site comprises a Frt site.

[0112] In some embodiments, at least one trans-acting integration sequence comprises a transposase and / or a polypeptide, protein, nucleic acid or polynucleotide product thereof. In some embodiments, the insect cells and / or library constructs provided comprise at least one pair of cis-acting integration sequences flanking the first group of viral repeat sequences, and wherein the cis-acting integration sequence comprises a transposase recognition site. In some embodiments, the transposase comprises a Piggybac transposase, a Sleeping Beauty transposase and / or a Tn5 transposase or a derivative thereof. In some specific embodiments, the transposase comprises a Piggybac transposase or a derivative thereof. In some specific embodiments, the transposase comprises a Sleeping Beauty transposase or a derivative thereof. In some specific embodiments, the transposase comprises a Tn5 transposase or a derivative thereof.

[0113] In some embodiments, the insect cell population produces an altered viral vector relative to a reference population. In some embodiments, the provided insect cells and / or insect cell populations produce an altered viral vector in the manner in which nucleic acid is transferred to cells relative to a reference population. In some embodiments, the provided insect cells and / or insect cell populations produce an altered viral vector in therapy relative to a reference population. In some embodiments, the provided insect cells and / or insect cell populations produce an altered viral vector in intended application relative to a reference population.

[0114] In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are less functional in an application relative to a reference population. In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are not functional in an application relative to a reference population. In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are less functional and / or nonfunctional in transferring nucleic acids to cells relative to a reference population. In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are less functional and / or nonfunctional in therapy relative to a reference population. In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are less functional and / or nonfunctional in intended applications relative to a reference population.

[0115] In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are more functional and / or enhanced in applications relative to a reference population. In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are more functional and / or enhanced in transferring nucleic acids to cells relative to a reference population. In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are more functional and / or enhanced in therapy relative to a reference population. In some embodiments, the insect cells and / or insect cell populations provided produce viral vectors that are more functional and / or enhanced in intended applications relative to a reference population.

[0116] In some embodiments, the insect cells and / or insect cell populations provided comprise at least one engineered sequence (e.g., perturbation) that alters viral vector production under production specifications relative to a reference cell population. In some embodiments, the insect cells and / or insect cell populations provided comprise at least one engineered sequence (e.g., perturbation) that provides increased viral vector production under production specifications relative to a reference cell population. In some embodiments, the insect cells with altered viral vector production comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 or more perturbations relative to a reference cell population.

[0117] In some embodiments, the insect cells and / or insect cell populations provided comprise at least one engineered sequence (e.g., perturbation) that provides increased viral vector production under then current good manufacturing practices (cGMP). In some embodiments, at least one engineered sequence (e.g., perturbation) provides increased viral vector production under good manufacturing practices (GMP). In some embodiments, the insect cells and / or insect cell populations provided comprise at least one engineered sequence (e.g., perturbation) that provides increased viral vector production under non-good manufacturing practices (non-GMP).

[0118] In some embodiments, the provided insect cells and / or insect cell populations comprise at least one engineered sequence (e.g., perturbation) that provides increased insect cell population viability relative to a reference cell population. In some embodiments, the provided insect cells and / or insect cell populations comprise at least one perturbation that provides increased duration of insect cell population production of viral vectors relative to a reference cell population. In some embodiments, the provided insect cells and / or insect cell populations comprise at least one engineered sequence (e.g., perturbation) that provides increased genomic stability of the insect cell population relative to a reference cell population.

[0119] In some embodiments, the insect cells and / or insect cell populations provided comprise at least one engineered sequence (e.g., perturbation) that provides a reduced percentage of viral vectors produced under production specifications relative to a reference cell population, and the viral vectors are less functional in applications. In some embodiments, the insect cells and / or insect cell populations provided comprise at least one perturbation that provides a reduced percentage of viral vectors produced under production specifications relative to a reference cell population, and the viral vectors are non-functional in applications. In some embodiments, the viral vectors with a reduced percentage are less functional and / or non-functional in transferring nucleic acids to cells relative to a reference cell population. In some embodiments, the viral vectors with a reduced percentage are less functional and / or non-functional in treatment relative to a reference cell population. In some embodiments, the viral vectors with a reduced percentage are less functional and / or non-functional in intended applications relative to a reference cell population.

[0120] In some embodiments, the insect cells and / or insect cell populations provided comprise at least one engineered sequence (e.g., perturbation) that provides an increased percentage of viral vectors produced under production specifications relative to a reference cell population, and the viral vectors are more functional or enhanced in applications. In some embodiments, the viral vectors with an increased percentage are more functional and / or enhanced in transferring nucleic acids to cells relative to a reference cell population. In some embodiments, the viral vectors with an increased percentage are more functional and / or enhanced in treatment relative to a reference cell population. In some embodiments, the viral vectors with an increased percentage are more functional and / or enhanced in intended applications relative to a reference cell population.

[0121] In some embodiments, at least one engineered sequence (e.g., perturbation) provides, under production specifications, an increased percentage of viral vectors that contain all and / or necessary nucleic acid sequences and / or other elements for their intended application, relative to a reference cell population.

[0122] In some embodiments, at least one engineered sequence (e.g., perturbation) provides, under production specifications, a reduced percentage of viral vectors that have lost, and / or mutated, all and / or essential nucleic acid sequences and / or other elements for their intended application, relative to a reference cell population.

[0123] In some embodiments, provided insect cells and / or insect cell populations and / or viral vectors comprise a plurality of engineered sequences, wherein the plurality of engineered sequences comprises a plurality of perturbations.

[0124] In some embodiments, the reference cell population is: (a) a comparable insect cell population that does not comprise the at least one engineered sequence; and / or (b) a standard cell population that is capable of producing a viral vector.

[0125] In some embodiments, the viral vector produced by the insect cells described herein comprises an engineered sequence (e.g., a perturbation) that alters viral vector production under production specifications relative to a reference cell population. In some embodiments, the viral vector comprises a perturbation that alters function (e.g., therapeutic function, ability to transfer nucleic acid to cells), genomic stability, insect cell production yield, insect cell production duration, percentage of viral vectors produced containing all necessary nucleic acid sequences, and / or another feature related to viral vector production, viral vector activity, and / or viral vector application.

[0126] In some embodiments, the population of insect cells is generated by: (a) introducing a plurality of library constructs comprising a plurality of engineered sequences into a plurality of insect cells, wherein an individual library construct comprises at least one identifier located between a first set of two viral repeat sequences, and (b) introducing at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector into the plurality of insect cells.

[0127] In some embodiments, the population of insect cells is produced by introducing a plurality of library constructs comprising a plurality of engineered sequences into a plurality of insect cells, wherein an individual library construct comprises at least one identifier positioned between a first set of two viral repeat sequences, and wherein the plurality of insect cells comprises one or more nucleic acid sequences necessary for production of a viral vector.

[0128] In some embodiments, a method of producing a viral vector is provided, comprising: culturing a population of insect cells of the present disclosure under conditions such that the insect cells produce the viral vector, and wherein each produced viral vector comprises at least one identifier derived from at least one identifier of the insect cell that produced the viral vector. In some embodiments, each produced viral vector comprises at least one identifier that is identical to at least one identifier of the insect cell that produced the viral vector.

[0129] In some embodiments, provided methods include: (a) generating a viral vector from an insect cell library, wherein the insect cell library comprises a plurality of insect cells, wherein each insect cell in the plurality individually comprises: (i) at least one engineered sequence, (ii) an identifier, and (iii) at least one polynucleotide comprising one or more nucleic acid sequences necessary to generate the viral vector, and wherein each viral vector comprises an identifier derived from an identifier of the insect cell that generated the viral vector; and (b) detecting the identifier in the viral vector. In some embodiments, each viral vector comprises an identifier that is the same as the identifier of the insect cell that generated the viral vector.

[0130] In some embodiments, provided methods include: (a) generating a viral vector from an insect cell library, wherein the insect cell library comprises a plurality of insect cells, wherein each insect cell in the plurality individually comprises: (i) at least one engineered sequence, (ii) at least one identifier, and (iii) at least one polynucleotide comprising one or more nucleic acid sequences necessary to generate the viral vector, and wherein each viral vector comprises at least one identifier derived from at least one identifier of the insect cell that produced the viral vector; and (b) detecting the one or more identifiers in the viral vector by next generation sequencing. In some embodiments, each viral vector comprises at least one identifier that is identical to at least one identifier of the insect cell that produced the viral vector.

[0131] In some embodiments, provided methods include: (a) generating an AAV library, wherein the AAV library comprises a plurality of AAV vectors from an insect cell library, wherein the insect cell library comprises a plurality of insect cells, wherein each insect cell in the plurality individually comprises: (i) at least one engineered sequence, (ii) at least one barcode sequence, and (iii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein each AAV viral vector comprises at least one construct, and wherein at least one construct comprises a barcode sequence derived from at least one barcode sequence of an insect cell producing the AAV viral vector; and (b) detecting one or more barcode sequences in the AAV library. In some embodiments, each AAV viral vector comprises at least one construct, and wherein at least one construct comprises a barcode sequence identical to at least one barcode sequence of an insect cell producing the AAV viral vector.

[0132] In some embodiments, provided methods include: (a) generating an AAV library, wherein the AAV library comprises a plurality of constructs from an insect cell library, wherein the insect cell library comprises a plurality of insect cells, wherein each of the plurality of insect cells individually comprises: (i) at least one engineered sequence, (ii) at least one barcode sequence, and (iii) at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector, wherein each AAV viral vector comprises at least one construct, and wherein the at least one construct comprises a barcode sequence derived from at least one barcode sequence of an insect cell producing the AAV viral vector; and (b) detecting one or more barcode sequences in the AAV library by next generation sequencing. In some embodiments, each AAV viral vector comprises at least one construct, and wherein at least one construct comprises a barcode sequence identical to at least one barcode sequence of an insect cell producing the AAV viral vector. In some embodiments, the provided methods further comprise the step of performing single-cell sequencing on at least one or all nucleic acid sequences or derivatives thereof within each individual cell of the insect cell library, wherein at least one or all nucleic acid sequences or derivatives thereof comprise a single-cell identity sequence during the single-cell sequencing method, and wherein at least one or all nucleic acid sequences or derivatives thereof comprise at least one library construct.

[0133] In some embodiments, the methods provided by the present disclosure further comprise performing single-cell sequencing on at least one or all nucleic acid sequences or derivatives thereof within each individual cell of the insect cell library, wherein at least one or all nucleic acid sequences or derivatives thereof comprise a single-cell identity sequence during the single-cell sequencing method, and wherein at least one or all nucleic acid sequences or derivatives thereof comprise at least one library variant comprising at least one identifier.

[0134] In some embodiments, the method provided by the present disclosure also includes introducing a second library construct into an insect cell, wherein the insect cell comprises at least one perturbation derived from the first library construct, and wherein the second library construct comprises at least one engineered sequence comprising at least one identifier located between two viral repeat sequences of the first group. In some embodiments, a second plurality of library constructs are introduced into a plurality of insect cells, wherein the plurality of insect cells comprise at least one perturbation derived from the first plurality of library constructs, and wherein the second plurality of library constructs comprise a plurality of engineered sequences, wherein each individual library construct in the second plurality of library constructs comprises at least one identifier located between two viral repeat sequences of the first group. In some embodiments, the method provided also includes detecting one or more identifiers and / or one or more engineered sequences by single cell sequencing and / or next generation sequencing. In some embodiments, the method provided includes more than two rounds of library construct introduction and detection of one or more identifiers and / or one or more engineered sequences. In some embodiments, the method provided also includes using a machine learning method to develop a machine learning model to identify the desired combination of target perturbations.

[0135] In some embodiments, the methods provided by the present disclosure further include the step of removing at least one identifier of the insect cell. In some embodiments, where the provided insect cells and / or library constructs comprise a reporter gene and / or a selection marker, the methods provided may include the step of removing the reporter gene and / or the selection marker.

[0136] Throughout the specification, where a system or composition is described as having, including, or comprising particular components, or where a method is described as having, including, or comprising particular steps, it is contemplated that there are additionally systems or compositions of the invention consisting essentially of or consisting of the described components, and there are methods of the invention consisting essentially of or consisting of the described steps.

[0137] It should be understood that the order of steps or the order in which certain actions are performed is not important, as long as the present invention remains operable. In addition, two or more steps or actions can be performed simultaneously.

[0138] The following description is intended to illustrate and exemplify the present disclosure only and is not intended to limit the invention to the particular embodiments described. BRIEF DESCRIPTION OF THE DRAWINGS

[0139] The drawings included herein consist of the following figures and are for illustration purposes only and are not intended to be limiting.

[0140] Figure 1A schematic diagram depicting a technology platform for identifying or characterizing viral vector production from insect cells in a library, wherein the viral vectors acquire identifiers associated with the insect cells in which they are expressed.

[0141] Figure 2 An exemplary scheme for generating an insect cell library expressing an AAV viral vector comprising an identifier is depicted.

[0142] Figure 3 Depicted is an exemplary protocol for identifying and / or characterizing viral vector production by insect cells in a library by determining the relative enrichment of identifiers in the viral vector pool and identifying engineered sequences in insect cells using a single-cell sequencing approach.

[0143] Figure 4 Schematic diagram depicting exemplary library constructs for methods of generating insect cell libraries expressing AAV viral vectors. pSFX-AAV is an exemplary AAV construct for episomal expression, while pSFX-PB-AAV is an exemplary AAV-in-Transposase library construct.

[0144] Figure 5 An exemplary schematic overview of sequencing a viral vector nucleic acid (eg, an identifier (eg, barcode) sequence from a viral vector (eg, an AAV viral vector) or cellular genomic DNA) is depicted.

[0145] Figure 6 Depicted is an exemplary scheme for generating an insect cell library expressing AAV viral vectors using a library of AAV-in-BAC constructs containing identifiers.

[0146] Figure 7 Depicted is an exemplary scheme for generating an insect cell library expressing AAV viral vectors using a library of AAV-in-Transposase constructs containing identifiers.

[0147] Figure 8 Depicted is an exemplary scheme for generating an insect cell library expressing an AAV viral vector using a library of episomal constructs containing an identifier.

[0148] Some definitions

[0149] In order to make it easier to understand the present invention, some terms are first defined below. Additional definitions of the following terms and other terms are set forth throughout the specification. Publications and other reference materials cited herein to describe the background of the present invention and to provide additional details about its practice are hereby incorporated by reference.

[0150] In this application, unless the context clearly indicates otherwise, (i) the terms "a" and "an" are used herein to refer to one or more than one (i.e., to at least one) of the grammatical objects of the article; (ii) the term "or" may be understood to mean "and / or"; (iii) the terms "comprising" and "including" may be understood to cover the listed components or steps, whether presented by themselves or together with one or more additional components or steps; and (iv) where a range is provided, the endpoints are included.

[0151] Throughout the specification, whenever a polynucleotide or polypeptide is represented by a letter sequence (e.g., A, C, G and T, representing adenosine, cytidine, guanosine and thymidine, respectively, in the case of a polynucleotide), such polynucleotide or polypeptide is presented in order from left to right, 5' to 3' or N-terminus to C-terminus.

[0152] About or approximately: As used herein, the term "about" or "approximately" can be applied to one or more values ​​of interest, including values ​​similar to the stated reference values. Generally speaking, those skilled in the art who are familiar with the context will understand the relevant degree of difference covered by "about" or "approximately" in the context. In some embodiments, the term "about" or "approximately" refers to a value range falling within ± 20% (greater than or less than) of a specified reference value, unless otherwise specified or otherwise apparent from the context. For example, in some embodiments, the term "about" or "approximately" can be included in a value range within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of a reference value.

[0153] Amino Acid: As used herein, the term "amino acid" refers to any compound and / or substance that can be incorporated into a polypeptide chain, for example, by forming one or more peptide bonds. In some embodiments, an amino acid has a general structure, for example, H2N-C(H)(R)-COOH. In some embodiments, the amino acid is a naturally occurring amino acid. In some embodiments, the amino acid is a non-natural amino acid; in some embodiments, the amino acid is a D-amino acid; in some embodiments, the amino acid is an L-amino acid. "Standard amino acid" refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. "Non-standard amino acid" refers to any amino acid other than the standard amino acids, whether prepared synthetically or obtained from a natural source. As will be clear from the context, in some embodiments, the term "amino acid" may be used to refer to a free amino acid; in some embodiments, it may be used to refer to an amino acid residue of a polypeptide.

[0154] Related to: As used herein, if the presence, level and / or form of one event or entity is related, associated or associated with the presence, level and / or form of another event or entity, the phrase "related to" describes the two events or entities. For example, if the presence and / or level of a first entity (e.g., an identifier) ​​is associated with the presence and / or level of a second entity (e.g., an engineered sequence) (e.g., in an insect cell, e.g., by cell division and / or genetic manipulation), the first entity is considered to be associated with the second entity. In some embodiments, if two or more entities are present in the same cell, genome, chromosome or genetic region (e.g., such that they are inherited together through multiple generations of insect cell divisions), they are physically "associated" with each other. In some embodiments, if the presence, level and / or form of a particular entity (e.g., an identifier and / or an engineered sequence) is associated with, for example, the level or penetrance of a change in a particular phenotype (e.g., cell production of a viral vector) (e.g., the entity exhibits cells that increase viral vector production), the entity is considered to be associated with the phenotype. In some embodiments, two or more entities are physically associated with each other, interact directly or indirectly, so that they are physically close to each other and / or remain in physical proximity to each other. In some embodiments, two or more entities that are physically associated with each other are covalently attached to each other; in some embodiments, two or more entities that are physically associated with each other are not covalently attached to each other, but are non-covalently associated, such as by hydrogen bonds, van der Waals interactions, hydrophobic interactions, magnetism, and combinations thereof.

[0155] Barcode: As used herein, the term "barcode" refers to any molecular feature (e.g., nucleic acid sequence) that is capable of substantially distinguishing an entity (e.g., molecule, nucleic acid, virus, cell, etc.) or a combination of entities in a larger heterogeneous group of entities. In some embodiments, a barcode is an engineered sequence. In some embodiments, a barcode is an engineered nucleic acid sequence. In some embodiments, a barcode is part of a library construct. In some embodiments, a library construct may include more than one barcode. In the case where a library construct includes one or more barcodes, the one or more barcodes may be included in (i) an identifier, (ii) outside the identifier, or (iii) inside and outside the identifier. In some embodiments, one or more barcodes indicate the identity of one or more library variants that are not directly detected (e.g., by a next-generation sequencing method) when detected (e.g., by a next-generation sequencing method). In some embodiments, a barcode may include a nucleic acid sequence from a known nucleic acid sequence pool. In some embodiments, a barcode is an exogenous nucleic acid sequence. In some embodiments, a barcode is an endogenous nucleic acid sequence. In some embodiments, the barcode may include an exogenous sequence and an endogenous sequence. Typically, the barcode includes a sequence with a length in the range of 3 nucleotides to 50 nucleotides. For example, in some embodiments, the barcode includes a sequence with a length in the range defined by a lower limit and an upper limit (the upper limit is greater than the lower limit). In some embodiments, the lower limit may be about 5 nucleotides, about 6 nucleotides, about 7 nucleotides, about 8 nucleotides, about 9 nucleotides, about 10 nucleotides, about 11 nucleotides, about 12 nucleotides, about 13 nucleotides, about 14 nucleotides, or about 15 nucleotides. In some embodiments, the upper limit may be about 10 nucleotides, about 15 nucleotides, about 20 nucleotides, about 25 nucleotides, about 30 nucleotides, about 35 nucleotides, about 40 nucleotides, about 45 nucleotides, or about 50 nucleotides. In some specific embodiments, the barcode includes a sequence with a length in the range of 5 nucleotides to 25 nucleotides. In some specific embodiments, the barcode comprises a sequence that is about 5 nucleotides, about 10 nucleotides, about 15 nucleotides, about 20 nucleotides, or about 25 nucleotides in length.

[0156] Biologics: As used herein, the term "biologics" in its broadest sense refers to products made from or derived from living organisms (e.g., manufactured in a living system). According to the present disclosure, biologics include, but are not limited to, proteins, polypeptides, nucleic acids, polynucleotides, viruses, viral vectors, therapeutic serums, toxins, antitoxins, vaccines, allergen extracts, blood components or derivatives, gene therapy products, human tissues, or cell products. In some embodiments, biologics are or contain polypeptide-based molecules that can be used to treat, cure, alleviate, prevent, or diagnose serious or life-threatening diseases or medical conditions. In some embodiments, biologics are therapeutic biologics. Therapeutic biologics are those that can be used to prevent, treat, or cure diseases or conditions (e.g., in mammals, e.g., in humans). In some embodiments, biologics are diagnostic biologics. In some embodiments, biologics are used to manufacture (e.g., manufacture gene therapy products or cell therapy products). In some specific embodiments, biologics are viral vectors.

[0157] Cell Identity Sequence: as used herein, refers to a nucleic acid sequence used to tag all nucleic acids from a particular insect cell to be sequenced as part of a single cell sequencing method. The present disclosure encompasses the recognition that single cell sequencing using a cell identity sequence can be used in methods where a library construct comprises multiple discontinuous nucleic acid sequences. In such methods, a given cell identity sequence can provide an association of all identifiers and / or library variants present in the same cell. An exemplary schematic of a method using a discontinuous library construct and single cell sequencing is depicted in Figure 3 . However, the present disclosure also encompasses the recognition that single-cell sequencing using cell identity sequences can also be used in some embodiments for methods where the library construct comprises a single contiguous nucleic acid sequence. The present disclosure also encompasses the recognition that during single-cell sequencing methods, single-cell identity sequences are specifically appended during reverse transcription of expressed RNA. It should be understood that constructs or nucleic acids intended for single-cell sequencing should be contained in the expressed RNA so that all transcripts can be single-cell labeled with the cell identity sequence using appropriate primers during the reverse transcription step.

[0158] Cis-acting integration sequence: As used herein, the phrase "cis-acting integration sequence" with respect to a library construct refers to a nucleic acid sequence on the library construct itself that promotes integration into a cell genome (e.g., an insect cell genome) through one or more trans-acting integration sequences and / or its polypeptide, protein, nucleic acid, or polynucleotide product. In some embodiments, the cis-acting integration sequence is contained in the library construct and flanks a portion of the library construct to be integrated into the cell genome. In some embodiments, the cis-acting integration sequence comprises homology arms, recognition sites, and / or viral repeat sequences.

[0159] Comparable: As used herein, the term "comparable" refers to two or more agents, entities, situations, condition sets, subjects, groups, etc., which may not be identical to each other, but are similar enough to allow comparison between them, so that those skilled in the art will understand that it is possible to reasonably draw conclusions based on the observed differences or similarities. In some embodiments, the set of comparable agents, entities, situations, condition sets, subjects, groups, etc. are characterized by a plurality of substantially identical features and one or a small amount of different features. Those of ordinary skill in the art will understand that in the context, in any given case, what degree of identity is required for two or more such agents, entities, situations, condition sets, subjects, groups, etc. to be considered comparable. For example, those of ordinary skill in the art will understand that when the set of agents, entities, situations, condition sets, subjects, groups, etc. are characterized by the following, they are comparable to each other: a sufficient number and type of substantially identical features to ensure that the following reasonable conclusions are drawn: the differences in the results or observed phenomena obtained under different environmental sets, stimuli, agents, entities, situations, condition sets, subjects, groups, etc. are caused by changes in those different features or indicate changes in those different features.

[0160] Complementary: As used herein, the term "complementary" refers to nucleotides or nucleotide sequences that perform base pairing according to the standard Watson-Crick complementary rules (adenine "A" base pairs with thymine "T", and guanine "G" base pairs with cytosine "C"). "100% complementary" nucleotide sequences or nucleotide sequences that exhibit "100% complementarity" are nucleotide sequences that base pair with each other in the entirety of at least one of the two nucleotide sequences. An oligonucleotide can be "100% complementary" to a template polynucleotide that is longer than the oligonucleotide (i.e., if the entire sequence of the oligonucleotide is base paired with a portion of the template polynucleotide, the oligonucleotide is "100% complementary" to the template polynucleotide). However, "complementary" nucleic acid sequences do not have to be 100% complementary. Generally, the term "complementary" with respect to two or more nucleic acid sequences refers to sufficient complementarity between the two nucleic acid sequences so that they hybridize under stringent conditions and / or at the temperature used during the annealing phase of an amplification method (e.g., PCR or LCR).

[0161] Construct: As used herein, the term "construct" refers to an entity capable of carrying at least one polynucleotide. In some embodiments, the construct can be a plasmid, a transposon, a cosmid or an artificial chromosome (e.g., a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a bacterial artificial chromosome or a P1 derived artificial chromosome (PAC)). In some embodiments, the construct facilitates the transfer of polynucleotides to a cell. Certain constructs can replicate autonomously in the host cell into which they are introduced (e.g., a plasmid with a replication origin). Other constructs can be integrated into the genome of the host cell, thereby replicating with the host genome. In some embodiments, a construct encoding one or more elements of a viral vector is provided. For example, in some embodiments, a plasmid encoding one or more elements of a viral vector for expression in insect cells is provided. In some embodiments, a construct encoding one or more elements of a viral vector is provided. In some embodiments, a construct is a viral vector.

[0162] Control: As used herein, the term "control" refers to the meaning of the art understanding of "control", which is a standard for comparing with the result. Generally, the control is used to enhance the integrity of the experiment by separating variables so as to draw conclusions about such variables. In some embodiments, the control is a reaction or determination carried out simultaneously with the test reaction or determination to provide a comparator. For example, in one experiment, a "test" (i.e., the variable tested) was applied. In a second experiment, a "control" was applied and the variable tested was not applied. In some embodiments, the control is a historical control (e.g., a historical control of a previously performed test or determination, or a previously known amount or result). In some embodiments, the control is or includes a printed or otherwise preserved record. In some embodiments, the control is a positive control. In some embodiments, the control is a negative control.

[0163] Corresponding to: As used herein, in the context of polypeptides and nucleic acids, the term "corresponding to" specifies the position / identity of an amino acid residue or nucleotide residue, respectively, by comparison with an appropriate reference polypeptide or nucleic acid sequence. For example, in some embodiments, a monomer residue in a polymer (e.g., an amino acid residue in a polypeptide or a nucleic acid residue in a polynucleotide) can be identified as a residue "corresponding to" an appropriate reference polymer. For example, one of ordinary skill in the art will understand that, for simplicity purposes, a canonical numbering system based on a reference to a related polypeptide is often used to designate residues in a polypeptide, such that an amino acid "corresponding to" a residue at position 190, for example, does not actually have to be the 190th amino acid in a particular amino acid chain, but rather corresponds to the residue found at position 190 in a reference polypeptide; one of ordinary skill in the art readily understands how to identify a "corresponding" amino acid (see, e.g., Benson et al. Nucl. Acids Res. (Jan. 1, 2013) 41(D1):D36-D42; Pearson et al. PNAS Vol. 85, pp. 2444-2448, April 1988). Those skilled in the art will be aware of a variety of sequence alignment strategies, including software programs (eg, BLAST, FASTA, etc.) that can be used, for example, to identify "corresponding" residues in polypeptides and / or nucleic acids according to the present disclosure.

[0164] Endogenous: As used herein, the term "endogenous" refers to anything that is present in its natural environment. With respect to nucleic acids, "endogenous" may, for example, refer to a nucleic acid or sequence thereof that originates from the interior of a cell. For example, an endogenous nucleic acid sequence is a nucleic acid sequence that is naturally present in the genome of an insect cell without human manipulation (e.g., in its natural location and under the control of a native expression element).

[0165] Engineered: As used herein, the term "engineered" refers to aspects that have been artificially manipulated. In the context of nucleic acids, engineering can include any type of modification that can be performed on nucleic acids. In some embodiments, when a sequence has been artificially manipulated to produce a sequence that does not exist in a natural environment, for example, including deletion, insertion, substitution, replacement, rearrangement and / or fusion to a second sequence, a polynucleotide can be considered to be "engineered". For example, an engineered polynucleotide can include two or more sequences that are not linked together in this order in nature, but because they are artificially manipulated to be directly connected to each other in an engineered polynucleotide. Similarly, if a cell or organism has been manipulated so that its genetic information changes (for example, a previously non-existent new genetic material has been introduced, for example, by transformation, pairing, somatic cell hybridization, transfection, transduction or other mechanisms, or a previously existing genetic material is, for example, changed or removed by substitution or deletion mutation or by a pairing scheme), then it is considered that a cell or organism is "engineered". In some embodiments, engineered cells (e.g., engineered insect cells) refer to cells that have been operated so that their heredity, epigenetic and / or phenotypic characteristics are changed relative to appropriate reference cells (such as other identical cells that have not been so operated). In some embodiments, operation is or includes genetic manipulation. In some embodiments, engineered cells are cells that have been operated so that they contain and / or express the amount of change and / or the specific agent (e.g., protein, nucleic acid and / or its specific form) of the attention of the timing of changes relative to such appropriate reference cells. As usual and understood by those skilled in the art, the offspring of engineered polynucleotides or cells are typically still referred to as "engineered", even if the actual operation is performed on a previous entity.

[0166] Engineered sequence: As used herein, the phrase "engineered sequence" refers to a sequence (e.g., a sequence of nucleotides) that has been artificially manipulated. In some embodiments, an engineered sequence is an engineered nucleic acid sequence. In some embodiments, an engineered nucleic acid sequence may include a sequence read in the 5' to 3' direction and / or the 3' to 5' direction. An engineered nucleic acid sequence may include any type of modification (e.g., introduction, substitution, deletion, replacement, rearrangement, epigenetic modification, etc.) that may be performed on a nucleic acid. In some embodiments, an engineered sequence is or includes a genetic modification of an insect cell genome sequence. In some embodiments, an engineered sequence is or includes an epigenetic modification of an insect cell genome DNA. In some embodiments, an engineered sequence is or includes a free sequence (e.g., introducing or modifying a sequence that is free and present in a cell). In some embodiments, an engineered sequence is or includes a free sequence with one or more epigenetic features. In some embodiments, an engineered sequence is or includes an identifier. In some embodiments, an engineered sequence is or includes a polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector. In some embodiments, an engineered sequence is or includes a disturbance. In some embodiments, the engineered sequence is or includes a library variant. In some embodiments, the engineered sequence is or includes a payload. In some embodiments, the engineered sequence is or includes a perturbation additional sequence. In some embodiments, the engineered sequence is or includes a trans-acting integration sequence. In some embodiments, the engineered sequence is or includes a cis-acting integration sequence. In some embodiments, the engineered sequence is or includes a library construct. In some embodiments, the engineered sequence is or includes a barcode.

[0167] Episome: As used herein, the term "episome" refers to extrachromosomal genetic material that can replicate autonomously. In some embodiments, the episome genetic material (e.g., DNA) can be in the context of a plasmid, a cosmid, a fosmid, an artificial chromosome (e.g., a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a bacterial artificial chromosome, or a P1-derived artificial chromosome (PAC)) or a viral vector (e.g., a baculovirus vector).

[0168] Exogenous: As used herein, the term "exogenous" refers to any entity that is introduced or has been introduced into an organism or cell. For example, an "exogenous nucleic acid" is a nucleic acid derived from outside an organism or cell. In some embodiments, the exogenous nucleic acid in an insect cell has been introduced through the cell membrane (e.g., by artificial means). In some embodiments, the exogenous nucleic acid may be or include a nucleotide sequence present in a natural genome in a non-natural environment (e.g., at a different location and / or under the control of a non-natural expression element). In some embodiments, the exogenous nucleic acid may be or include a nucleotide sequence that was not previously present in the genome of an organism or cell (e.g., from a different organism). Exogenous nucleic acids include exogenous genes. "Exogenous genes" are nucleic acids or sequences thereof that have been introduced into an organism or cell (e.g., by transformation / transfection) that encode the expression of RNA and / or protein, and are also referred to herein as "transgenics."

[0169] Extrachromosomal: As used herein, the term "extrachromosomal" refers to genetic material that is not contained in chromosomes. In the case of insect cells, chromosomes include nuclear chromosomes and mitochondrial chromosomes. Extrachromosomal genetic material includes free genetic material.

[0170] Gene: As used herein, the term "gene" refers to a DNA sequence encoding a gene product (e.g., an RNA product, e.g., a polypeptide product) in a chromosome. In some embodiments, a gene includes a coding sequence (i.e., a sequence encoding a specific product). In some embodiments, a gene includes a non-coding sequence. In some specific embodiments, a gene may include both a coding (e.g., exon) sequence and a non-coding (e.g., intron) sequence. In some embodiments, a gene may include one or more regulatory sequences (e.g., promoters, enhancers, etc.) and / or intron sequences, which, for example, may control or affect one or more aspects of gene expression (e.g., cell type-specific expression, inducible expression, etc.). As used herein, the term "gene" generally refers to a portion of a nucleic acid encoding a polypeptide or a fragment thereof; the term may optionally encompass regulatory sequences, which will be clear to a person of ordinary skill in the art from the context. This definition is not intended to exclude the application of the term "gene" to non-protein coding expression units, but to clarify that, in most cases, the term as used herein refers to a polypeptide encoding nucleic acid. In some embodiments, a gene may encode a polypeptide, but the polypeptide may not be functional, for example, a gene variant may encode a polypeptide that does not function in the same manner or at all relative to the wild-type gene.

[0171] Genome: As used herein, the term "genome" refers to the total genetic information carried by an individual organism or cell, represented by the complete nucleic acid sequence of its chromosomes.

[0172] Guide sequence: As used herein, the term "guide sequence" refers to a nucleic acid sequence corresponding to the nucleic acid sequence of a guide RNA for nuclease-mediated editing (e.g., with an RNA-guided nuclease). The terms "guide RNA" and "gRNA" refer to any nucleic acid that promotes the specific association (or "targeting") of an RNA-guided nuclease (such as Cas9 or Cpf1) with a target sequence (such as a genome or free sequence in a cell). The gRNA can be unimolecular (comprising a single RNA molecule, referred to as chimeric), or modular (comprising more than one, usually two independent RNA molecules, such as crRNA and tracrRNA, which are usually associated with each other, for example, by duplexing). Guide RNAs, whether unimolecular or modular, contain a "guide sequence" that is fully or partially complementary to a sequence within the target (such as a DNA sequence in the genome of a cell to be edited). Guide sequences are referred to by various names in the literature, including but not limited to "targeting domain", "complementary region" (e.g., WO 2016 / 073990 by Cotta-Ramusino et al.), "spacer" (e.g., Briner et al., Molecular Cell 56(2), 333-339, October 23, 2014) and generally "crRNA" (e.g., Jiang et al. Nat Biotechnol. 2013 Mar; 31(3): 233–239). Regardless of their names, guide sequences are generally about 10 to 30 nucleotides in length. In some embodiments, the guide sequence is 15 to 25 nucleotides in length. In certain embodiments, the guide sequence is 16 to 24 nucleotides in length (e.g., 16, 17, 18, 19, 20, 21, 22, 23, or 24 nucleotides in length). In some embodiments, the guide sequence is located at or near the 5' end of the gRNA (e.g., for Cas9 or a nuclease derived or obtained therefrom). In some embodiments, the guide sequence is located at or near the 3' end of the gRNA (eg, for Cpf1 or a nuclease derived or obtained therefrom).

[0173] Heterologous: As used herein, the term "heterologous" refers to any entity that does not naturally occur in a particular environment (e.g., a cell or organism) in which it exists. In the context of nucleic acids, heterologous refers to sequences that do not naturally occur together (e.g., in the same polynucleotide or in the same cell). In some embodiments, a heterologous sequence can be a sequence rearranged, replaced, inserted, substituted into a non-endogenous environment (e.g., from a different genomic location or from a different organism). For example, a heterologous promoter sequence or a heterologous enhancer sequence can be a sequence that is naturally associated with a different gene or from a different organism. In some embodiments, a heterologous sequence is present in the genome of an insect cell. In some embodiments, a heterologous sequence is present free in an insect cell.

[0174] Homology: As used herein, the terms "homology" or "homologs" refer to the overall relatedness between oligonucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. In some embodiments, oligonucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules are considered "homologous" to each other if their sequences are at least 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% identical. In some embodiments, if the sequences of oligonucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% similar (e.g., containing residues with related chemical properties at corresponding positions), they are considered to be "homologous" to each other. For example, as is well known to those of ordinary skill in the art, certain amino acids are often classified as "hydrophobic" or "hydrophilic" amino acids, and / or have "polar" or "non-polar" side chains, similar to each other. The substitution of one amino acid for another amino acid of the same type can generally be considered a "homologous" substitution.

[0175] Identifier: As used herein, refers to an element that (i) can be detected (e.g., by next generation sequencing) and (ii) enables identification of insect cells or clonal cell lines that produce or derive viral vectors. The present disclosure provides identifiers that are shared and / or transferred between insect cells and viral vectors. In some embodiments, the identifier comprises a nucleic acid sequence. In some embodiments, the identifier comprises one or more barcodes, one or more library variants, or a combination thereof. In some embodiments, the identifier comprises a sequence that can be detected, for example, by PCR (e.g., quantitative PCR), hybridization (e.g., using a probe) and / or sequencing (e.g., next generation sequencing and / or Sanger sequencing). In some embodiments, the identifier is or is contained in a nucleic acid sequence that is shared and / or transferred between insect cells and viral vectors. In some embodiments, the identifier is contained in a library construct (e.g., for introduction into insect cells). In some embodiments, the identifier is contained in a library construct between genetic structures (e.g., viral repeat sequences, e.g., AAV ITR sequences) suitable for packaging the identifier into a viral vector. In some embodiments, the identifier is present in the genome of the viral vector (e.g., between viral repeat sequences). In some embodiments, detection of an identifier in the viral vector genome (e.g., between viral repeat sequences) is associated with an insect cell or clonal cell line from which the viral vector was produced or derived. In some embodiments, detection of an identifier in the viral vector genome (e.g., between viral repeat sequences) is associated with the presence of one or more library constructs and / or one or more library variants associated with an insect cell or clonal cell line from which the viral vector was produced or derived. In some embodiments, provided methods can include a step of sequencing the identifier (e.g., using a next generation sequencing method) to determine the relative abundance of a particular viral vector in a viral vector pool or sample.

[0176] Identity: As used herein, the term "identity" refers to the overall relatedness between polymer molecules, such as nucleic acid molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules. For example, the calculation of the percentage identity of two nucleic acid or polypeptide sequences can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first sequence and the second sequence for optimal alignment, and non-identical sequences can be ignored for comparison purposes). In some embodiments, the length of the sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence; the nucleotides at corresponding positions are then compared. When a position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as the corresponding position in the second sequence, the two molecules (i.e., the first and second) are identical at the position. The percentage identity between two sequences is the function of the number of spaces and the length of each space that need to be introduced for the best comparison of two sequences, the number of the same positions shared by the two sequences being compared. The sequence comparison between two sequences and the determination of percentage identity can be completed using a mathematical algorithm. For example, the percentage identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17, which is incorporated herein by reference in its entirety), which has been incorporated into the ALIGN program (version 2.0).

[0177] Integration construct: as used herein, refers to a construct that facilitates genomic integration of a construct such as a library construct. In some embodiments, the integration construct is an insect viral vector such as, for example, J. juncea densovirus (JcDNV) or a derivative thereof. In some embodiments, the integration construct includes a cis-acting integration sequence and / or a trans-acting integration sequence.

[0178] Isolated: as used herein, refers to a substance and / or entity that has been (1) separated from at least some of the components with which it was originally associated (whether in nature and / or in an experimental setting), and / or (2) designed, produced, prepared and / or manufactured by the human hand. An isolated substance and / or entity may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which it was originally associated. In some embodiments, the purity of the separated agent is about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more than about 99%. As used herein, a substance is "pure" if it is substantially free of other components. In some embodiments, as will be appreciated by those skilled in the art, a substance may still be considered "separated" or even "pure" after having been combined with certain other components such as one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such embodiments, the percentage separation or purity of the substance is calculated without including such carriers or excipients. As just one example, in some embodiments, a biopolymer such as a polypeptide or polynucleotide that occurs in nature is considered "isolated" if: a) by virtue of its source or source of derivation, it is not associated with some or all of the components that naturally accompany it in nature; b) it is substantially free of other polypeptides or nucleic acids from the same species as the species in which it is produced in nature; c) it is expressed by or otherwise associated with components of a cell or other expression system from a species other than the species in which it is produced in nature. Thus, for example, in some embodiments, a polypeptide that is chemically synthesized or synthesized in a cellular system different from that in which it is produced in nature is considered an "isolated" polypeptide. Alternatively or additionally, in some embodiments, a polypeptide that has been subjected to one or more purification techniques may be considered an "isolated" polypeptide to the extent that it has been separated from other components that a) are associated with it in nature; and / or b) were associated with it when originally produced.

[0179] Library construct: As used herein, refers to one or more nucleic acid constructs for generating insect cell libraries. As used herein, a library construct comprises (i) at least one identifier, (ii) a genetic structure suitable for packaging the identifier into a viral vector (e.g., a viral repeat sequence, e.g., an AAV ITR sequence), and (iii) any library variants (if not already included in the identifier). The library construct may also include other engineered sequences, such as, but not limited to, any cis-acting integration sequence (if the genomic integration of the library construct is associated), and / or any barcode. In some embodiments, all elements of the library construct are contained on a single (i.e., one) continuous nucleic acid (e.g., DNA) fragment. In some embodiments, a library construct refers to multiple, separate and discontinuous nucleic acid (e.g., DNA) fragments. When a library construct comprises multiple nucleic acids (i.e., a discontinuous library construct), it will include at least one construct comprising an identifier located between sequences (e.g., viral repeat sequences, e.g., AAV ITR sequences) for packaging the identifier into a viral vector. In some embodiments where the library construct is discontinuous, the library construct further comprises one or more constructs, wherein each individual construct comprises one or more library variants. The provided methods employing discontinuous library constructs will also include a step of identifying one or more library variants of the library construct (e.g., single cell sequencing of insect cells). For example, Figure 3 Depicted is a method in which a library construct comprises individual DNA fragments, showing cells containing a construct comprising an identifier (e.g., a barcode flanked by ITRs) and three other constructs comprising library variants (e.g., three independent and unique gRNAs), wherein the identifier (e.g., barcode) is packaged into a viral vector, and the association with the library variant is determined by single cell sequencing. It is contemplated that single cell sequencing is not always required for many methods employing a single continuous library construct, but may still be useful in some cases.

[0180] Library variant: As used herein, it refers to an element of a library construct that produces a disturbance that varies between cells. For example, in a cell population, each cell will obtain a different library construct that contains a unique library variant or a combination of library variants. For example, a library variant may include a gene, an ORF, a gRNA sequence, a non-coding nucleic acid, or a plurality and / or combination thereof. In the context of the present disclosure, a library variant is different from a barcode, but one or more library variants may be associated with one or more barcodes. In some embodiments, one or more library variants and / or barcodes may be included within or outside an identifier within a library construct. In some embodiments, one or more barcodes themselves may be directly detected (for example, in a next generation sequencing method) instead of the library variant itself. In some embodiments, a library variant may be referred to herein as an effector, whereby the library variant affects or causes a disturbance that varies between cells. In some embodiments, the library variant itself may become a disturbance that varies between cells. For example, in some embodiments, library variants that are gRNAs are effectors that, together with RNA-guided nucleases (e.g., perturb additional sequences), result in deletions in the genomic DNA of a cell. In other embodiments, library variants that are ORFs or gene sequences, when transfected into cells and in some cases integrated into genomic DNA (e.g., as performed by trans- and cis-acting integration sequences), themselves become perturbations or modifications of the genetic material of the cell.

[0181] Nucleic acid: As used herein, in its broadest sense, refers to any compound and / or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is or is a compound and / or substance that can be incorporated into an oligonucleotide chain via a phosphodiester linkage. It will be clear from the context that in some embodiments, "nucleic acid" refers to individual nucleic acid residues (e.g., nucleotides and / or nucleosides); in some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, "nucleic acid" is or includes RNA; in some embodiments, "nucleic acid" is or includes DNA. In some embodiments, a nucleic acid is, includes, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, includes, or consists of one or more nucleic acid analogs.

[0182] Payload: As used herein, the term "payload" refers to any entity of interest delivered by a viral vector produced by the method of the present disclosure. For example, it may be desirable to introduce such a payload into a cell, an organ, an organism, and / or a biological system (e.g., including a cell). In some embodiments, the payload sequence is or comprises a heterologous nucleic acid sequence delivered by a viral vector of the present disclosure. In some embodiments, the payload sequence comprises one or more of the following: a coding region, a gene regulatory element, and a transcription terminator. Non-limiting examples of gene regulatory elements include promoters, transcription activators, enhancers, and polyadenylation signals. In some embodiments, the payload sequence comprises a coding region, a gene regulatory element, and a transcription terminator, which are positioned relative to each other so that the coding region is located between the gene regulatory element and the transcription terminator. In some embodiments, the coding region encodes a gene product. In some embodiments, the gene product is RNA. In some embodiments, the coding region encodes a polypeptide (such as a protein, such as a glycoprotein). In some embodiments, the coding region encodes a fusion polypeptide and / or a chimeric polypeptide. In some embodiments, the coding region encodes a gene product. In some embodiments, the coding region encodes more than one gene product (e.g., 2, 3, 4, 5, 6, 7 or more gene products). In some embodiments, the coding region encodes regulatory RNA (e.g., siRNA, microRNA, etc.). In some specific embodiments, the payload encodes one or more entities for gene editing (e.g., gRNA-mediated editing system). In some embodiments, the payload encodes a protein product.

[0183] Perturbation: As used herein, refers to a genetic modification in an insect cell, a viral vector produced, a polynucleotide necessary for producing a viral vector, and / or other constructs, which is produced and / or identified by the methods described herein. In some embodiments, the insect cell, the viral vector produced, the polynucleotide necessary for producing a viral vector, and / or other constructs contain one or more perturbations. These are generated, produced, identified, and / or selected from the insect cell library for expressing and / or producing a viral vector disclosed herein. In some embodiments, the perturbation is the result of one or more library variants. In some embodiments, the perturbation is a genetic modification that is not the result of a library variant, but a genetic modification produced and / or identified by the methods described herein. In some embodiments, the perturbation is included in a genetic modification in at least one polynucleotide comprising one or more nucleic acid sequences necessary for producing a viral vector. In some embodiments, the perturbation is associated with one or more desired features of an insect cell (e.g., for expressing a viral vector (e.g., independently and / or synthetically)) or a viral vector. In some embodiments, the perturbation includes genomic sequence changes (e.g., genomic insertions, deletions, substitutions, rearrangements, etc.), free sequence changes, and / or epigenetic modifications.

[0184] Perturbation additional sequence: As used herein, it includes any sequence that facilitates the generation of perturbations in combination with a library construct. For example, in some embodiments, the library construct comprises a library variant comprising a gRNA, and the perturbation additional sequence comprises a sequence encoding an RNA-guided nuclease or other element for nuclease-mediated perturbations.

[0185] Polypeptide: As used herein, the term "polypeptide" refers to any polymer chain of residues (e.g., amino acids) that are usually linked by peptide bonds. In some embodiments, the polypeptide has a naturally occurring amino acid sequence. In some embodiments, the polypeptide has a non-naturally occurring amino acid sequence. In some embodiments, the polypeptide has an engineered amino acid sequence because it is designed and / or produced by artificial action. In some embodiments, the polypeptide may comprise natural amino acids, non-natural amino acids, or both, or be composed of them. In some embodiments, the polypeptide may comprise one or more side groups or other modifications, for example, at the N-terminus of the polypeptide, at the C-terminus of the polypeptide, or any combination thereof, or be attached to one or more amino acid side chains. In some embodiments, such side groups or modifications may be acetylation, amidation, lipidation, methylation, pegylation, etc., including combinations thereof. In some embodiments, the polypeptide may contain L-amino acids, D-amino acids, or both, and may contain any of a variety of amino acid modifications or analogs known in the art. In some embodiments, useful modifications may be or include, for example, terminal acetylation, amidation, methylation, etc. In some embodiments, proteins may comprise natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof. The term "peptide" is generally used to refer to polypeptides of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids in length. In some embodiments, the protein is an antibody, an antibody fragment, a biologically active portion thereof, and / or a characteristic portion thereof.

[0186] Polynucleotide: As used herein, the term "polynucleotide" refers to a polymeric chain of any nucleic acid. In some embodiments, a polynucleotide is or comprises RNA; in some embodiments, a polynucleotide is or comprises DNA. In some embodiments, a polynucleotide is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a polynucleotide is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, polynucleotide analogs differ from nucleic acids in that polynucleotide analogs do not utilize a phosphodiester backbone. Alternatively or additionally, in some embodiments, a polynucleotide has one or more thiophosphates and / or 5'-N-phosphoramidite linkages instead of phosphodiester bonds. In some embodiments, a polynucleotide is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine). In some embodiments, the polynucleotide is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, inserted bases, and combinations thereof). In some embodiments, the polynucleotide comprises one or more sugars that are modified compared to sugars in natural nucleic acids (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose). In some embodiments, polynucleotides have nucleotide sequences encoding functional gene products such as RNA or proteins. In some embodiments, polynucleotides include one or more introns. In some embodiments, polynucleotides are prepared by one or more methods in the following: separation from natural sources, enzymatic synthesis (in vivo or in vitro) by polymerization based on complementary templates, replication and chemical synthesis in recombinant cells or systems. In some embodiments, the polynucleotide is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more residues in length.In some embodiments, the polynucleotide is partially or entirely single-stranded; in some embodiments, the polynucleotide is partially or entirely double-stranded. In some embodiments, the polynucleotide has a nucleotide sequence that includes at least one element that encodes a polypeptide or is the complement of a sequence that encodes a polypeptide. In some embodiments, the polynucleotide has enzymatic activity.

[0187] Predetermined: As used herein, the term "predetermined" refers to before the experiment and / or analysis begins. For example, in some embodiments, the location or characteristics of an engineered sequence can be considered predetermined when a set of possible outcomes (e.g., insertion sites) are known prior to the physical act of introducing the engineered sequence (e.g., the engineered sequence can be inserted into one of several different genomic locations).

[0188] Protein: As used herein, the term "protein" refers to a polypeptide (i.e., a string of at least two amino acids linked to each other by peptide bonds). Proteins may contain moieties other than amino acids (e.g., may be glycoproteins, proteoglycans, etc.) and / or may be processed or modified in other ways. One of ordinary skill in the art will understand that a "protein" may be a complete polypeptide chain (with or without a signal sequence) as produced by a cell, or may be a characteristic portion thereof. One of ordinary skill will understand that a protein may sometimes contain more than one polypeptide chain, for example linked by one or more disulfide bonds or associated by other means.

[0189] Reference: As used herein, the term "reference" describes a standard or control, and the comparison is made relative to the standard or control. For example, in some embodiments, the agent, animal, individual, population, sample, sequence or value of interest is compared to a reference or control agent, animal, individual, population, sample, sequence or value, respectively. In some embodiments, the reference or control is tested and / or determined substantially simultaneously with the test or determination of interest. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as will be understood by those skilled in the art, the reference or control is measured or characterized under conditions or environments comparable to the conditions or environments under evaluation. Those skilled in the art will understand when there is enough similarity to justify reliance on a particular possible reference or control and / or comparison with a particular possible reference or control. In some embodiments, the reference is a negative control reference; in some embodiments, the reference is a positive control reference. In some embodiments, the reference cell or reference cell population is compared, and the reference cell or reference cell population has comparable genetic characteristics and has been cultured under comparable conditions (except for the variables being analyzed). In some specific embodiments, the reference cell differs in the presence of at least one engineered sequence and / or at least one barcode sequence, but is otherwise comparable.

[0190] RNA-guided nuclease: As used herein, the term "RNA-guided nuclease" refers to a polypeptide that binds to a specific target nucleotide sequence in a sequence-specific manner, and the polypeptide is guided to the target nucleotide sequence by a guide RNA molecule that is complexed with the polypeptide and hybridized to the target sequence. Although RNA-guided nucleases are capable of cutting the target sequence after binding, the term RNA-guided nuclease also encompasses RNA-guided nucleases with no nuclease activity that can bind but not cut the target sequence. Cutting of the target sequence by RNA-guided nucleases can result in single-stranded or double-stranded breaks. RNA-guided nucleases that can only cut single strands of double-stranded nucleic acid molecules are referred to herein as nickases. In some embodiments, the RNA-guided nuclease is or is derived from Cas9, Cas Z, CpfI and / or Fok1.

[0191] Trans-acting integration sequence: As used herein, the phrase "trans-acting integration sequence" with respect to a library construct refers to a nucleic acid sequence that is not necessarily included as part of the library construct itself, which is necessary for integration of the library construct into the insect cell genome. The trans-acting integration sequence and / or its polypeptide, protein, nucleic acid or polynucleotide product (e.g., recombinase) achieves integration of the library construct or a portion thereof into the cell genome (e.g., insect cell) in coordination with the cis-acting integration sequence (e.g., recombinase site). In some embodiments, more than one trans-acting integration sequence is necessary for integration of the library construct.

[0192] Transformation or transfection: As used herein, the term "transformation" or "transfection" refers to any process in which exogenous DNA is introduced into a host cell (e.g., an insect host cell). Transformation can be performed under natural or artificial conditions using various methods well known in the art. Transformation can rely on any known method to insert an exogenous nucleic acid sequence into a eukaryotic host cell. In some embodiments, a specific transformation method is selected based on the host cell to be transformed, and may include, but is not limited to, viral infection or transduction, electroporation, liposome transfection. In some embodiments, "transformed" cells are stably transformed because the inserted DNA is able to replicate as an autonomously replicating plasmid or as a part of the host chromosome. In some embodiments, the transformed cells transiently express the introduced nucleic acid within a limited period of time.

[0193] Viral vector: As used herein, the term "viral vector" refers to an entity that (i) is capable of carrying at least one polynucleotide, and (ii) comprises a viral protein (e.g., a capsid protein, e.g., a viral capsid protein and / or a variant or derivative thereof). In some embodiments, the viral vector comprises one or more nucleic acid molecules. In some embodiments, the viral vector can facilitate the transfer of nucleic acid to a cell. In some embodiments, the viral vector comprises one or more nucleic acid sequences and one or more viral capsid proteins. In some embodiments, the viral vector comprises a capsid protein and / or a nucleic acid sequence derived from an adeno-associated virus (AAV) vector, an adenoviral vector, a baculoviral vector, a lentiviral vector, and / or a retroviral vector. In some embodiments, the viral vector comprises an envelope.

[0194] All documents and similar materials cited in this application, including but not limited to patents, patent applications, articles, books, papers, and web pages, regardless of the format of such documents and similar materials, are expressly incorporated by reference in their entirety. If one or more of the incorporated documents and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, etc., this application shall prevail. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described in any way. DETAILED DESCRIPTION

[0195] Biological preparations include cell and gene therapy, vaccines and biological reagents, and are a rapidly growing market. Insect cells can effectively express recombinant proteins and can be used to produce a variety of biological products, including, for example, viruses, virus-like particles and / or vaccines. However, the supply chain for producing biological preparations, especially those using viral vectors, is very inefficient. Even subtle changes in viral vectors or insect host cells can affect production yields. For example, viral vector payloads and serotypes can affect insect cell metabolism, vitality, viral vector assembly, viral vector production and / or viral vector expression. In order to reduce costs and comply with good manufacturing practices, the biological production of viral vectors (such as in insect cell culture) is very important. Insect cells contain most of the post-translational modification pathways present in mammalian systems, thereby being able to produce biological products that are more similar (for example, antigenicity, immunogenicity and / or functionality) to natural mammalian proteins than those expressed in yeast cells or prokaryotic cells. The present disclosure recognizes that the problem with viral vector production is that insect cell lines are usually not optimized and / or the screening platform for separating optimized cell lines is also inefficient. The current manufacturing of viral vectors is insufficient due to both the high cost and long production time of bioproduction as well as the increasing market demand for larger quantities of viral vectors.

[0196] The present disclosure provides, in particular, platform technologies for expressing viral vectors in insect cells. The present disclosure provides methods for screening, evaluating and / or characterizing insect cells or cell lines based on their ability to express viral vectors using a library-based method. The technology provided encompasses the following insights: enabling the viral vector to obtain an identifier (e.g., including a barcode sequence and / or library variant) of the insect cell expressing it, thereby enabling the viral vector genome (e.g., between viral repeats) to be sequenced to provide an effective and robust method for identifying insect cells with other features of higher viral vector expression and / or viral vector production. The methods, systems and compositions provided provide a fast and robust platform for engineering insect cells with beneficial viral vector features (e.g., increased viral vector expression, increased expression duration, increased stability, etc.).

[0197] Insect cell platform for viral vector expression

[0198] The present disclosure provides a platform technology for producing, screening, selecting, engineering and / or identifying insect cells or cell lines for expressing viral vectors. The present disclosure provides a method for indicating the source of insect cells in a library with an identifier using a library-based method. The present disclosure provides a new platform technology, in which the viral vectors expressed by insect cells obtain identifiers (e.g., including barcodes and / or library variants). The viral vectors produced by the insect cell library can be merged and analyzed (e.g., by sequencing, e.g., by next generation sequencing) for the desired characteristics. The viral vectors obtain identifiers to make it possible to quickly identify the insect cells that produce the viral vectors, and the insect cells have the desired characteristics, such as but not limited to enhanced or improved viral vector production. The present disclosure encompasses the following understanding: the insect cell library can be screened by sequencing the identifiers of the viral vectors (e.g., including barcodes and / or library variants) to obtain a cell line with the desired viral vector production characteristics (e.g., improved viral vector production). For example, the relative abundance of a particular identifier in a pool of identifiers of viral vectors expressed from an insect cell library can be correlated to the relative viral vector productivity of a particular insect cell line in the library (e.g., a high abundance of a particular identifier can be associated with an insect cell line with a higher viral vector productivity).

[0199] Figure 1 Schematic diagrams of exemplary techniques for screening insect cells for viral vector expression or other viral vector characteristics are provided. The provided techniques employ insect cell libraries that are engineered to contain an identifier (e.g., containing a barcode and / or library variants) and appropriate genetic elements for packaging the identifier into a viral vector (e.g., a viral repeat sequence, e.g., AAV ITR for expression of an AAV vector) (depicted in Figure 1, step A). ​​In some embodiments, the identifier is in the context of the library construct, which can be a single continuous polynucleotide or two or more discontinuous polynucleotides. In some embodiments, the library construct further comprises, for example, at least one library variant. In some embodiments, the library variant can affect viral vector production or other characteristics. In some embodiments, the library variant can cause disturbances, such as one or more genetic modifications that can affect viral vector production or other characteristics. In some embodiments, the insect cell is genetically engineered to include one or more engineered sequences, the one or more engineered sequences including an identifier located between the viral packaging sequences and optionally any of the following: disturbances, library variants, payloads, disturbance additional sequences, trans-acting integration sequences and / or cis-acting integration sequences.

[0200] The insect cells of the insect cell library may also contain (e.g., already present episomally and / or integrated into the insect cell genome) or be engineered (e.g., transfected) to contain genetic material sufficient to express a viral vector (depicted in Figure 1 , step B). Transfection or transduction of an insect cell library with genetic material (eg, one or more engineered sequences) can be used to generate an insect cell library that produces viral vectors.

[0201] The genetic material may include, for example, viral genes for replication and viral genes encoding essential viral proteins such as capsid proteins. For AAV vectors, genetic material sufficient to express the viral vector may include (i) genes encoding AAV Rep proteins and AAV Cap proteins; and (ii) adenoviral genes (e.g., E2, E4, and VARNA) required to support AAV replication. In some embodiments, the viral vector also includes a payload (e.g., a nucleic acid encoding a payload). In some embodiments, the payload includes an expression cassette with a promoter, an ORF, and a polyA signal. In some embodiments, the insect cells of the insect cell library are transfected with genetic material sufficient to express a viral vector comprising a payload and an identifier.

[0202] In some embodiments, the technology provided includes a unique method whereby a viral vector acquires an identifier (e.g., in a viral vector genome, e.g., between viral repeat sequences). Therefore, each clonal group of insect cells in the library will express a viral vector with a unique identifier. This enables direct characterization of the viral vector and identification of the insect cells that produce it. Typically, the insect cell library of viral vectors produced in the present disclosure will include at least one engineered sequence, the at least one engineered sequence including an identifier located between sequences (e.g., viral repeat sequences, e.g., AAV ITRs for expressing AAV vectors) for packaging the identifier into the viral vector and genetic material sufficient to express the viral vector of interest. The insect cells of the insect cell library producing viral vectors may also include one or more (e.g., up to 100 unique) library variants and / or perturbations. One or more perturbations may be present in insect cells and / or viral vectors expressed by insect cells.

[0203] Any engineered sequence (e.g., encoding a viral vector, an identifier, and / or other engineered sequence) can be free (e.g., on one or more plasmids) and / or integrated into the genome of an insect cell. For example, in some embodiments, one or more nucleic acid sequences necessary for producing a viral vector can be integrated into an insect cell. In some embodiments, one or more nucleic acid sequences necessary for producing a viral vector can be free in an insect cell. In some embodiments, one or more nucleic acid sequences necessary for producing a viral vector can be induced to express (e.g., under the control of an inducible promoter).

[0204] In some embodiments, a library of insect cells producing viral vectors is cultured and the viral vectors are harvested using any suitable method known in the art (depicted in Figure 1 , step C). In some embodiments, the total viral vectors produced by the insect cells of the library are harvested. In some embodiments, the viral vectors produced by the insect cells of the library are harvested corresponding to the time intervals. For example, the viral vectors can be harvested every day, every two days, every 3 days or at longer intervals to evaluate the production of viral vectors over a period of time. In some embodiments, the insect cells can be washed and the viral vectors can be harvested after a long period of time (e.g., to evaluate the continued production of viral vectors). In some embodiments, the genetic material of the viral vector (e.g., including the identifier) ​​is isolated.

[0205] The viral vectors can be combined and the genetic material sequenced (e.g., using next generation sequencing) (depicted in Figure 1, step D). The presence of the identifier in the viral vector pool indicates that the insect cells or insect clonal cell lines (also having identifiers) in the insect cell library can produce viral vectors. In some embodiments, the relative abundance of one or more identifiers is determined. In some embodiments, the relative abundance of the identifiers determined from the viral vector pool is associated with the relative viral vectors produced by the corresponding cell line. In some embodiments, the relative abundance of the identifiers can be used to determine the quantity (e.g., relative quantity) of specific viral vectors produced by different insect cells in the library. In some embodiments, the abundance of the identifiers in the viral vector pool can be used to determine the effects of various engineered sequences (e.g., library variants and / or perturbations) on the viral vector production capacity of insect cells in the library.

[0206] The present disclosure recognizes that the amount or abundance of viral vectors can reflect deviations (e.g., increased cell division or cell number of a particular insect cell or insect clonal cell line), and is not necessarily a viral vector production level associated with an insect cell or clonal cell line. Therefore, in some embodiments, the amount or abundance of viral vectors can be normalized. In some embodiments, the amount or abundance of viral vectors detected can be normalized, for example, to the amount of cells and / or cellular DNA. In some embodiments, a cell library comprises approximately the same number of cells in each cell sample in the library.

[0207] Insect cells related to desired viral vector characteristics (e.g., high expression) can be identified, and their engineered sequences can be determined (e.g., by genome sequencing). For example, insect cells that show increased viral vector production under production specifications (e.g., under current good manufacturing practices (cGMP)) compared to reference cells can be selected. Compared to reference cells, the increased viral vector production can be an increase in the number of viral vectors in a fixed time period or the generation of an extended amount of time. In some embodiments, insect cells that produce viral vectors longer (e.g., due to increased vigor, increased genomic stability, and / or increased duration of viral vector production) can be selected relative to reference cells. Reference cells can include comparable insect cells and / or standard cells (e.g., capable of producing viral vectors) that do not include engineered sequences.

[0208] The selected insect cell candidates can generally be used to generate viral vectors and / or corresponding library variants and / or the identified perturbations can be used to inform the construction of new insect cell libraries (depicted in Figure 1, Figure F). The library-based platform method can be repeated until an engineered insect cell expressing a viral vector with a desired feature and / or a desired number is identified. The engineered sequence associated with the desired feature can be analyzed, for example, using a machine learning (ML) method to develop a machine learning model. The trained machine learning model can be used to provide information for future designs and reduce the number of insect cell libraries to be screened and / or the size of each insect cell library, thereby reducing time and cost. In some embodiments, an insect cell library can be designed and / or the method can be performed to identify engineered sequences that interact synergistically (e.g., two or more engineered sequence combinations) in insect cells to have a desired feature (e.g., a certain level of viral vector production). In some embodiments, the resulting insect cells obtained from the platform technology described herein will have one, two, three, four, five, six, seven, eight, nine, ten or more engineered sequences (e.g., one, two, three, four, five, six, seven, eight, nine, ten or more perturbations). In some embodiments, the methods provided can be used to generate, screen, select, engineer and / or identify insect cells with desired viral vector production characteristics (e.g., a certain level of production, production of a desired duration, etc.). In some embodiments, the methods provided can be used to generate, screen, select, engineer and / or identify one or more perturbations or combinations of perturbations that affect viral vector production. In some embodiments, selected insect cell candidates can be used to produce viral vectors after additional modifications (e.g., removal of identifiers). In some embodiments, the corresponding library variants and / or perturbations identified can be used to provide information for the construction of similar insect cell lines or cell lines (e.g., perturbations can be introduced into the same ancestral cell line, a similar ancestral cell line (wherein one or more polynucleotides comprising one or more nucleic acid sequences necessary for producing viral vectors are integrated into the insect cell genome) and / or very different ancestral cell lines).

[0209] In some embodiments, insect cells are engineered to contain one or more components of a viral vector, the one or more components being under the control of an inducible transcriptional control element (e.g., a promoter). In some embodiments, insect cells comprising genetic elements of a viral vector are manipulated to further comprise a library construct. In some embodiments, insect cells comprise polynucleotides having one or more elements necessary for producing a viral vector under the control of an inducible transcriptional control element (e.g., free and / or integrated into the insect genome), and are further engineered to comprise a library construct.

[0210] Those skilled in the art will recognize that although Figure 1The schematic diagram depicts engineering an insect cell library to contain one or more engineering sequences and one or more identifiers, and then introducing genetic elements of a viral vector, but these steps for engineering an insect cell library for expressing a viral vector can be performed in any order and using any method known in the art. For example, engineering an insect cell library for expressing a viral vector can be performed in any order and using any method known in the art. For example, in some embodiments, engineering sequences, identifiers, and elements of a viral vector are introduced simultaneously or substantially simultaneously. In some embodiments, an insect cell library is generated that contains unique engineering sequences and polynucleotides necessary to form a viral vector, and then an identifier is introduced. In some embodiments, an insect cell library is generated that contains unique engineering sequences containing identifiers, and then polynucleotides necessary to form a viral vector are introduced.

[0211] The provided method can be used to generate, identify and / or select insect cells with the desired characteristics of producing any desired viral vector. Generally, such viral vectors will be functional for their desired purpose. For example, in some embodiments, the viral vectors used for gene therapy will have the function of delivering a payload (e.g., nucleic acid, for example, to a target cell). In some embodiments, the viral vector is an oncolytic viral vector capable of killing cancer cells. In some embodiments, the viral vector has therapeutic activity. However, in some embodiments, the provided method can produce a non-functional viral vector lacking one or more functional characteristics but retaining other features of interest. In some embodiments, the viral vector is non-functional or has reduced functionality for a particular feature. For example, in some embodiments, the viral vector may have a reduced ability to transfer a payload or may not be able to transfer a payload. In some embodiments, the viral vector may have a reduced ability to kill cancer cells. In some embodiments, the viral vector may not have therapeutic activity.

[0212] Viral vectors

[0213] In some embodiments, the insect cell lines of the present disclosure can be used to produce viral vectors. In some embodiments, the viral vectors produced are used as biological agents and / or treatments themselves. In some embodiments, the viral vectors produced are used to generate many biological agents and / or treatment research, production and / or manufacturing processes. For example, viral vectors can be used in a variety of ways, including but not limited to vaccines, cancer treatments (e.g., oncolytic therapy) and / or gene therapy (e.g., in vivo gene and / or genome editing). As another example, viral vectors can be used in a variety of ways, including but not limited to research, production and / or manufacture: vaccines, cancer treatments (e.g., oncolytic therapy), gene therapy (e.g., ex vivo gene and / or genome editing) and / or cell therapy (e.g., ex vivo gene and / or genome editing). Therefore, there are a large number of viral vectors that can be used for these different applications.

[0214] The methods of the present disclosure can be used to select and / or identify insect cells having beneficial characteristics for expressing a viral vector, for example, any viral vector known in the art or described herein; the present disclosure is not limited to any particular viral vector.

[0215] Viral vectors can have different sizes, carrying capacities, have different genomic structures (e.g., DNA and / or RNA, and single-stranded and / or double-stranded). In some embodiments, viral vectors can be used to deliver nucleic acids to cells for transient expression or long-term expression. In some embodiments, viral vectors have a wide range of host cells. In some embodiments, viral vectors can have limited and / or specific types of host cells.

[0216] The insect cell and / or insect cell group provided comprises one or more polynucleotides, and the one or more polynucleotides comprise one or more nucleic acid sequences necessary for producing viral vectors. In some embodiments, the polynucleotides comprising one or more nucleic acid sequences necessary for producing viral vectors are free present in insect cells. In some embodiments, the polynucleotides comprising one or more nucleic acid sequences necessary for producing viral vectors are present in the insect cell genome. In some embodiments, the one or more nucleic acid sequences necessary for producing viral vectors are under the control of inducible transcription control elements. For example, in some specific embodiments, the one or more nucleic acid sequences necessary for producing viral vectors can be integrated into the insect cell genome and under the control of inducible transcription control elements (e.g., inducible promoters and / or inducible enhancers). Viruses from which viral vectors can be derived include, but are not limited to, adeno-associated virus (AAV), adenovirus, baculovirus (e.g., Autographa californica multinucleopolyhedrosis virus (AcMNPV)), lentivirus, alphavirus (e.g., Sindbis virus), retrovirus (e.g., gammaretrovirus), polyomavirus (e.g., Simian virus 40 (SV40)), papillomavirus (e.g., bovine papillomavirus (BPV)), poxvirus (e.g., vaccinia virus), herpes simplex virus (HSV), measles virus, rhabdovirus (e.g., rabies virus), serotype (e.g., serotype (serotype (serotype (serotype (serotype (serotype (s Canine disease virus), vesicular stomatitis virus (VSV), picornavirus (e.g., poliovirus), reovirus, Senecavirus, echovirus (e.g., RIGVIR), Semliki Forest virus (SFV), Flavivirus, Anellovirus (https: / / www.ringtx.com), Newcastle disease virus (NDV), paramyxovirus (e.g., Sendai virus), Sendai virus vectors, orthomyxovirus (e.g., influenza virus), coronavirus and hybrid and / or engineered viruses and / or viral vectors.

[0217] In some specific embodiments, the viral vectors in the context of the present disclosure are derived from an adeno-associated virus, an adenovirus, a baculovirus, a lentivirus, a retrovirus, and / or a herpes simplex virus.

[0218] In some embodiments, the insect cell lines of the present disclosure can be used to produce viral vectors, such as adeno-associated viral vectors, adenoviral vectors, baculoviral vectors, lentiviral vectors, retroviral vectors, and / or herpes simplex viral vectors.

[0219] In some embodiments, the viral vectors produced by the present disclosure are suitable for use in the production and / or manufacturing process of generating many biologics and / or treatments using current good manufacturing practices (cGMP). In some embodiments, the viral vectors are suitable for industrial-scale manufacturing of biologics products. In some embodiments, the viral vectors are suitable for manufacturing methods that meet local regulatory standards (e.g., FDA and / or EMA regulatory standards).

[0220] The viral vector can be live and attenuated. In some embodiments, the viral vector can be replication conditional. In some embodiments, the viral vector can be replication defective. In some embodiments, the viral vector can be replication incompetent. In some embodiments, the viral vector is replication defective. In some embodiments, the viral vector has replication competence. In some embodiments, the viral vector is non-pathogenic.

[0221] In some embodiments, the disclosure provides a unique method whereby a viral vector obtains an identifier from an insect cell expressing it and incorporates it into its viral nucleic acid (e.g., a viral genome or construct, such as between viral repeat sequences). Therefore, the viral vectors produced by the insect cells and / or techniques of the present disclosure will have identifiers in their viral nucleic acids (e.g., viral genomes or constructs, such as between viral repeat sequences). In some embodiments, the viral vectors produced by the insect cells and / or methods of the present disclosure will include capsids and engineered sequences such as nucleic acids, wherein the nucleic acid includes (i) a payload, (ii) an identifier, and (iii) one or more sequences of the viral genome (e.g., for AAV, between AAV ITR sequences). In some embodiments, the identifier and / or payload, or a portion thereof, is subsequently removed from the viral vector. In some embodiments, the identifier and / or payload, or a portion thereof, is subsequently removed from the viral vector, wherein the payload, or a portion thereof, is replaced by another payload, or a portion thereof.

[0222] Adeno-associated virus (AAV) vector

[0223] In some embodiments, the viral vector produced by the methods and insect cells of the present disclosure is an adeno-associated virus (AAV) vector. AAV is a common viral vector for gene delivery. In some embodiments, the AAV vector has low immunogenicity (e.g., in humans). In some embodiments, the AAV vector is compatible with a wide range of host cells. In some embodiments, the AAV vector can transduce dividing cells and resting cells. In some embodiments, the insect cells of the present disclosure produce AAV vectors as described herein.

[0224] In some embodiments, the present disclosure provides nucleic acid sequences encoding one or more elements necessary for producing AAV vectors. The basic elements of AAV vectors may include Rep proteins and / or capsid (Cap) proteins (e.g., VP1, VP2, and VP3 forming AAV capsids). In some embodiments, the basic elements of AAV vectors may be encoded on one or more constructs (e.g., they may be integrated into or free present in insect cells). In some embodiments, nucleic acids encoding one or more elements necessary for producing AAV vectors are integrated into the genome of insect cells. In some embodiments, nucleic acids encoding one or more elements necessary for producing AAV vectors are free present in insect cells.

[0225] In some embodiments, the present disclosure provides an AAV vector comprising a capsid and a nucleic acid comprising a payload. In some embodiments, the AAV vector has an icosahedral protein capsid comprising a linear single-stranded DNA nucleic acid.

[0226] In some embodiments, the viral vector produced by the insect cells and / or methods of the present disclosure will comprise an AAV capsid and a nucleic acid, wherein the nucleic acid comprises (i) a payload, (ii) an identifier (e.g., comprising a barcode and / or a library variant), and (iii) two ITR sequences (e.g., derived from AAV).

[0227] In some embodiments, the AAV vector is derived from human AAV1; AAV2; AAV3b; AAV4; AAV5; AAV6; AAV7; AAV8; AAV9; AAV10; AAV11; AAV12; AAV13, or any derivative thereof. In some embodiments, the AAV vector is a synthetic and / or hybrid human AAV vector. In some embodiments, the AAV vector is derived from bovine AAV (b-AAV); canine AAV (CAAV); mouse AAV1; goat AAV; rat AAV; or avian AAV (AAAV).

[0228] In some embodiments, an AAV vector may be described as having a serotype, which is a description of the strain of the capsid strain and certain nucleic acid sequences (e.g., ITRs). For example, in some embodiments, an AAV vector may be described as AAV2, where the vector has an AAV2 capsid and nucleic acids comprising characteristic AAV2 inverted terminal repeats (ITRs). In some embodiments, an AAV vector may be described as a pseudotype, where the capsid and ITRs are derived from different AAV strains, e.g., AAV2 / 9 would refer to an AAV vector comprising a construct utilizing AAV2 ITRs and AAV9 capsid.

[0229] In some embodiments, the AAV vector has no serotype and / or pseudotype. In some embodiments, the AAV vector comprises an engineered AAV capsid and / or ITR (e.g., having no significant homology to the capsid and / or ITR of a known AAV serotype).

[0230] In some embodiments, the AAV vector of the present disclosure comprises an AAV capsid. In some embodiments, the AAV capsid is from or derived from an AAV capsid of an AAV2, 3, 4, 5, 6, 7, 8, 9, 10, rh8, rh10, rh39, rh43 or Anc80 serotype, or one or more hybrids thereof. In some embodiments, the AAV capsid is from an AAV ancestral serotype. In some embodiments, the AAV capsid is an ancestral (Anc) AAV capsid. The Anc capsid is created from a construct sequence, which is constructed using evolutionary probability and an evolutionary model to determine possible ancestral sequences. Therefore, it is not known whether there is an Anc capsid / construct sequence in nature. In some embodiments, the AAV capsid is an artificially engineered sequence (e.g., no significant homology with a known AAV serotype capsid).

[0231] As provided herein, the AAV vectors of the present disclosure can comprise any combination of an AAV capsid and an AAV nucleic acid (e.g., comprising a payload and / or AAV ITRs). For example, a wild-type or variant AAV capsid encapsulates an AAV nucleic acid comprising an identifier and / or a payload flanked by AAV-derived ITRs.

[0232] Typically, AAV nucleic acid is composed of single-stranded deoxyribonucleic acid (ssDNA). In some embodiments, AAV nucleic acid comprises one or more components derived from or modified from naturally occurring AAV genomes. In some embodiments, AAV nucleic acid comprises inverted terminal repeats (ITRs) derived from or modified from AAV. In some embodiments, AAV nucleic acid comprises a payload sequence and two ITRs. In some embodiments, the AAV vector comprises a capsid and ssDNA, and the ssDNA comprises a payload sequence and two viral repeats, such as ITR sequences, one at each end (5' and 3') of the DNA chain.

[0233] In some embodiments, the AAV nucleic acid provided comprises a payload comprising a coding sequence and one or more regulatory and / or control sequences, and optionally 5' and 3' AAV-derived inverted terminal repeats (ITRs). In some embodiments, the AAV nucleic acid provided is packaged into an AAV capsid to form an AAV vector.

[0234] In certain embodiments, a viral vector comprises a nucleic acid comprising an identifier and / or payload sequence and associated regulatory elements flanked by a 5' or "left" AAV ITR sequence and a 3' or "right" AAV ITR sequence. The 5' and left designations refer to the position of the ITR sequence relative to the entire construct, reading from left to right in the sense direction. One of ordinary skill in the art will understand how to modify a given ITR sequence for use as a 5' / left ITR or a 3' / right ITR, or an antisense version thereof.

[0235] In some embodiments, the AAV nucleic acid of the AAV vector described herein typically comprises a cis-acting 5'ITR sequence and a 3'ITR sequence (see, e.g., BJ Carter, in "Handbook of Parvoviruses," P. Tijsser, ed., CRC Press, pp. 155-168, 1990, which is incorporated herein by reference in its entirety). In some embodiments, at least 80% of the typical ITR sequences (e.g., at least 85%, at least 90%, or at least 95%) are incorporated into the constructs provided herein. The ability to modify these ITR sequences is within the capabilities of those skilled in the art. (See, e.g., texts such as Sambrook et al., "Molecular Cloning. A Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratory, New York, 1989; and K. Fisher et al., J Virol. 70:520-532, 1996, each of which is incorporated herein by reference). In some embodiments, the identifier and / or payload sequence is flanked by 5' and 3' AAV ITR sequences. In some embodiments, the AAV nucleic acid comprises an identifier and a payload flanked by 5' and 3' AAV ITR sequences. The AAV ITR sequences can be obtained from any known AAV, including the currently identified AAV types.

[0236] In some embodiments, the AAV vector nucleic acid comprises a payload, an identifier, and two AAV ITRs. In some embodiments, the AAV vector comprises a capsid and a dsDNA comprising (i) a payload and / or an identifier, and (ii) two AAV ITR sequences, one at each end (5' and 3') of the DNA strand.

[0237] Typically, ITRs are capable of forming hairpins. The ability to form hairpins can contribute to the self-priming ability of ITRs, allowing the synthesis of the second DNA chain independent of primase. ITRs can also help effectively encapsulate AAV constructs in AAV vectors. AAV ITR sequences can be obtained from any known AAV, including insect AAV types.

[0238] In some embodiments, the ITR includes one or more modifications of a naturally occurring ITR sequence, such as truncations, deletions, substitutions, or insertions. The ability to modify these ITR sequences is within the capabilities of those skilled in the art. (See, for example, texts such as Sambrook et al. "Molecular Cloning. A Laboratory Manual", 2nd Edition, Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520-532 (1996), each of which is incorporated herein by reference in its entirety). For example, the length of the AAV2-derived ITR sequence is about 145 nucleotides. In some embodiments, the ITR comprises less than 145 nucleotides, such as 127, 130, 134, or 141 nucleotides. For example, in some embodiments, the ITR comprises 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, or 145 nucleotides.

[0239] In some embodiments, the AAV vector payload further comprises conventional control elements operably linked to the coding sequence in a manner that allows it to be transcribed, translated, and / or expressed in cells transfected with the construct or infected with a viral vector produced by the disclosure. In some embodiments, the AAV vector payload optionally comprises a promoter, an enhancer, an untranslated region (e.g., 5'UTR, 3'UTR), a Kozak sequence, an internal ribosome entry site (IRES), a splice site (e.g., an acceptor site, a donor site), a polyadenylation site, and / or any combination thereof.

[0240] In some embodiments, the AAV vector payload is less than 4 kb. In some embodiments, the AAV vector payload may comprise at least 500 bp, at least 1 kb, at least 1.5 kb, at least 2 kb, at least 2.5 kb, at least 3 kb, at least 3.5 kb, at least 4 kb, or at least 4.5 kb of sequence. In some embodiments, the AAV vector payload may comprise at most 7.5 kb, at most 7 kb, at most 6.5 kb, at most 6 kb, at most 5.5 kb, at most 5 kb, at most 4.5 kb, at most 4 kb, at most 3.5 kb, at most 3 kb, or at most 2.5 kb of sequence. In some embodiments, the AAV vector payload can comprise a sequence of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 3 kb to about 4 kb, about 3 kb to about 5 kb, or about 4 kb to about 5 kb.

[0241] In some embodiments, the AAV vector can direct long-term expression of the payload. In some embodiments, the AAV vector can direct transient expression of the payload.

[0242] In some embodiments, the AAV vector produced by the insect cells and / or methods of the present disclosure will comprise an AAV capsid and a nucleic acid, wherein the nucleic acid comprises (i) a payload, (ii) an identifier (e.g., a barcode and / or a library variant), and (iii) two viral repeat sequences (e.g., ITRs derived from AAV).

[0243] In some embodiments, the insect cells of the insect cell library are genetically modified to include one or more nucleic acid sequences necessary for producing AAV vectors. In some embodiments, the insect cells of the insect cell library can have one or more AAV vector components provided, such as rep sequences, cap sequences, and auxiliary functions required for producing AAV vectors. In some embodiments, one or more components of the AAV vector (e.g., AAV Rep gene, AAV Cap gene, one or more auxiliary genes, or a combination thereof) are under the control of an inducible transcription control element (e.g., a promoter and / or enhancer). In some embodiments, the insect cell (e.g., the insect cell of an insect cell population) comprises: (i) an identifier located between two viral repeat sequences, and (ii) one or more polynucleotides comprising AAV Rep gene, AAV Cap gene, one or more auxiliary genes, and / or a combination thereof, wherein the insect cell produces an AAV vector comprising an identifier. In some embodiments, the AAV vector comprises a payload. In some embodiments, the identifier and / or payload or a portion thereof is subsequently removed from the AAV vector. In some embodiments where the identifier and / or payload or a portion thereof is removed from the AAV vector, the payload or a portion thereof is replaced by a different payload or a portion thereof.

[0244] Adenoviral vector

[0245] In some embodiments, the viral vector produced by the methods and insect cells of the present disclosure is an adenoviral vector. Adenoviruses are non-enveloped viruses that are often used as vaccines due to the strong immunogenic response they induce. Some adenoviruses are used in cancer therapy because of their ability to preferentially infect and kill cancer cells.

[0246] In some embodiments, the adenoviral vector is derived from a human adenovirus. Human adenovirus encompasses a family of at least 51 serotypes, which are classified into several subgroups. For example, subgroup A includes adenovirus serotypes 12, 18, and 31. Subgroup B includes adenovirus serotypes 3, 7, 11a, 11p, 14, 16, 21, 34, 35, and 50. Subgroup C includes adenovirus serotypes 1, 2, 5, and 6. Subgroup D includes adenovirus serotypes 8, 9, 10, 13, 15, 17, 19, 19p, 20, 22-30, 32, 33, 36-39, 42-49, and 51. Subgroup E includes adenovirus serotype 4. Subgroup F includes adenovirus serotypes 40 and 41. The adenoviral vectors disclosed herein may belong to any adenovirus group, subgroup, and / or serotype.

[0247] In some embodiments, the adenoviral vector is derived from any serotype, such as serotype 1 to serotype 51 (e.g., 1, 2, 4, 5...51). For example, in some embodiments, the adenovirus is a type 2 adenovirus or a type 5 adenovirus. In certain embodiments, the adenoviral vector is derived at least in part from a type 5 adenovirus.

[0248] In some embodiments, the adenoviral vector is replication defective (e.g., certain essential viral genes are deleted and / or replaced with payload sequences). Any adenoviral vector used in the methods described herein may include a deletion in any one or more of the E1, E2a, E2b, E3 or E4 coding regions. In some embodiments, the adenoviral vector is replication defective and lacks the E4 locus (e.g., the E4 coding region is deleted). In some embodiments, the replication defective adenoviral vector can be used as a vaccine for cancer treatment and / or gene therapy.

[0249] In general, adenoviruses are characterized by high transduction efficiency and direct high transgene expression. In some embodiments, adenoviral vectors can direct transient expression of a payload. In some embodiments, adenoviral vectors direct transient expression of a payload in a target cell.

[0250] In some embodiments, the adenoviral vector is replication-competent. For example, a replication-competent adenoviral vector (e.g., an oncolytic vector) can be engineered to preferentially replicate in cancer cells and destroy cancer cells by the natural process of lytic viral replication.

[0251] In some embodiments, the disclosure provides an adenoviral vector comprising a capsid and a nucleic acid comprising a payload. In some embodiments, the adenoviral vector has an icosahedral protein capsid comprising a linear duplex nucleic acid. In some embodiments, the adenoviral vector has an icosahedral protein capsid comprising a linear double-stranded DNA.

[0252] Typically, adenoviral vector nucleic acid consists of double-stranded DNA (dsDNA) and has one or more components derived from or modified from a naturally occurring adenoviral genome. In some embodiments, adenoviral vector nucleic acid comprises an inverted terminal repeat (ITR) sequence derived from or modified from an adenovirus of any serotype (e.g., adenovirus type 5). In some embodiments, adenoviral vector nucleic acid comprises a payload and two viral repeat sequences, such as ITR. In some embodiments, adenoviral vector nucleic acid comprises an identifier and two viral repeat sequences, such as ITR. In some embodiments, adenoviral vector nucleic acid comprises a payload, an identifier, and two viral repeat sequences, such as ITR. In some embodiments, an adenoviral vector comprises a capsid and a dsDNA, the dsDNA comprising (i) a payload and / or an identifier, and (ii) two ITR sequences, one at each end (5' and 3') of the DNA chain.

[0253] In some embodiments, the adenovirus ITR has a sequence length of about 40 bp to about 200 bp. For example, the ITR of human adenovirus type 5 is 103 bp. In some embodiments, the adenovirus ITR has a length of about 30 bp, about 40 bp, about 50 bp, about 60 bp, about 70 bp, about 80 bp, about 90 bp, about 100 bp, about 110 bp, about 120 bp, about 130 bp, about 140 bp, about 150 bp, about 160 bp, about 170 bp, about 180 bp, about 190 bp, about 200 bp, about 220 bp, about 240 bp, about 260 bp, about 280 bp, about 300 bp, about 325 bp, about 350 bp, about 375 bp, or about 400 bp. In some specific embodiments, the adenovirus ITR sequence is about 50 to about 250 bp.

[0254] In some embodiments, the adenoviral vector provided comprises an adenovirus-derived capsid and a nucleic acid comprising a payload and one or more adenovirus-derived sequences (such as ITRs). In some embodiments, the adenoviral vector provided comprises an adenovirus-derived capsid and a nucleic acid comprising an identifier, a payload, and at least two viral repeats. In some embodiments, the adenoviral vector comprises an identifier comprising a barcode and / or a library variant. In some embodiments, the adenoviral vector payload comprises a coding sequence and one or more regulatory and / or control sequences. In some embodiments, the adenoviral vector comprises 5' and 3' adenovirus-derived inverted terminal repeats (ITRs). In some specific embodiments, the adenoviral vector comprises a capsid and an engineered adenoviral genome, wherein the engineered genome comprises a deletion of certain sequences (e.g., an E1 deletion and / or an E3 deletion) and an insertion of a payload and / or an identifier.

[0255] In some embodiments, the adenoviral vector payload is less than 7.5 kb. In some embodiments, the adenoviral vector payload may comprise at least 500 bp, at least 1 kb, at least 1.5 kb, at least 2 kb, at least 2.5 kb, at least 3 kb, at least 3.5 kb, at least 4 kb, at least 4.5 kb, at least 5 kb, at least 5.5 kb, at least 6 kb, at least 6.5 kb, at least 7 kb, at least 7.5 kb of sequence. In some embodiments, the adenoviral vector payload may comprise at most 10 kb, at most 9.5 kb, at most 9 kb, at most 8.5 kb, at most 8 kb, at most 7.5 kb, at most 7 kb, at most 6.5 kb, at most 6 kb, at most 5.5 kb, at most 5 kb, at most 4.5 kb, or at most 4 kb of sequence. In some embodiments, the adenoviral vector payload can comprise a sequence of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 1 kb to about 9 kb, about 1 kb to about 10 kb, about 2 kb to about 4 kb, about 2 kb to about 6 kb, about 2 kb to about 8 kb, about 2 kb to about 10 kb, about 4 kb to about 6 kb, about 4 kb to about 8 kb, or about 5 kb to about 8 kb.

[0256] In some embodiments, an adenoviral vector produced by the insect cells and / or methods of the present disclosure will comprise an adenoviral capsid and a nucleic acid, wherein the nucleic acid comprises (i) a payload, (ii) an identifier (e.g., a barcode and / or a library variant), and (iii) two viral repeat sequences (e.g., ITRs derived from an adenovirus).

[0257] In some embodiments, the insect cells of the insect cell library are genetically modified to contain one or more nucleic acid sequences necessary for producing adenoviral vectors. In some embodiments, the insect cells of the insect cell library may have one or more adenoviral vector components provided, such as rep sequences, cap sequences, and auxiliary functions required for producing adenoviral vectors. In some embodiments, one or more components of an adenoviral vector (e.g., an adenoviral Rep gene, an adenoviral Cap gene, one or more auxiliary genes, or a combination thereof) are under the control of an inducible transcription control element (e.g., a promoter and / or an enhancer). In some embodiments, an insect cell (e.g., an insect cell of an insect cell population) comprises: (i) an identifier located between two viral repeat sequences, and (ii) one or more polynucleotides comprising an adenoviral Rep gene, an adenoviral Cap gene, one or more auxiliary genes, and / or a combination thereof, wherein the insect cell produces an adenoviral vector comprising an identifier. In some embodiments, the adenoviral vector comprises a payload. In some embodiments, the identifier and / or payload, or a portion thereof, is subsequently removed from the adenoviral vector. In some embodiments in which the identifier and / or payload, or a portion thereof, is removed from the adenoviral vector, the payload, or a portion thereof, is replaced by a different payload, or a portion thereof.

[0258] Retroviral and lentiviral vectors

[0259] In some embodiments, the viral vector produced by the methods and insect cells of the present disclosure is a retroviral vector. Retroviruses are enveloped viruses that replicate in host cells by transcribing their RNA into DNA using a viral reverse transcriptase. Retroviral DNA replicates as part of the host genome and is referred to as a provirus. Retroviral vectors may include, but are not limited to, those based on or derived from murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), ecotropic retroviruses, simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV) and combinations thereof.

[0260] In some embodiments, the viral vector produced by the methods and insect cells of the present disclosure is a lentiviral vector. Lentiviral vectors are versatile tools because they have the ability to transduce non-dividing cells. In some embodiments, lentiviral vectors can infect dividing cells and non-dividing cells. Typically, lentiviral vectors enable long-term and / or stable gene expression and are integrated into the host cell genome.

[0261] Lentivirus is an enveloped particle with a diameter of about 80 to about 120 nm. In some embodiments, the present disclosure provides a lentiviral vector having a diameter in the range of about 50 nm to about 200 nm. In some embodiments, the present disclosure provides a lentiviral vector having a diameter in the range of about 80 nm to about 120 nm.

[0262] Lentiviruses can contain several structural proteins, including matrix, capsid, nucleocapsid, envelope, and reverse transcriptase protein. In some embodiments, the present disclosure provides a lentiviral vector comprising a capsid, an envelope. In some embodiments, the present disclosure provides a lentiviral vector comprising a capsid, an envelope, and a nucleic acid. In some embodiments, the present disclosure provides a lentiviral vector comprising a capsid, an envelope, and a nucleic acid comprising a payload and / or an identifier.

[0263] In some embodiments, the lentiviral vector produced by the insect cells and / or methods of the present disclosure will comprise a lentiviral capsid (or a derivative thereof), an envelope, and a nucleic acid, wherein the nucleic acid comprises (i) a payload, (ii) an identifier, and (iii) two long terminal repeat (LTR) sequences (e.g., derived from a lentivirus). In some embodiments, the two LTR sequences are capable of packaging the nucleic acid into a lentiviral vector. In some embodiments, the lentiviral vector comprises a lentiviral Psi sequence (or a derivative or engineered variant thereof).

[0264] In some embodiments, lentiviral vectors include those based on human immunodeficiency virus (HIV-1, HIV-2), feline immunodeficiency virus (FIV), equine infectious anemia virus, simian immunodeficiency virus (SIV), and Maeve-Visna virus (MVV). In some embodiments, the lentiviral nucleic acid (i.e., engineered genome) and envelope glycoproteins will be based on different viruses, such that the resulting viral vector is pseudotyped.

[0265] In some embodiments, the lentiviral vector is derived from HIV-1. In some embodiments, the lentiviral vector is derived from HIV-1 and comprises a capsid protein and a nucleic acid, the nucleic acid comprising (i) a payload, (ii) an identifier, and (iii) two long terminal repeat (LTR) sequences (e.g., derived from a lentivirus). In some embodiments, the lentiviral vector is an HIV vector and wherein the insect cell comprises two viral repeats comprising an HIV LTR sequence. In some embodiments, the lentiviral vector is an SIV vector and wherein the insect cell comprises two viral repeats comprising an SIV LTR sequence. In some embodiments, the lentiviral vector is an equine infectious anemia virus vector and wherein the insect cell comprises two viral repeats comprising an equine infectious anemia virus LTR sequence. In some embodiments, the lentiviral vector is an FIV vector and wherein the insect cell comprises two viral repeats comprising an FIV LTR sequence. In some embodiments, the lentiviral vector is a Vesna virus vector and wherein the insect cell comprises two viral repeats comprising a Vesna virus LTR sequence.

[0266] In some embodiments, the lentiviral vector comprises a gag protein or a fragment thereof. In some embodiments, the lentiviral vector comprises a gag protein comprising one or more domains selected from a matrix (MA), a capsid (CA), and a nucleocapsid (NC) domain. In some embodiments, the lentiviral vector comprises an envelope protein or a fragment thereof. In some embodiments, the lentiviral vector is a pseudotyped lentiviral vector, wherein the gag protein and the envelope protein are derived from different viruses. In some embodiments, the lentiviral vector comprises a gag protein and / or an env protein derived from a human immunodeficiency virus (HIV) vector, a simian immunodeficiency virus (SIV) vector, an equine infectious anemia virus vector, a feline immunodeficiency virus vector, a visna virus vector, or a derivative thereof.

[0267] In some embodiments, the lentiviral vector comprises (i) a lentiviral gag gene, (ii) a lentiviral env gene, (iii) a lentiviral pol gene, or (iv) a combination thereof. In some embodiments, the insect cell expressing the lentiviral vector comprises one or more of the following: (i) a lentiviral gag gene, (ii) a lentiviral env gene, and (iii) a lentiviral pol gene.

[0268] In some embodiments, safety features are incorporated into the lentiviral vector, which may include, for example, self-inactivating long terminal repeats (LTRs) and integration defects. In certain embodiments, integration defects may be conferred by elements of the vector genome, but may also originate from elements of the packaging system (e.g., a non-functional integrase protein that may not be part of the vector genome but is provided in trans).

[0269] A lentivirus has a single-stranded RNA (ssRNA) genome. In some embodiments, a lentiviral vector comprises a nucleic acid that is ssRNA, and comprises a payload and sequence derived from a lentivirus such as HIV-1 and / or SIV. In some embodiments, the payload is flanked by a long terminal repeat (LTR) sequence. In some embodiments, a lentiviral vector comprises a nucleic acid that is ssRNA, and comprises an identifier and a viral repeat sequence (e.g., HIV-1 and / or SIV LTR). In some embodiments, a lentiviral vector comprises a nucleic acid that is ssRNA, and comprises a payload, an identifier, and a viral repeat sequence (e.g., HIV-1 and / or SIV LTR).

[0270] In some embodiments, the lentiviral vector nucleic acid may comprise sequences from the 5'LTR and 3'LTR of a lentivirus, and in particular may comprise an R sequence and a U5 sequence from the 5'LTR of a lentivirus and an inactivated or self-inactivated 3'LTR from a lentivirus. The LTR sequences may be LTR sequences of any lentivirus from any species. For example, they may be LTR sequences from HIV, SIV, FIV, or BIV. In some embodiments, the LTR sequence is an HIV LTR sequence.

[0271] In some embodiments, the lentiviral vector payload is less than 8 kb. In some embodiments, the lentiviral vector payload may comprise at least 500 bp, at least 1 kb, at least 1.5 kb, at least 2 kb, at least 2.5 kb, at least 3 kb, at least 3.5 kb, at least 4 kb, at least 4.5 kb, at least 5 kb, at least 5.5 kb, at least 6 kb, at least 6.5 kb, at least 7 kb, at least 7.5 kb, or at least 8 kb of sequence. In some embodiments, the lentiviral vector payload may comprise at most 10 kb, at most 9.5 kb, at most 9 kb, at most 8.5 kb, at most 8 kb, at most 7.5 kb, at most 7 kb, at most 6.5 kb, at most 6 kb, at most 5.5 kb, at most 5 kb, at most 4.5 kb, or at most 4 kb of sequence. In some embodiments, the lentiviral vector payload can comprise a sequence of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 1 kb to about 9 kb, about 1 kb to about 10 kb, about 2 kb to about 4 kb, about 2 kb to about 6 kb, about 2 kb to about 8 kb, about 2 kb to about 10 kb, about 4 kb to about 6 kb, about 4 kb to about 8 kb, or about 5 kb to about 8 kb.

[0272] In some embodiments, the insect cells of the insect cell library are genetically modified to contain one or more nucleic acid sequences necessary for producing a lentiviral vector. In some embodiments, the insect cells of the insect cell library may have one or more lentiviral vector components provided. In some embodiments, one or more components of the lentiviral vector are under the control of an inducible transcriptional control element (e.g., a promoter and / or enhancer). In some embodiments, the insect cells (e.g., insect cells of an insect cell population) contain: (i) an identifier located between two viral repeat sequences, and (ii) one or more polynucleotides necessary for producing a lentiviral vector, wherein the insect cells produce a lentiviral vector comprising an identifier. In some embodiments, the lentiviral vector comprises a payload. In some embodiments, the identifier and / or payload or a portion thereof is subsequently removed from the lentiviral vector. In some specific embodiments in which the identifier and / or payload or a portion thereof is removed from the lentiviral vector, the payload or a portion thereof is replaced by a different payload or a portion thereof.

[0273] HSV vector

[0274] In some embodiments, the viral vector produced by the methods and insect cells of the present disclosure is a herpes simplex virus (HSV) vector. HSV is a large enveloped virus with an icosahedral capsid containing a circular dsDNA genome. HSV is characterized in vivo by a lifelong potential infection of neurons. This feature makes HSV vectors useful for long-term transgenic expression. In some embodiments, the HSV vector is a replication-competent attenuated vector, a replication-incompetent recombinant vector, or a replication-deficient helper-dependent vector.

[0275] In some embodiments, the HSV vector has a diameter in the range of about 120 nm to about 200 nm. In some embodiments, the HSV vector is an enveloped particle having a diameter of about 120 to about 200 nm. In some embodiments, the HSV vector has a diameter in the range of about 100 nm to about 200 nm.

[0276] In some embodiments, the HSV vector is from or derived from herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), human cytomegalovirus (HCMV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), human herpesvirus 6 and / or human herpesvirus 7 and / or derivatives thereof. In some embodiments, the HSV vector is from or derived from HSV-1, HSV-2, or a combination thereof (e.g., comprising a capsid from HSV-1 and comprising a nucleic acid sequence derived from HSV-2).

[0277] In some embodiments, the viral vector is a HSV-AAV hybrid vector.

[0278] The natural HSV-1 genome consists of two genomic coding regions, called the long unique segment and the short unique segment (SU). L and U S ), each of which is flanked by inverted repeat sequences (TR L / IR L and IR S / TR S ). In some embodiments, the HSV vector is engineered to lack or delete ICP0, ICP4, ICP22, ICP27, and / or ICP47 to reduce toxicity. Methods and considerations for designing HSV vectors are known in the art, for example, Manservigi et al., Open Virol J. 2010; 4: 123–156.

[0279] In some embodiments, the present disclosure provides an HSV vector comprising a capsid protein and a nucleic acid comprising a payload. In some embodiments, the HSV vector comprises a capsid comprising VP5, VP19C, VP23, pre-VP22a and / or a mature protease (UL26 gene product).

[0280] In some embodiments, the HSV nucleic acid further comprises a sequence obtained or derived from an HSV virus (e.g., TR L / IR L and / or IR S / TR S In some embodiments, the present disclosure provides an HSV vector comprising a capsid protein and comprising an HSV viral repeat sequence (e.g., TR L / IR L and / or IR S / TR S In some embodiments, the present disclosure provides an HSV vector comprising a capsid, an envelope, and a nucleic acid comprising a payload. In some embodiments, the present disclosure provides an HSV vector comprising a capsid, an envelope, and a nucleic acid comprising a payload and an HSV viral repeat sequence (e.g., TR L / IR L and / or IR S / TR S sequence) nucleic acid.

[0281] In some embodiments, the HSV vector payload is less than 100 kb. In some embodiments, the HSV vector payload can comprise at least 1 kb, at least 2 kb, at least 3 kb, at least 4 kb, at least 5 kb, at least 6 kb, at least 7 kb, at least 8 kb, at least 9 kb, at least 10 kb, at least 15 kb, at least 20 kb, at least 25 kb, at least 30 kb, at least 40 kb, or at least 50 kb of sequence. In some embodiments, the HSV vector payload can contain at most 150 kb, at most 140 kb, at most 130 kb, at most 120 kb, at most 110 kb, at most 100 kb, at most 90 kb, at most 80 kb, at most 70 kb, at most 60 kb, at most 50 kb, at most 40 kb, at most 30 kb, at most 25 kb, at most 20 kb, at most 15 kb, or at most 10 kb of sequence. In some embodiments, the lentiviral vector payload can comprise a sequence of about 1 kb to about 150 kb, about 1 kb to about 100 kb, about 1 kb to about 50 kb, about 1 kb to about 25 kb, about 5 kb to about 100 kb, about 5 kb to about 90 kb, about 5 kb to about 80 kb, about 5 kb to about 70 kb, about 5 kb to about 60 kb, about 5 kb to about 50 kb, about 5 kb to about 40 kb, about 5 kb to about 30 kb, about 5 kb to about 25 kb, about 5 kb to about 20 kb, about 5 kb to about 15 kb, about 5 kb to about 10 kb, about 10 kb to about 100 kb, about 10 kb to about 50 kb, or about 10 kb to about 25 kb.

[0282] In some embodiments, the present disclosure provides an HSV vector comprising a capsid protein and a nucleic acid comprising an identifier. In some embodiments, the present disclosure provides an HSV vector comprising a capsid protein and a nucleic acid comprising an identifier and an HSV viral repeat sequence (e.g., TR L / IR L and / or IR S / TR S In some embodiments, the present disclosure provides an HSV vector comprising a capsid, an envelope, and a nucleic acid comprising an identifier. In some embodiments, the present disclosure provides an HSV vector comprising a capsid, an envelope, and a nucleic acid comprising an identifier and an HSV viral repeat sequence (e.g., TR L / IR L and / or IR S / TR S In some embodiments, the HSV vector comprises two viral repeat sequences, and the two viral repeat sequences comprise a terminal a sequence.

[0283] In some embodiments, the HSV nucleic acid comprises a payload, an identifier, and one or more sequences obtained or derived from an HSV virus. In some embodiments, the HSV vector produced by the methods and / or insect cells of the present disclosure comprises an HSV capsid, an envelope, and a payload, an identifier, and one or more sequences obtained or derived from an HSV virus (e.g., TR L / IR L and / or IR S / TR S In some embodiments, the HSV vector comprises an HSV capsid, an envelope, and a nucleic acid comprising a payload and / or an identifier, flanked by HSV viral repeat sequences (e.g., TR L / IR L and / or IR S / TR S sequence) nucleic acid.

[0284] In some embodiments, the insect cells of the insect cell library are genetically modified to contain one or more nucleic acid sequences necessary for producing HSV vectors. In some embodiments, the insect cells of the insect cell library may have one or more HSV vector components provided. In some embodiments, one or more components of the HSV vector are under the control of an inducible transcription control element (e.g., a promoter and / or enhancer). In some embodiments, the insect cells (e.g., insect cells of an insect cell population) contain: (i) an identifier located between two viral repeat sequences, and (ii) one or more polynucleotides necessary for producing HSV vectors, wherein the insect cells produce HSV vectors comprising identifiers. In some embodiments, the HSV vector comprises a payload. In some embodiments, the identifier and / or payload or a portion thereof is subsequently removed from the HSV vector. In some specific embodiments in which the identifier and / or payload or a portion thereof is removed from the HSV vector, the payload or a portion thereof is replaced by a different payload or a portion thereof.

[0285] Baculovirus vector

[0286] Baculoviruses are the most significant viruses known to affect insect populations. They are double-stranded, circular, supercoiled DNA molecules located in a rod-shaped capsid. Baculoviruses have a double-stranded circular DNA genome that is usually between 80 kb and 200 kb in length.

[0287] Traditionally, baculoviruses are divided into two morphologically distinct genera: nuclear polyhedrosis virus (NPV) and granulovirus. Modern classifications generally divide baculoviruses into four genera: alpha baculovirus (NPV specific to Lepidoptera), beta baculovirus (granulovirus specific to Lepidoptera), gamma baculovirus (NPV specific to Hymenoptera), and delta baculovirus (NPV specific to Diptera). In some embodiments, the baculovirus is Autographa californica multinuclear polyhedrosis virus (AcMNPV) or a derivative thereof.

[0288] In some embodiments, the baculovirus expression vector comprises a payload. In some embodiments, the payload is inserted into a non-essential genomic locus of the baculovirus genome, such as, for example, the egt locus and / or the polyhedrin locus.

[0289] In some embodiments, one or more components of the viral vector are transferred to insect cells using a baculovirus vector. For example, in some embodiments, the baculovirus vector can include one or more sequences from an AAV vector in its genome. In some embodiments, the baculovirus vector includes an AAV ITR sequence and an identifier. In some embodiments, the baculovirus vector including an AAV ITR sequence and an identifier (e.g., between the ITR sequences) can also include a payload and / or one or more library variants.

[0290] Library constructs

[0291] In the context of the present disclosure, the present disclosure provides library constructs for engineered insect cells. In some embodiments, the library constructs can include two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more engineered sequences. In some embodiments, the library constructs can include up to 100 engineered sequences.

[0292] The library construct comprises at least an identifier and a genetic structure suitable for packaging the identifier into a viral vector. As used herein, the library construct will also comprise any library variant. In some embodiments, the library construct also comprises a payload for packaging into a viral vector (e.g., between viral repetitive sequences). For example, in some embodiments, the library construct comprises (i) an identifier and a payload, which is located between viral repetitive sequences, and (ii) at least one engineered sequence comprising at least one library variant.

[0293] In some embodiments, the library construct further comprises one or more constructs comprising cis-acting integration sequences (e.g., homology arms, recognition sites, and / or viral repeat sequences). For example, in some embodiments, the library construct comprises (i) an identifier and a payload located between viral repeat sequences, (ii) at least one engineered sequence comprising at least one library variant, and (iii) a cis-acting integration sequence for integrating the library construct or a portion thereof into the insect cell genome.

[0294] In some embodiments, the library construct further comprises at least one barcode. For example, in some embodiments, the library construct comprises (i) an identifier and a payload, which are located between viral repeat sequences, (ii) at least one engineered sequence comprising at least one library variant, and (iii) at least one barcode. As another example, in some embodiments, the library construct comprises (i) an identifier and a payload, which are located between viral repeat sequences, (ii) at least one engineered sequence comprising at least one library variant, (iii) at least one barcode, and (iv) a cis-acting integration sequence for integrating the library construct or a portion thereof into the insect genome.

[0295] In some embodiments, the library construct also includes at least one engineered sequence, and the at least one engineered sequence includes at least one reporter gene and / or a selective marker. In some embodiments, one or more polynucleotides comprising the library construct include a reporter gene and / or a selective marker. Any suitable reporter gene (for example, GFP, RFP, YFP, lacZ, etc.) or selective marker (for example, it gives a trait that can be artificially selected, for example, a resistance box, etc.) can be used in the context of the present disclosure.

[0296] Library construct contiguity

[0297] The library construct can be a single continuous construct or a plurality of discontinuous constructs. In some embodiments, the library construct is a single (i.e., one) continuous construct. In such embodiments with a single continuous library construct, the characterization of the resulting viral vector will directly provide information about any library variant (e.g., the determination of the viral vector identifier can be directly associated with any library variant). In some embodiments, the library construct comprises a plurality of discontinuous constructs. In such embodiments where the library construct is a discontinuous library construct, the method provided will also include the step of identifying the library variant in the insect cell (e.g., by single cell sequencing).

[0298] In some embodiments, the insect cell population comprises a plurality of library constructs, wherein each individual library construct consists of a single continuous nucleic acid sequence, and wherein the plurality of library constructs comprises a plurality of unique nucleic acid sequences. In some embodiments, the insect cell population comprises a plurality of library constructs, wherein each individual library construct consists of a discontinuous nucleic acid sequence, and wherein the plurality of library constructs comprises a plurality of unique nucleic acid sequences.

[0299] In some embodiments, the insect cells provided contain a library construct comprising a plurality of polynucleotides, wherein each individual insect cell contains exactly one unique polynucleotide in a first subset of the plurality of polynucleotides constituting the library construct and two or more unique polynucleotides in a second subset of the plurality of polynucleotides constituting the library construct. For example, in some embodiments, each individual insect cell contains exactly one unique identifier and two or more unique library variants. In some embodiments, the insect cells provided contain a library construct comprising a plurality of polynucleotides, wherein each individual insect cell contains exactly two unique polynucleotides in a first subset of the plurality of polynucleotides constituting the library construct and a plurality of unique polynucleotides in a second subset of the plurality of polynucleotides constituting the library construct. For example, in some embodiments, each individual insect cell contains exactly two unique identifiers and a plurality of unique library variants.

[0300] Continuous library constructs

[0301] In some embodiments, the library construct is a single continuous construct comprising at least one identifier, flanked by a genetic structure suitable for packaging the identifier into a viral vector (e.g., a viral repetitive sequence, e.g., an AAV ITR sequence), and any library variants. In some embodiments, a single continuous library construct comprises an identifier and one or more library variants, wherein the identifier and the library variant are located between the viral repetitive sequences. In some embodiments, a single continuous library construct comprises an identifier between the viral repetitive sequences and one or more library variants located outside the viral repetitive sequences. In some embodiments, a single continuous library construct comprises an identifier between the viral repetitive sequences and one or more library variants, and one or more other library variants located outside the viral repetitive sequences. In some embodiments, the library construct is a continuous library construct, and comprises a reporter gene and / or a selection marker. Some exemplary configurations of a single continuous library construct are provided in Table 1 below.

[0302] Table 1 - Exemplary library constructs as a single contiguous construct

[0303]

[0304]

[0305] Location and copy number in cells

[0306] In some embodiments, the library construct is episomal and / or integrated into the insect cell genome. In some embodiments, the library construct is a single continuous construct that is episomal. In some embodiments, the library construct is a single continuous construct that is integrated into the insect cell genome.

[0307] In some embodiments, the library construct further comprises a cis-acting integration sequence for integration into the insect cell genome. For example, any of the exemplary embodiments of Table 1 may further comprise a cis-acting integration sequence (e.g., homology arms, recognition sites and / or viral repeat sequences).

[0308] In some embodiments, a single continuous library construct is integrated into the insect cell genome. In some embodiments, a single continuous library construct comprises a cis-acting integration sequence. In some embodiments, a single continuous library construct comprises a cis-acting integration sequence at the 3' and 5' ends of the library construct. In some embodiments, a single continuous library construct is integrated into the insect cell genome with a low copy number (e.g., a library construct of 10 or less copies). In some embodiments, a single continuous library construct of four or less copies is integrated into the insect cell genome. In some embodiments, a single continuous library construct of three or less copies is integrated into the insect cell genome. In some embodiments, a single continuous library construct of two or less copies is integrated into the insect cell genome. In some embodiments, a single continuous library construct of a single copy is integrated into the insect cell genome.

[0309] In some embodiments, a single continuous library construct is present in insect cells free. In some embodiments, a single continuous library construct is present in insect cells free with a low copy number (e.g., 10 or fewer copies of the library construct, e.g., 4 or fewer copies of the library construct, e.g., 3 or fewer copies of the library construct, 2 or fewer copies of the library construct, e.g., a single (one) copy of the library construct).

[0310] Discontinuous library constructs

[0311] In some embodiments, the method and cell provided include discontinuous library constructs, which make it possible, for example, to screen multiple library variants simultaneously. In some embodiments, the library construct includes multiple discontinuous constructs, wherein at least one construct includes an identifier and is suitable for packaging the identifier into the genetic structure in a viral vector. In some embodiments, the discontinuous library construct includes a first construct, and the first construct includes an identifier and one or more other constructs positioned between viral repetitive sequences. In some embodiments, the discontinuous library construct includes a first construct, and the first construct includes an identifier and a payload positioned between viral repetitive sequences and one or more other constructs comprising one or more library variants. In some embodiments, the discontinuous library construct includes a first construct, and the first construct includes any single continuous library construct and one or more other constructs (for example, including other library variants) such as described in Table 1.

[0312] In some embodiments, other discontinuous library constructs include components of viral vectors, such as viral Cap genes and barcodes. In some embodiments, the library includes library constructs with engineered or different serotype viral vector components (e.g., Cap genes). For example, viral Cap gene libraries with Cap genes of different serotypes can be screened simultaneously (e.g., to select insect cells with improved characteristics for viral vectors of multiple different serotypes).

[0313] In some specific embodiments, one or more other constructs comprise library variants, which are variant viral vector components (e.g., engineered or of different serotypes). In some embodiments, the library construct comprises a library construct described in Table 1 and one or more other constructs, wherein at least one other construct comprises a viral Cap gene and a barcode.

[0314] In some embodiments, multiple different library variant libraries are screened, each library being associated with a different identifier. For example, a gRNA library variant library and a Cap gene variant library can be screened simultaneously; this will make it possible to select gRNA variants enriched in different Cap gene library variants (e.g., to select those gRNA-mediated perturbations that have a beneficial effect on different viral vector serotypes).

[0315] In some embodiments, the library construct further comprises one, two, three, four, five or more constructs, each of which comprises one or more library variants. In some embodiments, one or more of the other constructs comprising one or more library variants and / or the construct comprising the identifier further comprises one or more barcodes.

[0316] In some embodiments, the library construct is a discontinuous library construct comprising two, three, four, five, six, seven, eight, nine or ten discontinuous nucleic acid sequences (e.g., separate constructs). In some embodiments, the library construct is a discontinuous library construct comprising up to 20 discontinuous nucleic acid sequences, up to 30 discontinuous nucleic acid sequences, up to 40 discontinuous nucleic acid sequences, up to 50 discontinuous nucleic acid sequences, up to 60 discontinuous nucleic acid sequences, up to 70 discontinuous nucleic acid sequences, up to 80 discontinuous nucleic acid sequences, up to 90 discontinuous nucleic acid sequences or up to 100 discontinuous nucleic acid sequences.

[0317] In some embodiments, the library construct is discontinuous and one or more independent polynucleotides of the library construct comprise a reporter gene and / or a selection marker. In some embodiments, the library construct is discontinuous and a plurality of independent polynucleotides of the library construct comprise a reporter gene and / or a selection marker. In some embodiments, the library construct is discontinuous and each independent polynucleotide of the library construct comprises a reporter gene and / or a selection marker.

[0318] Table 2 - Exemplary discontinuous library constructs

[0319]

[0320] Location and copy number in cells

[0321] In some embodiments, the library constructs are discontinuous and one or more individual constructs are episomal. In some embodiments, the library constructs are discontinuous and one or more individual constructs are integrated into the insect cell genome. In some embodiments, the library constructs are discontinuous and at least one construct is episomal and at least one construct is integrated into the insect cell genome.

[0322] In some embodiments, one or more independent constructs of discontinuous library constructs are integrated into the insect cell genome. In some embodiments, one or more independent constructs of discontinuous library constructs include cis-acting integration sequences. In some embodiments, one or more independent constructs of discontinuous library constructs include cis-acting integration sequences at the 3' and 5' ends of each construct. In some embodiments, the cis-acting integration sequence includes a viral repetitive sequence (e.g., outside any viral repetitive sequence for packaging into a viral vector).

[0323] In some embodiments where the library construct comprises a plurality of discontinuous constructs, one or more separate constructs are present in insect cells free. In some embodiments, one or more separate constructs are present in insect cells free with low copy numbers (e.g., 10 or fewer copies of library constructs, e.g., 4 or fewer copies of library constructs, e.g., 3 or fewer copies of library constructs, 2 or fewer copies of library constructs, e.g., a single (one) copy of library constructs).

[0324] Identifier

[0325] The present disclosure provides an identifier that can be detected and enables identification of insect cells or cloned cell lines that produce and / or derive viral vectors to become possible. In some embodiments, the relative abundance of a specific identifier can be characterized, detected and / or quantified in a combined sample of a viral vector (e.g., each comprising an identifier). In some embodiments, at least a portion of the identifier is detected. In some embodiments, the identifier is detected by sequencing (e.g., by next generation sequencing). For example, in some embodiments, at least a portion of the identifier is detected by next generation sequencing and / or single cell sequencing and / or Sanger sequencing.

[0326] In some embodiments, the identifier is present in an insect cell and is also present in a viral vector expressed by an insect cell. In some embodiments, the disclosure provides an identifier present in the context of a library construct. In some embodiments, the identifier is located between sequences (e.g., viral repetitive sequences, such as AAV ITRs for expressing AAV vectors) for packaging into a viral vector. In some embodiments, the viral vector expressed by insect cells as described herein comprises an identifier, for example, in a nucleic acid of a viral vector. In some embodiments, the viral vector expressed by insect cells as described herein comprises a nucleic acid comprising an identifier between two viral repetitive sequences (e.g., ITRs of AAV vectors). In some embodiments, at least a portion of the identifier in the viral vector nucleic acid is detected by next generation sequencing and / or single cell sequencing and / or Sanger sequencing.

[0327] In some embodiments, the insect cell expressing the viral vector and the expressed viral vector both comprise the same identifier. In some embodiments, the identifier of the viral vector corresponds to the identifier of the insect cell producing the viral vector. In some embodiments, the identifier of the viral vector is derived from the identifier of the insect cell producing the viral vector. In some embodiments, the identifier of the viral vector is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the identifier of the insect cell producing the viral vector.

[0328] In some embodiments, the identifier comprises a barcode. In some embodiments, the identifier is or comprises a barcode and is present in a library construct between sequences (e.g., viral repeats, such as AAV ITRs for expressing AAV vectors) for packaging into a viral vector. In some embodiments, the identifier is or comprises a barcode present in a viral vector nucleic acid. In some embodiments, the methods provided include detecting an identifier comprising a barcode from a viral vector sample.

[0329] In some embodiments, the identifier comprises a library variant. In some embodiments, the identifier comprises a library variant and is present in a library construct between sequences (e.g., viral repeats, such as AAV ITRs for expressing AAV vectors) for packaging into a viral vector. In some embodiments, the identifier comprises a library variant present in a viral vector nucleic acid. In some embodiments, the method provided includes detecting an identifier comprising a library variant from a viral vector sample.

[0330] In some embodiments, the identifier comprises a barcode and a library variant. In some embodiments, the identifier comprises a barcode and a library variant and is present in a library construct between sequences (e.g., viral repeats, such as AAV ITRs for expressing AAV vectors) for packaging into a viral vector. In some embodiments, the identifier comprises a barcode and a library variant present in a viral vector nucleic acid. In some embodiments, the provided method comprises detecting at least a portion of an identifier comprising a barcode and a library variant from a viral vector sample.

[0331] Barcode

[0332] The present disclosure encompasses the recognition that barcodes can be used to track associations between different components. In some embodiments, the barcode is an engineered sequence. In some embodiments, the barcode is an engineered nucleic acid sequence. In some embodiments, the barcode is part of a library construct.

[0333] In some embodiments, the library construct comprises one or more barcodes that, when detected (e.g., by next generation sequencing methods), indicate the identity of one or more library variants and / or other engineered sequences that are not directly detected. In some embodiments, one barcode is associated with one or more engineered sequences. For example, in some embodiments, one barcode is associated with one or more library variants. In some embodiments, one barcode is associated with one engineered sequence. For example, in some embodiments, one barcode is associated with one library variant.

[0334] In some embodiments, the barcode does not constitute an identifier. In some embodiments, the barcode constitutes an identifier. In some embodiments, the barcode constitutes an identifier comprising a nucleic acid sequence. In some embodiments, the barcode constitutes an identifier comprising an engineered sequence. In some embodiments, the identifier does not comprise a barcode. In some embodiments, the identifier comprises a barcode. In some embodiments, the identifier comprises a barcode comprising a nucleic acid sequence. In some embodiments, the identifier comprises a barcode comprising an engineered sequence. In some embodiments, the insect cell comprises a plurality of barcodes, wherein at least one barcode is an identifier and at least one barcode is not an identifier.

[0335] In some embodiments, the library construct comprises a barcode. In some embodiments, the barcode is used as an identifier. In some embodiments, the barcode is used as an identifier and is located between two viral repetitive sequences. In some embodiments, the barcode is not used as an identifier. In some embodiments, the barcode is not used as an identifier and is located between two viral repetitive sequences, but is not detected (e.g., by next generation sequencing). In some embodiments, the library construct comprises a barcode sequence located outside the two viral repetitive sequences and is therefore not packaged into a viral vector.

[0336] In some embodiments, a barcode is used as an identifier, wherein the barcode is present in a library construct between sequences for packaging into a viral vector (e.g., viral repeats, e.g., AAV ITRs for expression of an AAV vector). In some embodiments, a barcode is used as an identifier that enables identification of insect cells or clonal cell lines that produce and / or derive viral vectors. In some embodiments, the relative abundance of a barcode indicates the relative productivity of the insect cell from which it is derived. In some embodiments, a barcode is used as an identifier and also indicates the identity of one or more library variants and / or engineered sequences that are not directly detected when detected (e.g., by a next generation sequencing method).

[0337] In some embodiments, the barcode is not used as an identifier, but indicates the identity of one or more library variants and / or engineered sequences that are not directly detected when detecting (e.g., by next-generation sequencing methods and / or single-cell sequencing methods). For example, in some embodiments where the library construct is discontinuous, the barcode can be used to track one or more library variants. In some embodiments, the discontinuous library construct comprises a first construct and one or more other constructs each comprising a barcode, wherein the first construct comprises an identifier located between viral repetitive sequences. In some embodiments, the library construct further comprises one, two, three, four, five or more constructs, each of which comprises one or more library variants, wherein each individual construct further comprises a barcode. In some embodiments, each library variant is associated with a unique barcode. As another example, in some embodiments where the library construct is continuous, the barcode can also be used to track one or more library variants. In some embodiments, the continuous library construct comprises an identifier located between viral repetitive sequences. In some embodiments, the library construct further comprises one or more library variants and one or more barcodes. In some embodiments, each library variant is associated with a unique barcode.

[0338] In some embodiments, the barcode comprises a nucleic acid sequence with a length in the range of 3 nucleotides to 50 nucleotides. In some embodiments, the barcode comprises a nucleic acid sequence with a length in the range of a lower limit and an upper limit (the upper limit is greater than the lower limit). In some embodiments, the lower limit can be about 5 nucleotides, about 6 nucleotides, about 7 nucleotides, about 8 nucleotides, about 9 nucleotides, about 10 nucleotides, about 11 nucleotides, about 12 nucleotides, about 13 nucleotides, about 14 nucleotides, or about 15 nucleotides. In some embodiments, the upper limit can be about 10 nucleotides, about 15 nucleotides, about 20 nucleotides, about 25 nucleotides, about 30 nucleotides, about 35 nucleotides, about 40 nucleotides, about 45 nucleotides, or about 50 nucleotides. In some specific embodiments, the barcode comprises a sequence with a length in the range of 5 nucleotides to 25 nucleotides. In some specific embodiments, the barcode comprises about 5 nucleotides, about 10 nucleotides, about 15 nucleotides, about 20 nucleotides, or about 25 nucleotides. In some embodiments, the barcode comprises DNA and / or RNA. In some embodiments, the barcode comprises a DNA sequence ranging from 3 nucleotides to 50 nucleotides or from about 5 nucleotides to about 25 nucleotides in length. In some embodiments, the barcode comprises an RNA sequence ranging from 3 nucleotides to 50 nucleotides or from about 5 nucleotides to about 25 nucleotides in length.

[0339] In some embodiments, provided methods include detecting a barcode (eg, by sequencing, such as by next generation sequencing and / or single cell sequencing and / or Sanger sequencing).

[0340] Library variants

[0341] The present disclosure provides insect cells comprising one or more library variants, wherein the one or more library variants cause disturbances that change between insect cells in the library. In some embodiments, library variants cause disturbances that may affect certain features of viral vector production. In some embodiments, library variants include engineered sequences that cause disturbances. In some embodiments, library variants are sequence changes. In some embodiments, library variants are epigenetic changes. In some embodiments, library variants are in effectors, whereby library variants affect or cause disturbances that change between cells. In some embodiments, library variants themselves can become disturbances that change between cells. For example, in some embodiments, library variants that are gRNAs are effectors, which together with RNA-guided nucleases (e.g., perturbation additional sequences) cause deletions in cell genomic DNA. In other embodiments, library variants are ORFs or gene sequences, which are transfected into cells and integrated into genomic DNA in some cases (e.g., as performed by trans-acting and cis-acting integration sequences), themselves become disturbances or modifications of the genetic material of cells.

[0342] In some embodiments, the library variant comprises a guide RNA sequence. In some embodiments, the library variant comprising a guide RNA sequence can also be an identifier (e.g., a unique gRNA sequence that associates a viral vector with an insect cell that produces it). In some embodiments, the insect cell comprises a library variant comprising a guide sequence that can be obtained by a viral vector. In some embodiments, the length of the guide sequence is about 10 to 30 nucleotides. In some embodiments, the length of the guide sequence is 15 to 25 nucleotides. In certain embodiments, the length of the guide sequence is 16 to 24 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides in length). In some embodiments, the guide sequence is located at or near the 5' end of the gRNA (e.g., for Cas9 or a nuclease derived or obtained therefrom). In some embodiments, the guide sequence is located at or near the 3' end of the gRNA (e.g., for Cpf1 or a nuclease derived or obtained therefrom).

[0343] In some embodiments, library variants encode guide RNA sequences associated with introducing genomic deletions. In some embodiments, library variants encode guide RNA sequences associated with introducing genomic mutations (e.g., SNPs). In some embodiments, library variants encode guide RNA sequences associated with introducing genomic rearrangements. In some embodiments, library variants encode guide RNA sequences associated with changing the expression (e.g., activation and / or inhibition) of a gene.

[0344] In some embodiments, the library variant comprises one or more ORFs. In some embodiments, the library variant comprises an ORF. In some embodiments, the library variant comprises an ORF encoding an RNA sequence. In some embodiments, the ORF encodes a polypeptide (such as a protein, such as a glycoprotein). In some embodiments, the ORF encodes a fusion polypeptide and / or a chimeric polypeptide.

[0345] In some embodiments, the library variants comprise one or more genes. In some embodiments, the library variants comprise genes. In some embodiments, the library variants comprise genes encoding RNA sequences. In some embodiments, the genes encode polypeptides (such as proteins, such as glycoproteins). In some embodiments, the genes encode fusion polypeptides and / or chimeric polypeptides. In some embodiments, the library variants comprise insect genes. In some embodiments, the library variants comprise viral genes (e.g., Cap genes).

[0346] In some embodiments, the library variants encode non-coding nucleic acid sequences. In some embodiments, the library variants encode regulatory RNA sequences (eg, siRNA, microRNA, etc.).

[0347] In some embodiments, the library variant or a portion thereof is also an identifier, but the library construct may include one or more other library variants that are not identifiers. In some embodiments, the library variant or a portion thereof is an identifier, wherein the library variant is located between sequences for packaging into viral vectors (e.g., viral repeats, e.g., AAV ITRs for expressing AAV vectors). In some embodiments, the library variant is not an identifier (e.g., not packaged into a viral vector). In some embodiments where the library variant or a portion thereof is an identifier, the library variant or a portion thereof will be unique for this particular insect cell or cell line (and the viral vector expressed therefrom).

[0348] In some embodiments, library variants include components of viral vectors. For example, engineered components of viral vectors and / or components of different serotypes. In this way, viral vectors of different engineering or serotypes can be screened. In some embodiments, library variants include Cap genes (e.g., Cap genes of different serotypes).

[0349] In some embodiments, the insect cell provided comprises at least one library variant individually, wherein the at least one library variant comprises at least one engineered sequence, the at least one engineered sequence comprises at least one gene, at least one ORF, at least one gRNA sequence, at least one unique non-coding nucleic acid, or a combination and / or multiple thereof. In some embodiments, the insect cell or insect cell population comprises a plurality of library variants, wherein the plurality of library variants comprises at least one engineered sequence, the at least one engineered sequence comprises: at least one unique gene, at least one unique ORF, at least one unique gRNA sequence, and / or at least one unique non-coding nucleic acid, or a combination and / or multiple thereof.

[0350] In some embodiments, the insect cell provided comprises one or more library variants. In some embodiments, the insect cell provided comprises two, three, four, five, six, seven, eight, nine or ten library variants. In some embodiments, the insect cell provided comprises at least 100 library variants. In some embodiments, the insect cell provided comprises about 2 to about 100 library variants, about 2 to about 20 library variants, about 3 to about 30 library variants, about 4 to about 40 library variants, about 5 to about 50 library variants. In some embodiments, the insect cell provided comprises no more than 10 library variants, no more than 20 library variants, no more than 30 library variants, no more than 40 library variants, no more than 50 library variants, no more than 60 library variants, no more than 70 library variants, no more than 80 library variants, no more than 90 library variants, or no more than 100 library variants.

[0351] In some embodiments, the library construct comprises at least one library variant and at least one identifier, wherein the at least one library variant and at least one identifier are both located between two viral repetitive sequences. In some embodiments, the library construct comprises at least one library variant and at least one identifier, wherein the at least one identifier is located between two viral repetitive sequences, and the at least one library variant is located outside the two viral repetitive sequences. In some embodiments, the library construct comprises at least two library variants and an identifier, wherein the identifier and at least one library variant are located between two viral repetitive sequences, and at least one library variant is located outside the two viral repetitive sequences. In some embodiments, the library construct further comprises one or more other engineered sequences located between and / or outside the two viral repetitive sequences. For example, in some embodiments, the library construct further comprises a payload located between the two viral repetitive sequences. As another example, in some embodiments, the library construct further comprises one or more other barcodes located between and / or outside the two viral repetitive sequences.

[0352] In some embodiments, the library construct comprises an identifier for a library variant and one or more other library variants. In some embodiments, the library construct is a single continuous library construct comprising an identifier, which is a library variant between sequences (e.g., viral repeats, e.g., AAV ITR for expressing AAV vectors) for packaging into a viral vector, and one or more other library variants outside the sequence for packaging into a viral vector. In some embodiments, the library construct is a discontinuous library construct comprising an identifier, which is a library variant between sequences (e.g., viral repeats, e.g., AAV ITR for expressing AAV vectors) for packaging into a viral vector, and the library construct is one or more other constructs comprising one or more other library variants. In some specific embodiments, one or more other library variants comprise components (e.g., Cap genes) of viral vectors.

[0353] In some embodiments, the library construct comprises an identifier that is a barcode and one or more library variants. In some embodiments, the library construct is a single continuous library construct comprising an identifier that is a barcode between sequences for packaging into a viral vector (e.g., viral repeats, e.g., AAV ITRs for expressing AAV vectors), and a single continuous library construct comprises one or more library variants outside the sequence for packaging into a viral vector. In some embodiments, the library construct is a discontinuous library construct comprising an identifier that is a barcode between sequences for packaging into a viral vector (e.g., viral repeats, e.g., AAV ITRs for expressing AAV vectors), and the library construct is one or more other constructs comprising one or more library variants.

[0354] Some exemplary configurations of library variants in library constructs are provided in Table 3 below.

[0355] Table 3 - Exemplary library variants in library constructs

[0356]

[0357]

[0358] In some embodiments, provided methods include detecting one or more library variants (eg, by sequencing, eg, by next generation sequencing).

[0359] Viral repetitive sequences

[0360] The present disclosure provides structures suitable for packaging identifiers into viral vectors, such as viral repetitive sequences. In some embodiments, viral repetitive sequences are DNA and / or RNA sequences. In some embodiments, viral repetitive sequences are DNA sequences. In some embodiments, viral repetitive sequences are RNA sequences. In some embodiments, any nucleic acid sequence between two viral repetitive sequences will be packaged into a viral vector.

[0361] In some embodiments, the viral repetitive sequence is derived from the same type of virus as the target viral vector. For example, in some embodiments, the target viral vector is an AAV vector and the viral repetitive sequence is derived from AAV. In some embodiments, the viral repetitive sequence is derived from the same viral strain as the target viral vector. For example, in some embodiments, the target viral vector is an AAV5 vector and the viral repetitive sequence is the ITR derived from AAV5. In some embodiments, the viral repetitive sequence is derived from a viral strain different from the target viral vector, but can still be packaged into the target viral vector. In some embodiments, the viral repetitive sequence is an engineered viral repetitive sequence (for example, including sequences derived from two or more viruses). In some embodiments, the viral repetitive sequence is a synthetic viral repetitive sequence (for example, based on a common viral repetitive sequence design).

[0362] In some embodiments, the target viral vector is an AAV vector and the viral repetitive sequence comprises an AAV ITR sequence or a derivative thereof. In some embodiments, the viral repetitive sequence is derived from an AAV strain different from the AAV vector, but can still be acquired by the target viral vector. In some embodiments, the viral repetitive sequence is an engineered AAV ITR sequence. In some embodiments, the viral repetitive sequence is a synthetic AAV ITR sequence.

[0363] In some embodiments, the target viral vector is an adenoviral vector and the viral repetitive sequence comprises an adenoviral ITR sequence or a derivative thereof. In some embodiments, the viral repetitive sequence is derived from an adenoviral strain different from the adenoviral vector, but can still be acquired by the target viral vector. In some embodiments, the viral repetitive sequence is an engineered adenoviral ITR sequence. In some embodiments, the viral repetitive sequence is a synthetic adenoviral ITR sequence.

[0364] In some embodiments, the target viral vector is a lentiviral vector and the viral repeat sequence comprises a lentiviral ITR sequence or a derivative thereof. In some embodiments, the target viral vector is an HIV-1 vector and the viral repeat sequence comprises an HIV-1 ITR sequence or a derivative thereof. In some embodiments, the viral repeat sequence is derived from a lentiviral strain different from the target lentiviral vector, but can still be acquired by the target lentiviral vector. In some embodiments, the viral repeat sequence is an engineered adenovirus ITR sequence. In some embodiments, the viral repeat sequence is a synthetic adenovirus ITR sequence.

[0365] In some embodiments, the target viral vector is an HSV vector and the viral repeat sequence comprises an HSV TR L / IR L and / or HSV IR S / TR S In some embodiments, the target viral vector is an HSV-1 vector and / or an HSV-2 vector, and the viral repeat sequence comprises an HSV TR L / IR L and / or HSV IR S / TR S In some embodiments, the viral repeat sequence is derived from an HSV strain different from the target HSV vector, but can still be acquired by the target HSV vector. In some embodiments, the viral repeat sequence is an engineered HSV TR L / IR L and / or HSV IR S / TR S In some embodiments, the viral repeat sequence is a synthetic HSV TR L / IR L and / or HSV IR S / TR S sequence.

[0366] Payload

[0367] The present disclosure particularly provides a viral vector comprising a payload. Payload is generally a sequence of any concern that is desired to be introduced into a cell, an organ, an organism and / or a biological system (e.g., comprising a cell). For example, in some embodiments, a viral vector may include a payload that can be used to edit a cell (e.g., an encoding genome editing tool, e.g., for gene therapy and / or cell therapy). In some embodiments, the payload is included in a library construct. In some embodiments, the payload is included in a library construct and is located between sequences (e.g., viral repetitive sequences, e.g., for expression of AAV ITRs of AAV vectors) for packaging into a viral vector.

[0368] In some embodiments, the payload sequence comprises one or more of the following: a coding region, a gene regulatory element, and a transcription terminator. Non-limiting examples of gene regulatory elements include promoters, transcription activators, enhancers, and polyadenylation signals. In some embodiments, the payload sequence comprises a coding region, a gene regulatory element, and a transcription terminator, which are positioned relative to each other so that the coding region is located between the gene regulatory element and the transcription terminator.

[0369] In some embodiments, the coding region encodes a gene product. In some embodiments, the gene product is RNA. In some embodiments, the coding region encodes a polypeptide (such as a protein, such as a glycoprotein). In some embodiments, the coding region encodes a fusion polypeptide and / or a chimeric polypeptide. In some embodiments, the coding region encodes a gene product. In some embodiments, the coding region encodes more than one gene product (e.g., 2, 3, 4, 5, 6, 7 or more gene products). In some embodiments, the payload sequence comprises a regulatory nucleic acid, such as tRNA, rRNA, tmRNA, miRNA, siRNA, piRNA, shRNA, antisense RNA, double-stranded RNA, snRNA, snoRNA and / or long non-coding RNA (IncRNA). In some embodiments, the coding region encodes a regulatory RNA (e.g., siRNA, microRNA, etc.).

[0370] In some embodiments, the payload of the viral vector described herein can be a gene therapy payload and can encode any protein or a portion thereof that is beneficial to a subject (such as a subject suffering from a disease or condition). The protein can be an extracellular protein, an intracellular protein, or a membrane-bound protein. In some embodiments, the protein encoded by the payload sequence includes, but is not limited to, a mammalian protein, such as a human protein.

[0371] In some embodiments, the encoded protein is or includes a glycoprotein. In some embodiments, the encoded protein is or includes an antibody and / or Fc fusion protein. In some embodiments, the encoded protein is or includes an antigen.

[0372] Protein can be a therapeutic protein. In some embodiments, the subject to whom gene therapy is administered suffers from a disease or illness, whereby the subject's endogenous version of the protein is defective or limited in amount or not produced at all. In some such embodiments, the payload encodes a non-defective version of the protein. In some embodiments, the subject to whom gene therapy is administered suffers from a disease or illness mediated by a target gene (e.g., by the expression level of the target gene and / or the activity level of the target polypeptide), and the payload encodes an inhibitor of the target gene or target polypeptide. Examples of therapeutic proteins include, but are not limited to, infusible or injectable therapeutic proteins, enzymes, enzyme cofactors, hormones, blood or blood coagulation factors, cytokines and interferons, growth factors, adipose tissues, etc.

[0373] In some embodiments, the payload may include gene editing components. In some embodiments, the payload may include excision nucleic acid (e.g., wherein a viral vector delivers an RNA-guided nuclease to a target cell). In some embodiments, the payload comprising gene editing components may encode any suitable endonuclease known in the art. For example, the payload may encode or include one or more components of a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas system.

[0374] The payload sequence can be any length compatible with the relevant viral vector. In some embodiments, the flank of the payload sequence is one or more sequences obtained from or derived from a virus (e.g., ITR sequences of AAV). In some embodiments, the payload sequence is located between sequences for packaging into a viral vector. In some embodiments, the payload sequence is located between viral repetitive sequences (e.g., ITR sequences of AAV).

[0375] In some embodiments, the payload comprises a promoter. In some cases, the payload may comprise an enhancer sequence.

[0376] In some embodiments, any payload described herein may include an untranslated region (UTR), such as a 5'UTR or a 3'UTR. The UTR of a gene is transcribed but not translated. The 5'UTR starts at the transcription start site and continues to the start codon, but does not include the start codon. The 3'UTR starts immediately after the stop codon and continues until the transcription termination signal.

[0377] In some embodiments, the payload encoding the protein provided herein may include a polyadenylation (poly (A)) signal sequence. Most nascent eukaryotic mRNAs have a poly (A) tail at their 3' end, which is added in a complex process that includes cleavage of the primary transcript and a coupled polyadenylation reaction driven by a poly (A) signal sequence (see, e.g., Proudfoot et al., Cell 108: 501-512, 2002, which is incorporated herein by reference in its entirety). The poly (A) tail confers mRNA stability and transferability (B. Alberts et al., Molecular Biology of the Cell, 3rd edition, Garland Publishing, 1994, which is incorporated herein by reference in its entirety). In some embodiments, the poly (A) signal sequence is located 3' of the coding sequence.

[0378] In some embodiments, the protein-encoding payload may include an internal ribosome entry site (IRES). The IRES forms a complex secondary structure that allows translation initiation to occur from any position, with the mRNA immediately downstream of the location of the IRES (see, e.g., Pelletier and Sonenberg, Mal. Cell. Biol. 8(3): 1103-1112, 1988). Several IRES sequences are known to those skilled in the art, including those from, for example, foot-and-mouth disease virus (FMDV), encephalomyocarditis virus (EMCV), human rhinovirus (HRV), cricket paralysis virus, human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis C virus (HCV), and poliovirus (PV).

[0379] In some embodiments, any construct provided herein can comprise a splice donor and / or splice acceptor sequence that is functional in the RNA processing that occurs during transcription. In some embodiments, the splice site participates in trans-splicing.

[0380] In some embodiments, the payload provided herein may optionally include a sequence encoding a reporter polypeptide and / or protein ("reporter sequence") and / or a sequence encoding a selection marker (e.g., it confers a trait that can be artificially selected, e.g., a resistance box, etc.). Non-limiting examples of reporter sequences include DNA sequences encoding: β-lactamase, β-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), red fluorescent protein, mCherry fluorescent protein, yellow fluorescent protein, chloramphenicol acetyltransferase (CAT), and luciferase. Other examples of reporter sequences are known in the art. When associated with a control element that drives its expression, the reporter sequence can provide a signal detectable by conventional means, including enzymatic, radiographic, colorimetric, fluorescent or other spectral measurements; fluorescence activated cell sorting (FACS) assays; immunological assays (e.g., enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and immunohistochemistry). Similarly, when associated with a control element that drives its expression, the selection marker sequence can confer a trait that can also be artificially selected by conventional means.

[0381] Promoter

[0382] The term "promoter" refers to a DNA sequence recognized by an enzyme / protein that can start and / or initiate transcription of an operably connected coding sequence (e.g., a gene). For example, a promoter generally refers to a nucleotide sequence to which, for example, RNA polymerase and / or any associated factor binds and to which the promoter can initiate transcription. Therefore, in some embodiments, the payload comprises a coding sequence operably connected to one of the non-limiting example promoters described herein.

[0383] In some embodiments, the promoter is functional in insect cells. In some embodiments, the promoter is a baculovirus ie1 promoter. In some embodiments, the promoter is a promoter derived from a baculovirus polyhedrin (polh) gene, a p6.9 gene, and / or a p10 gene.

[0384] In some embodiments, the promoter is an inducible promoter, a constitutive promoter, an insect cell promoter, a viral promoter, a chimeric promoter, an engineered promoter, a tissue-specific promoter, or any other type of promoter known in the art.

[0385] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a coding sequence (eg, a protein coding sequence), results in transcription of RNA from a nucleic acid in a cell under most or all physiological conditions.

[0386] Examples of constitutive promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter, the cytomegalovirus (CMV) promoter (see, e.g., Boshart et al., Cell 41:521-530, 1985, which is incorporated herein by reference in its entirety), the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1-α promoter (Invitrogen).

[0387] Inducible promoters allow for the regulation of gene expression and can be regulated by exogenously provided compounds, environmental factors such as temperature or a particular physiological state, for example an acute phase, a particular differentiation state of the cell, or presence only in replicating cells. Inducible promoters and inducible systems can be obtained from a variety of commercial sources, including but not limited to Invitrogen, Clontech and Ariad. Other examples of inducible promoters are known in the art.

[0388] Examples of inducible promoters regulated by exogenously provided compounds include the zinc-inducible sheep metallothionein (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system, the ecdysone insect promoter, the tetracycline-repressible system, the tetracycline-inducible system, the RU486-inducible system, and the rapamycin-inducible system.

[0389] The term "tissue-specific" promoter refers to a promoter that is active only in certain specific cell types and / or tissues (eg, transcription of a specific gene occurs only in cells that express a transcriptional regulatory and / or control protein that binds to the tissue-specific promoter).

[0390] In some embodiments, the regulatory and / or control sequence confers tissue-specific gene expression capability. In some cases, the tissue-specific regulatory and / or control sequence binds a tissue-specific transcription factor that induces transcription in a tissue-specific manner.

[0391] Enhancer

[0392] The term "enhancer" refers to a nucleotide sequence that can increase the transcription level of a nucleic acid coding sequence (e.g., protein). An enhancer sequence (length is generally 50-1500bp) is generally provided with other binding sites for transcription-related proteins (e.g., transcription factors) to improve the transcription level. In some embodiments, an enhancer sequence is present in an intron sequence. Different from a promoter sequence, an enhancer sequence can work at a position much farther from the transcription start site (e.g., compared to a promoter). The limiting examples of enhancers include RSV enhancers, CMV enhancers, CMV early enhancers, cAMP response element (CRE) enhancers, and / or SV40 enhancers.

[0393] In some embodiments, the enhancer comprises a baculovirus enhancer sequence (hr1).

[0394] Position of library construct elements relative to viral repeat sequences

[0395] The library construct may comprise one or more engineered sequences. In some embodiments, the library construct comprises multiple engineered sequences. In some embodiments, the library construct comprises viral repeat sequences for packaging viral vectors.

[0396] One or more and / or multiple engineered sequences on a library construct can be located at many positions and / or combinations of positions relative to each other and relative to viral repeat sequences on the library construct. For example, in some embodiments, an insect cell or population of insect cells comprises at least one library construct comprising a plurality of engineered sequences, wherein a first subset of the plurality of engineered sequences is located between viral repeat sequences, and a second subset of the plurality of engineered sequences is located outside of viral repeat sequences.

[0397] In some embodiments, a plurality of engineered sequences on the library construct comprises at least one library variant and at least one identifier. In some embodiments, all library variants and identifiers are located between viral repetitive sequences. In some embodiments, the identifier is located between viral repetitive sequences and all library variants are located outside viral repetitive sequences. In some embodiments, a plurality of engineered sequences comprises at least two library variants and at least one identifier. In some embodiments, the identifier and at least one library variant are located between viral repetitive sequences, and at least one library variant is located outside viral repetitive sequences.

[0398] In some embodiments, a plurality of engineered sequences comprise at least one library variant, at least one identifier and at least one payload. In some embodiments, all library variants, identifiers and payloads are located between viral repetitive sequences. In some embodiments, all identifiers and payloads are located between viral repetitive sequences, and all library variants are located outside viral repetitive sequences. In some embodiments, a plurality of engineered sequences comprise at least two library variants, at least one payload and at least one identifier. In some embodiments, all identifiers, payloads and at least one library variant are located between viral repetitive sequences, and at least one library variant is located outside viral repetitive sequences.

[0399] In some embodiments, the library construct further comprises at least one engineered sequence, and the at least one engineered sequence comprises at least one reporter gene and / or a selection marker. In some embodiments, all reporter genes and / or selection markers are located between viral repetitive sequences. In some embodiments, all reporter genes and / or selection markers are located outside viral repetitive sequences. In some embodiments, the library construct comprises at least one reporter gene and at least one selection marker. In some embodiments, at least one reporter gene and at least one selection marker are located between viral repetitive sequences. In some embodiments, at least one reporter gene and at least one selection marker are located outside viral repetitive sequences. In some embodiments, at least one reporter gene is located between viral repetitive sequences and at least one selection marker is located outside viral repetitive sequences. In some embodiments, at least one selection marker is located between viral repetitive sequences, and at least one reporter gene is located outside viral repetitive sequences.

[0400] In some embodiments, the library construct further comprises at least one engineered sequence comprising at least one barcode. In some embodiments, all barcodes are located between viral repetitive sequences. In some embodiments, all barcodes are located outside viral repetitive sequences. In some embodiments, the library construct comprises a plurality of barcodes, wherein a first subset is located between viral repetitive sequences and a second subset is located outside viral repetitive sequences.

[0401] In some embodiments, the library construct comprises at least one identifier and at least one barcode. In some embodiments, at least one barcode is used as an identifier, and in some embodiments, at least one barcode is not used as an identifier. In some embodiments, at least one barcode is located between viral repetitive sequences, and at least one barcode or a portion thereof is used as an identifier. In some embodiments, at least one barcode is located between viral repetitive sequences, and at least one barcode is not used as an identifier. In some embodiments, the library construct comprises at least one identifier and at least two barcodes. In some embodiments, all identifiers and at least one barcode are located between viral repetitive sequences, and at least one barcode is located outside viral repetitive sequences, wherein at least one barcode (or a portion thereof) located between viral repetitive sequences is used as an identifier. In some embodiments, all identifiers and at least one barcode are located between viral repetitive sequences, and at least one barcode is located outside viral repetitive sequences, wherein at least two barcodes are not used as identifiers.

[0402] In some embodiments, the library construct comprises at least two barcodes and further comprises at least one other engineered sequence, wherein no barcode is used as an identifier and all barcodes are used to track the other engineered sequence. For example, in some embodiments, the library construct comprises at least two barcodes and further comprises at least one library variant, wherein no barcode is used as an identifier and all barcodes are used to track the library variant. In some embodiments, one barcode is used as an identifier and the other barcode is used to track the library variant.

[0403] In some embodiments, one barcode indicates a single engineered sequence (e.g., a single library variant). In some embodiments, one barcode indicates more than one engineered sequence (e.g., more than one library variant). In some embodiments, more than one barcode indicates an engineered sequence (e.g., a library variant). In some embodiments, more than one barcode indicates more than one engineered sequence (e.g., more than one library variant). In some embodiments, no barcode is used as an identifier and all barcodes are used to track other engineered sequences comprising barcodes. In some embodiments, one barcode is used as an identifier and other barcodes are used to track other engineered sequences comprising barcodes.

[0404] Use of constructs in insect cells

[0405] Other features of constructs and engineered sequences

[0406] Promoter

[0407] In some embodiments, construct comprises a promoter.Term " promoter " refers to the DNA sequence recognized by enzyme / protein, and it can start and / or initiate the transcription of the operably connected coding sequence (for example, gene).For example, promoter generally refers to the nucleotide sequence that for example RNA polymerase and / or any related factor are combined and promoter can initiate transcription from it.Therefore, in some embodiments, engineered sequence comprises the coding sequence that is operably connected to promoter.Various promoters are known in the art, and it can be used for this article.

[0408] In some embodiments, the promoter is an inducible promoter, a constitutive promoter, an insect cell promoter, a viral promoter, a chimeric promoter, an engineered promoter, a tissue-specific promoter, or any other type of promoter known in the art.

[0409] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a coding sequence (eg, a protein coding sequence), results in transcription of RNA from a nucleic acid in a cell under most or all physiological conditions.

[0410] Examples of constitutive promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter, the cytomegalovirus (CMV) promoter (see, e.g., Boshart et al., Cell 41:521-530, 1985, which is incorporated herein by reference in its entirety), the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1-α promoter (Invitrogen).

[0411] Inducible promoters allow for the regulation of gene expression and can be regulated by exogenously provided compounds, environmental factors such as temperature or a particular physiological state, for example an acute phase, a particular differentiation state of the cell, or presence only in replicating cells. Inducible promoters and inducible systems can be obtained from a variety of commercial sources, including but not limited to Invitrogen, Clontech and Ariad. Other examples of inducible promoters are known in the art.

[0412] Examples of inducible promoters regulated by exogenously provided compounds include the zinc-inducible sheep metallothionein (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system, the ecdysone insect promoter, the tetracycline-repressible system, the tetracycline-inducible system, the RU486-inducible system, and the rapamycin-inducible system.

[0413] The term "tissue-specific" promoter refers to a promoter that is active only in certain specific cell types and / or tissues (eg, transcription of a specific gene occurs only in cells that express a transcriptional regulatory and / or control protein that binds to the tissue-specific promoter).

[0414] In some embodiments, the regulatory and / or control sequence confers tissue-specific gene expression capability. In some cases, the tissue-specific regulatory and / or control sequence binds a tissue-specific transcription factor that induces transcription in a tissue-specific manner.

[0415] Enhancer

[0416] In some cases, construct can include enhancer sequence.Term " enhancer " refers to the nucleotide sequence that can increase the transcription level of nucleic acid coding sequence (for example, protein).Enhancer sequence (length is usually 50-1500bp) usually improves transcription level by providing other binding sites for transcription-related proteins (for example transcription factor).In some embodiments, there is enhancer sequence in intron sequence.Different from promoter sequence, enhancer sequence can work at the position far away from transcription start site (for example, compared with promoter).Non-limiting examples of enhancer include RSV enhancer, CMV enhancer, CMV early enhancer, cAMP response element (CRE) enhancer and / or SV40 enhancer.

[0417] Other sequences

[0418] In some embodiments, any construct described herein may include an untranslated region (UTR), such as a 5'UTR or a 3'UTR. The UTR of a gene is transcribed but not translated. The 5'UTR starts at the transcription start site and continues to the start codon, but does not include the start codon. The 3'UTR starts immediately after the stop codon and continues until the transcription termination signal.

[0419] In some embodiments, the construct comprising an engineered sequence encoding a protein provided herein may comprise a polyadenylation (poly(A)) signal sequence. Most nascent eukaryotic mRNAs have a poly(A) tail at their 3' end, which is added in a complex process including cleavage of the primary transcript and a coupled polyadenylation reaction driven by a poly(A) signal sequence (see, e.g., Proudfoot et al., Cell 108:501-512, 2002, which is incorporated herein by reference in its entirety). The poly(A) tail confers mRNA stability and transferability (B. Alberts et al., Molecular Biology of the Cell, 3rd edition, Garland Publishing, 1994, which is incorporated herein by reference in its entirety). In some embodiments, the poly(A) signal sequence is located 3' of the coding sequence.

[0420] In some embodiments, the construct comprising the engineered sequence encoding the protein may comprise an internal ribosome entry site (IRES). The IRES forms a complex secondary structure that allows translation initiation to occur from any position, with the mRNA immediately downstream of the location of the IRES (see, e.g., Pelletier and Sonenberg, Mal. Cell. Biol. 8(3): 1103-1112, 1988). Several IRES sequences are known to those skilled in the art, including those from, for example, foot-and-mouth disease virus (FMDV), encephalomyocarditis virus (EMCV), human rhinovirus (HRV), cricket paralysis virus, human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis C virus (HCV), and poliovirus (PV).

[0421] In some embodiments, any construct provided herein can comprise a splice donor and / or splice acceptor sequence that is functional in the RNA processing that occurs during transcription. In some embodiments, the splice site participates in trans-splicing.

[0422] In some embodiments, any construct provided herein may optionally include a sequence encoding a reporter polypeptide and / or protein ("reporter sequence") and / or a sequence encoding a selection marker (e.g., it confers a trait that can be artificially selected, e.g., a resistance box, etc.). Non-limiting examples of reporter sequences include DNA sequences encoding: β-lactamase, β-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), red fluorescent protein, mCherry fluorescent protein, yellow fluorescent protein, chloramphenicol acetyltransferase (CAT), and luciferase. Other examples of reporter sequences are known in the art. When associated with a control element driving its expression, the reporter sequence can provide a signal detectable by conventional means, including enzymatic, radiographic, colorimetric, fluorescent or other spectral measurements; fluorescence activated cell sorting (FACS) assays; immunological assays (e.g., enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and immunohistochemistry). Similarly, when associated with a control element driving its expression, a selection marker sequence can confer a trait that can also be artificially selected by conventional means.

[0423] Insect cell engineering and cell construct entry

[0424] In some embodiments, the present disclosure provides methods including preparing or obtaining insect cell libraries. Any method suitable for genetic modification can be used to operate insect cells in the context of the present disclosure, for example, to introduce a library construct, introduce another construct, and / or introduce a perturbation. For example, many methods for introducing exogenous nucleic acids (e.g., DNA) into eukaryotic cells are known in the art, including transfection, infection (e.g., viral transduction), or electroporation.

[0425] The method for delivering the construct to the insect cell can be varied as needed. In certain embodiments, some constructs can be delivered as nucleic acid (e.g., DNA) constructs in one or more plasmids. Delivery methods include, but are not limited to, electroporation, microinjection, gene gun, puncture transfection, hydrostatic pressure, continuous infusion, ultrasonic treatment, magnetic transfection, chemical media (e.g., oligonucleotides, lipid complexes, polymer vesicles, complexes, dendrimers, inorganic nanoparticles, and cell-penetrating peptides), viral vectors (e.g., viral vectors with replication ability, viral vectors without replication ability, viral vectors lacking replication, viral vectors with replication defects, viral vectors with replication ability, and / or conditional replication viral vectors).

[0426] In some embodiments, the insect cell library is genetically modified to include library constructs and / or other constructs. Library constructs and / or other constructs can be delivered by any suitable method known in the art for nucleic acid manipulation technicians and include genetic engineering, recombinant engineering and synthetic techniques (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY, which is incorporated herein by reference in its entirety). In some embodiments, the method provided includes transfecting one or more nucleic acids constituting the library construct into the insect cells of the library.

[0427] In some embodiments, the insect cell library is genetically modified to contain one or more nucleic acid sequences necessary for producing viral vectors. In some embodiments, the insect cell library expressing and / or producing viral vectors can have one or more viral vector components provided to the insect cells in trans. For example, any appropriate construct can be used to deliver the recombinant AAV construct and / or engineered sequences, rep sequences, cap sequences, and auxiliary functions required for producing the AAV vectors of the present disclosure to the packaging host cells.

[0428] The construct encoding the viral element can be delivered by any suitable method known in the art to nucleic acid manipulation technicians, for example, and includes genetic engineering, recombinant engineering, and synthetic techniques (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY, which is incorporated herein by reference in its entirety). In some embodiments, the provided method includes transfecting one or more nucleic acids constituting viral constructs or encoding viral vector components into insect cells of the library. In some embodiments, the provided method includes transfecting one or more nucleic acid molecules containing or substantially consisting of encoding viral vectors. In some embodiments, the viral vector components are included in one or more plasmids transfected into cells. In some embodiments, the viral vector components are included in one, two, three or more plasmids each transfected into cells.

[0429] In some embodiments, the viral vector components are infected into insect cells using a baculovirus. In some embodiments, the viral vector components are contained on one or more baculovirus vectors that are transfected into insect cells.

[0430] In some embodiments, the viral vector is an adeno-associated virus (AAV), and viral transfection includes transfecting a plasmid containing a nucleic acid molecule encoding an AAV vector or consisting essentially of it into an insect cell, and providing an AAV vector rep and / or cap necessary for AAV vector replication and packaging. In some embodiments, one, two, three or more plasmids each comprising an AAV vector component are transfected into the cell. In some specific embodiments, a plasmid (e.g., 1 to 5 plasmids, e.g., 3 plasmids) providing various AAV components (including helper virus, payload (e.g., therapeutic gene), rep and / or cap) in combination is transfected into the cell.

[0431] In some specific embodiments, viral transfection of AAV constructs can be accomplished using a triple transfection method (e.g., as described in U.S. Pat. No. 6,001,650, which is incorporated herein by reference in its entirety). In some embodiments, AAV vectors are produced by transfecting host cells with one or more constructs comprising one or more nucleic acid sequences necessary for producing AAV vectors, including but not limited to rep sequences and / or cap sequences, and / or constructs comprising auxiliary functions. In some embodiments, rep and cap sequences act in trans for productive AAV vector replication and encapsidation. In some embodiments, constructs comprising rep and / or cap sequences support efficient AAV construct production without generating any detectable wild-type AAV vectors (i.e., AAV vectors containing functional rep and cap genes). Auxiliary function constructs encode nucleotide sequences of non-AAV derived viruses and / or cellular functions that AAV vector replication depends on, and the sequences may have those functions required for AAV construct replication, including but not limited to those parts involved in activation of AAV vector gene transcription, stage-specific AAV vector mRNA splicing, AAV DNA replication, synthesis of cap expression products, and / or AAV vector capsid assembly. These viral-based functions may be derived from any known helper virus, such as adenovirus, herpes virus (except herpes simplex virus type 1), and vaccinia virus.

[0432] In some embodiments, it may be beneficial to prevent the produced viral vector from reinfecting the insect cells of the insect cell library. In some embodiments, the insect cells of the insect cell library have been modified to destroy or remove receptors for the produced viral vector. In some embodiments, the insect cells have been treated with an infection / blocking agent.

[0433] Location of constructs and engineered sequences in insect cells

[0434] Any of the constructs described herein may be present in an extrachromosomal form in an insect cell and / or integrated into the insect cell genome.

[0435] In some embodiments, the library construct is free and / or is integrated into the insect cell genome. In some embodiments, the library construct is a free single continuous construct. In some embodiments, the library construct is a single continuous construct integrated into the insect cell genome. In some embodiments, the library construct is discontinuous and one or more independent constructs are free. In some embodiments, the library construct is discontinuous and one or more independent constructs are integrated into the insect cell genome. In some embodiments, the library construct is discontinuous and at least one construct is free and at least one construct is integrated into the insect cell genome.

[0436] In some embodiments, one or more sequences necessary for producing viral vectors are present in insect cells in an extrachromosomal form (e.g., free). In some embodiments, one or more sequences necessary for producing viral vectors are integrated into the genome of insect cells.

[0437] In some embodiments, one or more sequences necessary for producing viral vectors are integrated into the genome of insect cells, wherein one or more sequences are inducibly expressed. In some embodiments, all sequences necessary for producing viral vectors are integrated into the genome of insect cells, wherein one or more sequences are inducibly expressed. In some embodiments, all sequences necessary for producing viral vectors are integrated into the genome of insect cells, wherein two or more sequences are inducibly expressed. In some embodiments, all sequences necessary for producing viral vectors are integrated into the genome of insect cells, wherein all sequences are inducibly expressed.

[0438] Any method known in the art for integrating sequences can be used. In some embodiments, integration is targeted integration (e.g., at a predetermined site). In some embodiments, integration is random integration (e.g., at a random site). In some embodiments, integration is random in a predetermined genomic position subset.

[0439] In some embodiments, one or more engineering sequences (e.g., library constructs and / or other constructs) are pre-integrated into cells of an insect library using methods known in the art. In some embodiments, insect cells having one or more integration sequences are transfected with sequences encoding viral vectors. In some embodiments, one or more viral vector sequences are also integrated into the genome.

[0440] In some embodiments, the insect cell library for culturing viral vectors can be stably engineered to contain one or more such viral components (e.g., recombinant AAV constructs, rep sequences, cap sequences and / or auxiliary functions) using methods known to those skilled in the art. In some embodiments, such stable insect cells contain such viral vector components under the control of an inducible promoter. In some embodiments, such viral vector components can be under the control of a constitutive promoter. In some embodiments, selected stable insect cells can contain selected components under the control of a constitutive promoter and other selected components under the control of one or more inducible promoters. For example, such as containing E1 auxiliary functions under the control of a constitutive promoter, and stable insect cells of rep and / or cap genes under the control of an inducible promoter. Other stable insect cells can be generated by those skilled in the art using conventional methods as the basis for generating insect cell libraries. Such stable expression insect cell lines can then be operated to contain a variety of different engineered sequences, including identifier sequences, thereby generating insect cell libraries that produce viral vectors.

[0441] In some embodiments, exogenous DNA (e.g., library construct) is integrated into genomic DNA so that the exogenous DNA is adjacent to the genomic DNA of insect cells. In some embodiments, integration is mediated by the natural DNA repair mechanism endogenous to the cell. For example, by introducing exogenous DNA into cells, site-specific nucleases are made to produce integration sites, and donor DNA is integrated, and integration can occur. Cells can be kept in culture for enough time so that DNA is integrated. This will generally produce a mixed cell population, including (i) exogenous DNA integrated into recombinant cells therein at the integration site produced by site-specific nucleases, and optionally (ii) exogenous DNA is integrated into cells therein at sites other than the desired integration site and / or optionally (iii) exogenous DNA is not integrated into cells therein. Selection methods known in the art can be used to enrich cells with genetic compositions in libraries.

[0442] Episomal library constructs

[0443] In some embodiments, the disclosure provides insect cells, wherein one or more constructs (e.g., library constructs and / or constructs encoding sequences necessary for producing viral vectors) are not integrated into the insect cell genome but exist episomally. Any method known in the art for introducing episomal constructs into insect cells can be used.

[0444] In some embodiments, one or more constructs are baculovirus constructs. In some embodiments, the library constructs include baculovirus constructs.

[0445] In some embodiments, a single continuous library construct is present free in an insect cell. In some embodiments, one or more separate constructs of a discontinuous library construct are present free in an insect cell (e.g., a construct comprising an identifier and a viral packaging sequence). In some embodiments, all separate constructs of a discontinuous library construct are present free in an insect cell.

[0446] In some embodiments, exogenous nucleic acid (e.g., DNA) can be introduced into insect cells by standard transfection or electroporation methods. In some embodiments, the exogenous nucleic acid introduced into insect cells can be free in cells with single copy number, low copy number or high copy number. In some embodiments, the exogenous nucleic acid introduced into insect cells can exist in genome form and / or exist free with variable copy number. Selection and / or screening methods known in the art can be used for enrichment of cells with free constructs (e.g., library constructs).

[0447] In some embodiments, exogenous nucleic acid is introduced into insect cells using a baculovirus expression system. In some embodiments, baculovirus constructs facilitate transfer of nucleic acid into insect cells for free expression in insect cells. In certain embodiments, exogenous nucleic acid (e.g., DNA) encoding an AAV genome (e.g., a sequence flanked by ITR sequences) is introduced into insect cells using a baculovirus expression system.

[0448] In some embodiments, the viral vector pool generated by the first insect cell library is used to transfect insect cells to generate a second insect cell library. In some embodiments, the second insect cell library expresses library variants in a free form. In some embodiments, the viral vector pool generated by the first insect cell library is an AAV vector pool. In some embodiments, the AAV vector pool generated by the first insect cell library is used to transduce insect cells to generate a second insect cell library comprising an identifier in a free form.

[0449] Integrated library constructs

[0450] In some embodiments, the present disclosure provides insect cells, wherein one or more constructs (e.g., library constructs and / or constructs encoding sequences necessary for producing viral vectors) are integrated into the insect cell genome. Any method known in the art for integrating sequences can be used.

[0451] In some embodiments, integration of a construct (e.g., a library construct) into the insect cell genome is mediated by at least one trans-acting integration sequence. In some embodiments, at least one trans-acting integration sequence comprises (i) an integration construct, (ii) a recombinase, (iii) a nuclease, (iv) a transposase, and / or a derivative and / or fusion thereof. In some embodiments, integration of a construct (e.g., a library construct) into the insect cell genome is mediated by at least one trans-acting integration sequence coordinated with a cis-acting integration sequence. In some embodiments, a cis-acting integration sequence comprises (i) a viral repeat sequence, (ii) a recombinase recognition site, (iii) a homology arm, and / or (iv) a transposase recognition site and / or a derivative thereof.

[0452] In some embodiments, the construct to be integrated into the insect genome (e.g., a library construct) comprises at least one pair of cis-acting integration sequences flanking the sequence to be integrated. For example, a library construct is provided that comprises a first set of viral repeat sequences flanking an identifier and / or a payload, wherein the first set of viral repeat sequences is flanked by cis-acting integration sequences.

[0453] In some embodiments, integration of the construct into the insect cell genome is targeted integration. In some embodiments, integration of the construct into the insect cell genome is random integration. In some embodiments, the construct is integrated into the insect cell genome at a random insertion site. In some embodiments, the random insertion site is random in a predetermined subset of genomic positions. In some embodiments, the insertion of the library construct in the insect cell genome includes a predetermined insertion site.

[0454] In some embodiments, the library construct (e.g., one or more separate nucleic acids associated with the library construct) is integrated into the insect genome. In some embodiments, a single continuous library construct is integrated into the insect genome. In some embodiments, one or more separate constructs of a discontinuous library construct (e.g., a construct comprising an identifier and a viral packaging sequence) are integrated into the insect genome. In some embodiments, all separate constructs of a discontinuous library construct are integrated into the insect genome.

[0455] In some embodiments, exogenous nucleic acid (e.g., DNA) can be introduced into insect cells by standard transfection or electroporation methods. In some embodiments, the exogenous nucleic acid introduced into insect cells can be integrated into the genome with single copy number, low copy number or high copy number or be free in the cell with single copy number, low copy number or high copy number. In some embodiments, the exogenous nucleic acid introduced into insect cells can exist in genome form and / or be free with variable copy number. Selection and / or screening methods known in the art can be used for enrichment of cells with integrated constructs (e.g., library constructs).

[0456] Virus-mediated integration

[0457] In some embodiments, the library construct is integrated into the insect genome by viral transduction-mediated integration. In some embodiments, for example, a library construct is provided, comprising a first group of viral repeat sequences flanking an identifier and / or a payload, wherein the first group of viral repeat sequences flank a cis-acting integration sequence comprising a second group of viral repeat sequences. In some embodiments, at least one trans-acting integration sequence comprises an integration construct, wherein the integration construct is an invertebrate parvovirus vector, such as, for example, JcDNV or a derivative thereof. For example, see Bossin H, Fournier P, Royer C, et al. Junonia coenia densovirus-based vectors for stable transgene expression in Sf9 cells: influence of the densovirus sequences on genomic integration. J Virol. 2003; 77 (20): 11060-11071, which is hereby incorporated by reference in its entirety.

[0458] Nuclease-mediated integration

[0459] In some embodiments, the library construct is integrated into the insect genome by nuclease-mediated integration. In some embodiments, for example, a library construct is provided that comprises a first set of viral repeat sequences flanking an identifier and / or a payload, wherein the first set of viral repeat sequences is flanked by cis-acting integration sequences comprising homology arms.

[0460] In some embodiments, at least one trans-acting integration sequence comprises a nuclease and / or a fusion and / or derivative thereof comprising Cas9, CasZ, Cpf1, an engineered Fok1 nuclease domain fused to a programmable DNA binding domain such as a TALE protein (TALEN) or a zinc finger protein (ZFN), and / or a meganuclease and / or a derivative thereof. In some embodiments, the nuclease is or comprises Cas9.

[0461] In some embodiments, at least one trans-acting integration sequence comprises a zinc finger nuclease. Zinc finger nucleases (ZFNs) are artificial restriction enzymes that are generated by combining a zinc finger DNA binding domain with a DNA cleavage domain. The most common cleavage domain in ZFNs is a non-specific cleavage domain from a type IIs restriction endonuclease FokI, which can be targeted using a guide sequence. Methods using ZFNs are described in, for example, WO 2009146179A1, WO2008060510 A2, and CN 102174576 A, which are incorporated by reference in their entirety.

[0462] In some embodiments, at least one trans-acting integration sequence comprises a transcription activator-like effector nuclease (TALEN). TALEN is a restriction enzyme that can be engineered to cut a specific DNA sequence. Methods using TALEN are described in, for example, WO 2014134412 A1, WO 2013163628 A2, and WO 2014040370A1, which are incorporated by reference in their entirety.

[0463] In some embodiments, at least one trans-acting integration sequence comprises a non-RNA guided nuclease and / or a fusion and / or derivative thereof. In some embodiments, insertion of the library construct into the insect cell genome is mediated by at least two trans-acting integration sequences, wherein at least one trans-acting integration sequence comprises an RNA guided nuclease and / or a fusion and / or derivative thereof, and at least one trans-acting integration sequence comprises a gRNA sequence.

[0464] In some embodiments, the insertion of the library construct in the insect cell genome is mediated by at least one trans-acting integration sequence, and wherein at least one trans-acting integration sequence comprises a nuclease (e.g., an RNA-guided nuclease or a non-RNA-guided nuclease) and / or a fusion and / or derivative thereof, and wherein the library construct comprises at least one pair of cis-acting integration sequences that are homology arms. In some embodiments, the library construct comprises an identifier and / or a payload between two viral packaging sequences (e.g., viral repeat sequences), all of which are located between cis-acting integration sequences comprising homology arm sequences.

[0465] In some embodiments, the insertion of the library construct in the insect cell genome is mediated by at least two trans-acting integration sequences, wherein at least one trans-acting integration sequence comprises a nuclease (e.g., an RNA-guided nuclease) and / or a fusion and / or derivative thereof, and at least one trans-acting integration sequence comprises a gRNA sequence. In some embodiments, the library construct comprises an identifier and / or a payload between two viral packaging sequences (e.g., viral repeat sequences), all of which are located between cis-acting integration sequences comprising homology arm sequences.

[0466] In some embodiments, the library construct is integrated into the genome of the insect cell by nuclease-mediated integration (e.g., using CRISPR / Cas9). In some embodiments, the integration of the library construct is mediated by natural DNA repair mechanisms endogenous to the cell. For example, integration can occur by introducing exogenous DNA into the cell, causing site-specific nucleases to generate integration sites, and allowing donor DNA to be integrated.

[0467] In some embodiments, the insertion of the library construct into the insect cell genome is mediated by Cas9. In some embodiments, the library construct comprises an identifier and / or a payload between AAV ITR sequences, all of which are located between cis-acting integration sequences comprising homology arm sequences.

[0468] Some exemplary envisions of nuclease-mediated library construct integration are provided in Table 5 below. Each embodiment of Table 4 can be in the context of a single continuous library construct or a discontinuous library construct. In some embodiments, the library construct is a discontinuous library construct and the independent construct comprising the identifier is integrated into the genome. In some embodiments, the library construct is a discontinuous library construct, and two or more independent constructs of the library construct are integrated into the insect genome by nuclease-mediated integration. In some embodiments, all independent constructs of the discontinuous library construct are integrated into the insect genome by nuclease-mediated integration.

[0469] Table 4 - Exemplary scenarios for nuclease-mediated integration

[0470]

[0471] Recombinase-mediated integration

[0472] In some embodiments, the library construct is integrated into the insect genome by recombinase-mediated integration. In some embodiments, for example, a library construct is provided that comprises a first set of viral repeat sequences flanking an identifier and / or a payload, wherein the first set of viral repeat sequences is flanked by cis-acting integration sequences comprising a recombinase recognition site.

[0473] In some embodiments, at least one trans-acting integration sequence comprises a recombinase. In some embodiments, the recombinase comprises Cre, Flp, Dre, PhiC31 and / or Bxb1, and / or derivatives and / or fusions thereof.

[0474] In some embodiments, the trans-acting integration sequence comprises a recombinase comprising Cre. In some embodiments, Cre mediates inte...

Claims

1. A method comprising: a. generating a plurality of adeno-associated virus (AAV) vectors from an insect cell library, wherein the insect cell library comprises a plurality of insect cells, wherein each insect cell individually comprises: (i) a nucleic acid sequence comprising a barcode located between two functional AAV ITR sequences, (ii) one or more library variants resulting in one or more perturbations, wherein at least one library variant comprises a gRNA, (iii) RNA-guided nucleases, and (iv) one or more nucleic acid sequences necessary for the production of an AAV vector, wherein the plurality of insect cells produces a plurality of AAV vectors, wherein each AAV vector comprises an identifier corresponding to an identifier of the insect cell in which it was produced; and b. Detecting the barcodes of the plurality of AAV vectors.

2. A method for selecting insect cells for producing adeno-associated virus (AAV) vectors, the method comprising: a. transfecting a library of insect cells with one or more sequences necessary for producing an AAV vector, wherein each insect cell in the plurality individually comprises: (i) a nucleic acid sequence comprising a barcode located between two functional AAV ITR sequences, (ii) one or more library variants that result in one or more perturbations, wherein at least one library variant comprises a gRNA, and (iii) RNA-guided nucleases, b. generating a plurality of AAV vectors from the insect cell library, wherein each of the AAV vectors comprises a barcode corresponding to the individual insect cell from which it was produced; and c. detecting barcodes of the plurality of AAV vectors, wherein the abundance of the barcodes is associated with production and / or secretion of the AAV vectors by the insect cells.

3. The method of claim 1 or 2, wherein the one or more sequences necessary for producing an AAV vector are in the context of a baculovirus vector.

4. The method of any one of claims 1 to 3, further comprising the step of determining the relative abundance of a particular barcode relative to all barcodes present in the plurality of AAV vectors generated from the insect cell library.

5. The method of any one of claims 1 to 4, wherein the one or more perturbations are associated with an increase in AAV production and / or AAV secretion relative to a reference insect cell lacking the one or more perturbations.

6. The method of any one of claims 1 to 5, wherein at least one library variant is integrated into the insect cell genome between a pair of cis-acting integration sequences.

7. The method of any one of claims 1 to 6, wherein one or two copies of the engineered nucleic acid sequence are integrated into the insect cell genome.

8. The method of any one of claims 1 to 7, wherein at least one library variant is present episomally in the insect cell.

9. The method of any one of claims 1 to 8, wherein the two functional AAV ITR sequences comprise human AAV1 ITR, human AAV2 ITR, human AAV3b ITR, human AAV4 ITR, human AAV5 ITR, human AAV6 ITR, human AAV7 ITR, human AAV8 ITR, human AAV9 ITR, human AAV10 ITR, human AAV11 ITR, human AAV12 ITR, or human AAV13 ITR.

10. The method of any one of claims 1 to 8, wherein the two functional AAV ITR sequences comprise bovine AAV (b-AAV) ITRs, canine AAV (CAAV) ITRs, mouse AAV1 ITRs, goat AAV ITRs, rat AAV ITRs, or avian AAV (AAAV) ITRs.

11. The method of any one of claims 1 to 10, wherein the one or more sequences necessary for producing an AAV vector comprise (a) an AAV Rep gene, (b) an AAV Cap gene, (c) one or more AAV helper genes; or (d) a combination thereof.

12. The method of claim 11, wherein the one or more sequences necessary for producing an AAV vector comprise an AAV Cap gene encoding a human AAV1 capsid protein, a human AAV2 capsid protein, a human AAV3b capsid protein, a human AAV4 capsid protein, a human AAV5 capsid protein, a human AAV6 capsid protein, a human AAV7 capsid protein, a human AAV8 capsid protein, a human AAV9 capsid protein, a human AAV10 capsid protein, a human AAV11 capsid protein, a human AAV12 capsid protein, or a human AAV13 capsid protein.

13. The method of any one of claims 1 to 12, wherein the one or more perturbations comprise insertions, deletions, substitutions, replacements, epigenetic modifications and / or rearrangements of endogenous genomic coding sequences.

14. The method of any one of claims 1 to 13, wherein the one or more library variants comprise at least two library variants, wherein the at least two library variants comprise at least one unique gene, at least one unique ORF, at least one unique gRNA sequence, and / or at least one unique non-coding nucleic acid, or a combination and / or a plurality thereof.

15. The method of any one of claims 1 to 14, wherein the method further comprises single cell sequencing.

16. The method of any one of claims 1 to 15, wherein the insect cell library comprises Sf21 cells, Sf9 cells, BTI-TN-5B1-4 (High Five) cells, S2 cells, D.Mel2 cells or any derivative thereof.

17. An insect cell or insect cell population comprising a plurality of insect cells, wherein each insect cell comprises: (i) an engineered nucleic acid sequence comprising a barcode located between two functional AAV ITR sequences, wherein the nucleic acid sequence is present episomally in the insect cell, (ii) one or more library variants resulting in one or more perturbations, wherein at least one library variant comprises a gRNA, (iii) RNA-guided nucleases, and (iv) one or more nucleic acid sequences necessary for the production of an AAV vector, wherein the population of insect cells produces a plurality of AAV vectors, wherein each AAV vector comprises a barcode corresponding to the barcode of the insect cell that produced it.

18. An insect cell or insect cell population comprising a plurality of insect cells, wherein each insect cell comprises: (i) an engineered nucleic acid sequence comprising a barcode located between two functional AAV ITR sequences, wherein the nucleic acid sequence is integrated into the genome of an insect cell located between a pair of cis-acting integration sequences, (ii) one or more library variants resulting in one or more perturbations, wherein at least one library variant comprises a gRNA, (iii) RNA-guided nucleases, and (iv) one or more nucleic acid sequences necessary for the production of an AAV vector, wherein the population of insect cells produces a plurality of AAV vectors, wherein each AAV vector comprises a barcode corresponding to the barcode of the insect cell that produced it.

19. The insect cell or insect cell population according to claim 17 or 18, wherein the insect cells each individually comprise Sf21 cells, Sf9 cells, BTI-TN-5B1-4 (High Five) cells, S2 cells, D.Mel2 cells or any derivatives thereof.

20. The insect cell or insect cell population of any one of claims 17 to 19, wherein the AAV vector comprises a human AAV1 capsid protein; a human AAV2 capsid protein; a human AAV3b capsid protein; a human AAV4 capsid protein; a human AAV5 capsid protein; a human AAV6 capsid protein; a human AAV7 capsid protein; a human AAV8 capsid protein; a human AAV9 capsid protein; a human AAV10 capsid protein; a human AAV11 capsid protein; a human AAV12 capsid protein; or a human AAV13 capsid protein.

21. The insect cell or insect cell population of any one of claims 17 to 19, wherein the AAV vector comprises a human ancestral AAV capsid protein.

22. The insect cell or population of insect cells of any one of claims 17 to 21, wherein the viral vector comprises an AAV vector, wherein the AAV vector comprises a first set of two viral repeat sequences, the first set of two viral repeat sequences comprising a pair of inverted terminal repeat sequences (ITRs) that are or include human AAV1 ITRs; human AAV2 ITRs; human AAV3b ITRs; human AAV4 ITRs; human AAV5 ITRs; human AAV6 ITRs; human AAV7 ITRs; human AAV8 ITRs; human AAV9 ITRs; human AAV10 ITRs; human AAV11 ITRs; human AAV12 ITRs; or human AAV13 ITRs.

23. The insect cell or insect cell population of any one of claims 17 to 21, wherein the AAV vector comprises a bovine AAV (b-AAV) capsid protein; a canine AAV (CAAV) capsid protein; a mouse AAV1 capsid protein; a goat AAV capsid protein; a rat AAV capsid protein; or an avian AAV (AAAV) capsid protein.

24. The insect cell or insect cell population of any one of claims 17 to 23, wherein the viral vector comprises an AAV vector, wherein the AAV vector comprises a pair of ITRs, which are or comprise bovine AAV (b-AAV) ITRs; canine AAV (CAAV) ITRs; mouse AAV1 ITRs; goat AAV ITRs; rat AAV ITRs; or avian AAV (AAAV) ITRs.

25. The insect cell or insect cell population according to any one of claims 17 to 24, wherein at least one polynucleotide comprising one or more nucleic acid sequences necessary for forming a viral vector comprises: a.AAV Rep gene; b. AAV Cap gene; c. one or more AAV helper genes; or d. combinations thereof.

26. The insect cell population of any one of claims 17 to 25, wherein the one or more perturbations are associated with an increase in AAV production and / or AAV secretion relative to a reference insect cell population lacking the one or more perturbations.

27. The insect cell or insect cell population of any one of claims 17 to 26, which produces a population of AAV vectors comprising at least one improved characteristic compared to a population of AAV vectors produced by insect cells lacking the one or more perturbations.

28. The method of any one of claims 1 to 16 or the insect cell or population of insect cells of any one of claims 17 to 27, wherein the at least one barcode comprises a sequence of about 5 to about 25 nucleotides.

29. The method of any one of claims 1 to 16 or the insect cell or insect cell population of any one of claims 17 to 27, wherein the insect cells each individually comprise one, two, three, four, five, six, seven, eight, nine or ten library variants.

30. The method of any one of claims 1 to 16 or the insect cell or population of insect cells of any one of claims 17 to 27, wherein the insect cells each individually comprise up to 100 library variants.

Citation Information

Patent Citations

  • Directional knockout method for zinc-finger nuclease mediated endogenous genes of mammal as well as zinc-finger nuclease and expression vector of same

    CN102174576A

  • Novel crispr enzymes and systems

    US20160208243A1

  • High-efficiency wild-type-free AAV helper functions

    US6001650A

  • Zinc finger nuclease for targeting the human glucocorticoid receptor locus

    WO2008060510A2

  • Zinc finger nuclease for the CFTR gene and methods of use thereof

    WO2009146179A1